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Chapter 1
Parkinson’s disease (PD) is a neurodegenerative disorder with a prevalence of 100 to 
200 per 100,000 people and an annual incidence of 15 per 100,000 people [1]. Due 
to ageing and accompanying factors such as genetic mutations and environmental 
risk factors (e.g. pesticides), the occurrence of PD is increasing [1, 2]. Recently, PD 
has even been described as a pandemic [3].
PD was first described by James Parkinson in 1817 [4] as a neurological syndrome 
characterized by involuntary tremors and muscular weakness. He also stated ‘the 
senses and intellects being uninjured ’ [4]. However, Jean-Martin Charcot described 
PD as not only showing tremors, but also bradykinesia, autonomic dysfunction, 
and pain [5]. Furthermore, together with one of his students in 1892, he described 
depression and hallucinations in PD patients with dementia, as reported by 
Walusinski [6]. Nowadays, PD is characterized by its main motor symptoms 
bradykinesia, rigidity and tremor, and additional motor and non-motor symptoms. 
Non-motor characteristics may include cognitive dysfunction, autonomic failure, and 
neuropsychiatric symptoms and disorders such as anxiety, depression, psychosis, 
impulse control disorders, sleep disorders, and apathy [7, 8].
According to Braak and colleagues [9], PD is caused by a neuropathological process, 
affecting serotonergic, noradrenergic, cholinergic, and dopaminergic systems. This 
neuropathological process is defined by the accumulation of the protein alpha-
synuclein into so-called Lewy bodies, that spread out through the brain in a caudal 
(brainstem) to rostral (neocortex) gradient [9, 10]. This neurodegenerative process 
also affects the neurotransmitter systems. When over 60% of dopaminergic neurons 
of the basal ganglia have degenerated, the motor symptoms on which the clinical 
diagnosis of PD is based, appear [11]. Together with the affected dopaminergic 
system, the affected serotonergic, noradrenergic, and cholinergic systems are 
postulated to cause other motor and autonomic and neuropsychiatric symptoms.
As compared to the motor symptoms, neuropsychiatric symptoms are often 
reported to have a higher impact on quality of life of both patients and their 
caregivers [12-15]. Amongst neuropsychiatric symptoms, anxiety and depression 
are considered major predictors of quality of life, followed by cognitive dysfunction 
[13, 14]. The lifetime prevalence of an anxiety disorder in PD patients is 49% [16], 
depression occurs in up to 50% of PD patients at some point in the course of the 
disease [8], and up to 80% of PD patients develop PD dementia [17, 18].
Binnenwerk_Ires.indd   10 12-3-2021   13:47:23
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Debilitating neuropsychiatric symptoms are common, also without fulfillment of the 
criteria for specific disorders. Clinically relevant anxiety and depressive symptoms 
occur in 11-26% [19, 20] and 35% of patients [21], respectively.
The neurodegenerative process whereby neurotransmitter systems are extensively 
affected, and the high prevalence and impact of neuropsychiatric symptoms indicate 
that non-motor symptoms are an important part of the disease, in addition to the 
motor symptoms on which the PD diagnosis is mainly based.
Anxiety in PD
Currently, up to 45% of PD patients experience either clinically relevant anxiety 
symptoms or fulfill the criteria for an anxiety disorder, including generalized anxiety 
disorder, panic attacks, and social phobia [20, 22, 23].
According to the fifth edition of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-5) [24], anxiety disorders are characterized by certain affective, 
cognitive, physical, and behavioral symptoms. Affective symptoms include feeling 
nervous, fear of losing control, and feeling scared. Cognitive symptoms include 
ruminating, negative bias, and poor concentration. Physical symptoms include 
muscle tension, sweating, trembling, shortness of breath, and heart palpitations, 
amongst many others. Lastly, behavioral symptoms include avoidance and safety 
behaviors.
Diagnosing anxiety in PD is complicated. Physical symptoms of anxiety can be 
interpreted as motor or autonomic symptoms as part of the disease itself (e.g., 
tremor, rigidity, freezing, excessive daytime sweating) [25, 26]. In addition, anxiety 
frequently occurs comorbid or secondary to depression, psychosis, and cognitive 
decline [23, 27-29].
Detecting and quantifying anxiety can be done with self-report questionnaires, such 
as the Beck Anxiety Inventory (BAI) [30]. However, due to overlapping anxiety and 
PD-specific symptoms, and comorbidity with other neuropsychiatric symptoms, 
the interpretation of the total score on such self-report questionnaires in PD is 
complicated [25, 26] and raises the question whether these measures are suitable 
for investigating anxiety in PD [31]. Since it appears to be a complicated construct in 
PD, anxiety can be both over- as well as underdiagnosed in clinical practice [32, 33].
1
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The interplay between anxiety and motor symptoms
Anxiety in PD can also occur in the context of fluctuations in PD symptoms and is 
often dependent on available dopamine related to the timing of PD medication. 
First line treatment for PD symptoms is dopamine replacement therapy (DRT), 
e.g., levodopa [34]. In reaction to chronic DRT and due to the progressive nature 
of PD, patients eventually develop response fluctuations, including wearing-off. 
Wearing-off refers to the re-emergence of PD symptoms while transitioning from 
an ‘on’ state to an ‘off’ state, and typically occurs prior to the next scheduled dose 
of dopaminergic medication taking effect [35]. About 75% of patients with motor 
fluctuations experience fluctuations in mood and/or anxiety in parallel [36, 37]. 
Wearing-off related anxiety is characterized not only by subjective feelings of 
anxiety but also by physical complaints, such as sweating, abdominal distress and 
shortness of breath, and can include panic attacks [16]. Just like wearing-off related 
anxiety, fear of falling is a PD specific anxiety phenomenon associated with motor 
fluctuations [19, 35, 38].
Anxiety itself can worsen motor symptoms, such as tremor and freezing [39, 40] and 
a vicious cycle can emerge, in which motor symptoms trigger anxiety or distress, 
which can in turn exacerbate motor symptoms. As one can imagine, this interplay 
between motor and anxiety symptoms considerably complicates diagnosing and 
treating anxiety in PD.
Treatment of anxiety in PD
Evidence for the treatment of anxiety in PD patients is extremely limited [41-43]. 
No randomized controlled trials (RCTs) with anxiety as primary outcome measure 
have been performed. Only two studies, without control conditions, have been 
performed to investigate the effect of psychotherapy on anxiety in PD [44, 45]. 
Psychotherapy includes cognitive behavioral therapy (CBT) and mindfulness based 
treatments. Their effects on psychological distress (including anxiety) are reviewed 
and analyzed in chapter 6 [46].
Similar to psychotherapy, pharmacological treatments of anxiety in PD have not 
been investigated using RCT research designs. Non-RCT studies using serotonergic 
antidepressants have reported marginal secondary benefits for anxiety symptoms 
in PD, and treatment with benzodiazepines should be used with caution because 
of their propensity to increase cognitive impairment and risk of falling [8]. For 
patients who experience anxiety as part of an ‘off’ state, or as non-motor fluctuation, 
dopaminergic medication adjustments can be made in an attempt to decrease 
the duration and severity of these ‘off’ episodes [8, 43, 47]. However, the risk of 
Binnenwerk_Ires.indd   12 12-3-2021   13:47:24
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developing a dopamine dysregulation syndrome (DDS) is worth noticing, which 
refers to compulsive PD medication overuse. DDS is associated with wearing-off 
related anxiety and can develop after continually taking extra PD medication (which 
can be described as avoidance behavior) to prevent the debilitating ‘off’ state [48].
Since anxiety in PD is complex due to its reciprocal interactions with motor 
symptoms, treatment should preferably be multidisciplinary and integrated. Current 
treatment options seem inadequate and there is a need for further investigation 
and development [8, 13, 14, 49]. Not only the treatment of anxiety symptoms, but 
also the diagnosis, phenomenology, origin, contributing factors, and underlying 
mechanisms of anxiety in PD are in high need of further research.
Aims & outline thesis
The overall aim of this thesis was to investigate the phenomenology, associations 
and interactions, and treatment of anxiety in relation to motor and other non-motor 
symptoms in PD patients.
Part 1 (chapters 2 through 5) focuses on understanding the complex associations 
and interactions between anxiety, motor and other non-motor symptoms in PD. This 
can contribute to an improvement of the diagnosis of anxiety and help developing 
adequate treatment options for PD related anxiety. Subsequently, part 2 (chapters 
6 through 8) focuses on the role of psychotherapy for reducing symptoms of 
psychological distress (including anxiety) in PD patients, and investigates a newly 
developed multidisciplinary treatment to address interacting motor and anxiety 
symptoms.
Part 1
In chapter 2 we investigate the phenomenology of anxiety in PD by performing a 
principal component analysis to explore underlying symptom dimensions of anxiety 
as measured with the BAI [50]. These symptom dimensions can be considered 
subscales of anxiety. We also describe the associations of the resulting subscales 
with motor, autonomic, and depressive symptoms. Insight in the phenomenology of 
anxiety in PD patients, and its relatedness to other motor and non-motor symptoms, 
can improve recognition and diagnosis of anxiety in clinical practice.
To investigate the generalizability of the findings in chapter 2, chapter 3 describes 
the replication of the principal component analysis in a PD patient population 
referred for neuropsychiatric evaluation to a specialized psychiatric outpatient 
department [Ghielen et al., 2020 (under review)]. In order to investigate the clinical 
1
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implication of the replicated findings, we additionally performed a post-hoc analysis 
in which we investigated the predictive value of the principal component with the 
highest percentage of explained variance in whether or not patients received an 
anxiety disorder diagnosis.
Chapter 4 compares two symptom networks of anxious versus non-anxious PD 
patients, including anxiety and motor symptoms. We investigated whether anxiety 
and motor symptoms are more strongly connected in the anxious PD patient sample, 
compared to the non-anxious PD patient sample [Ghielen et al., 2020 (submitted)]. 
To test this hypothesis, we performed a network comparison test.
The previous chapters demonstrate relationships between anxiety and motor 
symptoms. However, no conclusions can be drawn concerning their relationships 
over time. Therefore, in chapter 5, we investigate the longitudinal associations 
between anxiety, fear of falling, and freezing of gait in PD [Ghielen et al., 2020]. In 
addition, we investigated which confounding factors influenced these associations, 
to gain further understanding of these relationships.
Part 2
To explore the current state of psychological treatment options, we describe 
two meta-analyses in which we investigated the effects of cognitive behavioral 
and mindfulness-based therapies on psychological distress in patients with 
neurodegenerative disorders in chapter 6 [46].
Since evidence for the treatment of anxiety in PD patients is extremely limited, 
and motor and non-motor symptoms appear to interact, especially in PD patients 
that experience symptom fluctuations, effective psychological treatment, especially 
multidisciplinary treatment is warranted [8, 13, 14]. Therefore, we developed 
a new intervention that combines acceptance and commitment therapy with 
physical therapy, to treat both non-motor and motor symptoms, including their 
interactions. In this treatment, we included PD patients that experience wearing-
off related anxiety. Chapters 7 & 8 describe the study protocol and subsequent 
results of a pilot randomized controlled trial in which we describe and investigate 
the effectiveness and feasibility of this new body awareness treatment (named 
BEWARE) [51, 52].
Finally, in chapter 9, a summary is provided of the main findings of this thesis, 
followed by a general discussion and directions for future research.
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Introduction: Anxiety disorders are highly prevalent in patients with Parkinson’s 
disease (PD) and have a major impact on wellbeing. They nevertheless receive 
limited scientific attention. This study aimed to establish the symptom dimensions 
of anxiety in PD, and their relationship with depression, autonomic failure and motor 
symptoms.
Methods: In this cross-sectional observational study, symptoms of anxiety were 
measured with the Beck Anxiety Inventory (BAI) in 294 PD patients. Symptom 
dimensions of anxiety in PD were explored through principal component analysis 
(PCA) of BAI items. The relationship between anxiety and depressive, autonomic 
and motor symptoms was assessed through PCA and regression analyses.
Results: Clinically relevant symptoms of anxiety were present in 45% of patients. 
PCA of the BAI resulted in five subscales, corresponding to a single affective and four 
somatic symptom dimensions (thermoregulation, hypotension, hyperventilation 
and trembling) of anxiety. Symptoms of anxiety and depression displayed a large 
overlap. All somatic BAI subscales were significantly influenced by motor and 
autonomic symptoms, while the affective subscale was not.
Conclusion: Anxiety in PD comprises affective and somatic symptom dimensions. 
The affective subscale of the BAI is not influenced by motor or autonomic symptoms, 
and may therefore prove useful for future research. Scores on the somatic 
subscales of the BAI were associated with autonomic failure and motor impairment, 
demonstrating a strong interplay between motor and non-motor symptoms in PD. 
These results stress the importance of a holistic approach of anxiety in PD.
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BAI factor analysis in PD patients
Introduction
Despite a high prevalence and a major impact on daily functioning and quality of 
life in patients with Parkinson’s disease (PD), anxiety has only recently attracted 
scientific attention. Estimates suggest that 40-50% of PD patients experience 
clinically relevant symptoms of anxiety [1, 2], and approximately one third suffers 
from an anxiety disorder as specified by the Diagnostic and Statistic Manual of 
mental disorders (DSM) IV-TR criteria [1-4]. Generalized anxiety disorder, social 
phobia and anxiety disorder not otherwise specified (NOS) are most frequently 
diagnosed in this population [2, 3, 5]. Anxiety disorders are more common in PD 
patients than in the general population, in primary care clinics or in patients with 
other chronic medical conditions, where prevalence rates vary between 5 and 11% 
[4]. Anxiety in PD patients is associated with increased subjective motor symptoms 
[6], more severe gait problems [7], dyskinesias [7], freezing [8], motor response 
fluctuations [6], and a decrease in health-related quality of life [9].
In clinical practice, anxiety disorders are often underdiagnosed in PD patients [10]. 
In a large proportion of patients with PD that report clinically relevant anxiety, the 
symptoms do not meet the criteria of a discrete DSM-IV disorder and are therefore 
classified as an anxiety disorder NOS [3]. This suggests that anxiety disorders may 
have an atypical presentation in this population. The poor recognition of anxiety 
might also be explained by the overlap and interaction with PD-related motor and 
non-motor symptoms, such as depression, motor symptoms and autonomic failure.
An improvement of the diagnostics of anxiety in PD could be aided by an in-depth 
study of the symptom dimensions covered by self-report questionnaires such as 
the Beck Anxiety Inventory (BAI) [11] and their relatedness to other motor and non-
motor symptoms. Factor analysis is a statistical technique that can help to explore 
the underlying factors or symptom dimensions covered by a questionnaire. In 
non-PD samples factor analysis has shown that the BAI comprises cognitive and 
somatic factors and that the BAI is able to differentiate between symptoms of 
anxiety and depression [12, 13]. Dimensionality of the BAI in PD patients was only 
addressed in a single study [14], but no satisfactory factor solution was found, 
possibly due to the heterogeneity of the study sample.
In the present study, we analyzed the symptom dimensions of the BAI within a large 
sample of PD patients. Secondly, we assessed the overlap of symptoms of anxiety 
with depression, autonomic dysfunction and motor disability in PD.
2





For this cross-sectional study, we used data collected during routine clinical 
assessments at the outpatient clinic for movement disorders of the VU University 
medical center (VUmc) in Amsterdam, the Netherlands, between May 2008 
and January 2013. In this period, 383 PD patients were assessed. Patients were 
clinically diagnosed with idiopathic PD using the United Kingdom PD Society Brain 
Bank (UKPDSBB) criteria. The clinical diagnosis was supported by both magnetic 
resonance imaging (MRI) and dopamine transporter single-photon emission 
computed tomography (DAT-SPECT) scans in 244 patients, by MRI only in 37 patients 
and by DAT-SPECT scan only in 23 patients. In the remaining 79 patients, no brain 
imaging was performed. All included patients gave written informed consent to 
use their clinical data for scientific purposes. Patients with severe cognitive decline, 
defined as a Mini Mental State Examination (MMSE) score < 24, were excluded.
Measurements
Anxiety
Symptoms of anxiety were measured with the BAI. The BAI is a 21-item self-report 
instrument asking for symptoms of anxiety over the past week [11]. Patients answer 
on a four-point Likert scale, ranging from 0 (not at all) to 3 (severely). In patients 
with PD, clinically relevant anxiety is defined as a BAI-score > 12 [14]. This cut-off 
score is lower than in the general population, due to a lower construct validity of 
the BAI in PD patients [14].
Clinical and demographic factors
Age, gender and the use of dopaminergic medication (0 = no, 1 = yes) were registered 
for use in statistical analyses.
The independent variables of major interest were symptoms of depression, motor 
dysfunction and autonomic failure. We evaluated symptoms of depression with the 
Beck Depression Inventory (BDI) [15]. Severity of motor symptoms was assessed 
using section III and V (Hoehn and Yahr stage) of the Unified Parkinson Disease 
Rating Scale (UPDRS) [16].
We used the Scales for Outcomes in Parkinson’s disease – Autonomic (SCOPA-AUT) 
[17] to assess autonomic failure. The SCOPA-AUT includes five questions on sexual 
function: item 22, 23 and 23a apply to men, and item 24 and 25 to women. The 
answers to these questions were unreliable on multiple occasions, e.g. patients 
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choosing “not applicable” for all five items, or male patients answering question 24 
or 25. Therefore, we decided to exclude the sexual items of the SCOPA-AUT from 
the analyses.
Statistical analyses
We performed all analyses using IBM SPSS Statistics 20 for Windows. The significance 
level was set at p < 0.05 with two-sided testing. Acceptability of missing values on 
the BAI, BDI and SCOPA-AUT was determined as less than 16.67% of items. In the 
event of more missing data, we excluded the patient for the analysis by pair-wise 
exclusion. When less than 16.67% of data was missing, we filled in missing values by 
mean imputation. We performed no imputation of missing data on the UPDRS-III, 
since we considered this to be unreliable for this scale.
In the first analysis, we assessed dimensionality of the BAI with a principal 
component analysis (PCA). To determine the number of extracted factors we 
combined the Cuttman-Kaiser Eigenvalue greater-than-one rule and the “scree plot” 
criterion. We used oblimin rotation because we expected the different factors to 
correlate with each other. The factors obtained in this analysis can be considered 
as subscales of the BAI or symptom dimensions of anxiety. Scores on the derived 
subscales of the BAI were used in further analyses.
Second, we studied the relationship between the BAI, BDI, SCOPA-AUT and 
UPDRS-III, by conducting multiple linear regression analyses. Assumptions for 
regression analyses (normality and homoscedasticity of residuals) were checked. 
Multicolinearity was evaluated with a correlation matrix and calculation of the 
variance inflation factor (VIF).
The total BAI score was the dependent variable in the first set of regression 
analyses. In the second set, it was the score on the subscale of the BAI, derived 
with PCA previously. The independent variables of interest were the total score on 
the BDI, SCOPA-AUT and UPDRS-III. We conducted all analyses first with only the 
independent variable of interest (unadjusted model). We then adjusted the model 
stepwise for age and gender (model 1), use of dopaminergic medication (model 2), 
and the other two independent variables of main interest, i.e. the BDI, SCOPA-AUT 
and/or UPDRS-III score (model 3). Finally, we examined confounding in all models.
2




Of the original sample of 382 PD patients, 75 patients met exclusion criteria (MMSE 
< 24). An additional 13 patients were excluded from the analyses for not meeting 
our standards of acceptability of missing values on the BAI. This resulted in a total 
sample size of 294 patients. Due to missing data on the BDI, UPDRS-III and/or SCOPA-
AUT, 3 to 18 additional patients were excluded pair-wise during statistical analyses. 
The majority of patients was male. Mean age was 64.5 years. Patients had a mean 
UPDRS-III score of 25.8 and a median Hoehn and Yahr stage of 2. Demographic and 
clinical characteristics of the sample are given in Table 1.
Table 1. Demographic and clinical characteristics of subjects (n = 294)
Mean SD Range
% Female 39.5
Age 64.5 10.3 27-89
Disease duration (yr) 5.1 5.6 0-40
MMSE score 28.0 1.7 24-30
BDI score 11.4 8.0 0-36
SCOPA-AUT score 35 10.0 0-64
UPDRS-III score 25.8 12.3 2-58
Hoehn & Yahr stage 2 (median) 1-5
% Use dopaminergic medication 48.6
Occurrence and symptom dimensions of anxiety in PD
The mean score on the BAI was 14.2 (SD 9.8, range 0-50). Forty-five percent of 
patients in our sample had a BAI score of 12 or more, which is considered to be a 
clinically relevant level of anxiety [14].
The Eigenvalue >1 criterium suggested that five factors should be extracted. This 
was confirmed by an inspection of the scree plot (see Figure S1 in the supplementary 
material). Items 3 ‘wobbliness in legs’, 7 ‘heart pounding/racing’ and 18 ‘indigestion’ 
had a loading of less than 0.4 on all factors and were therefore excluded from the 
factor solution.
The five obtained factors were interpreted as anxiety, thermoregulation, hypotension, 
hyperventilation and trembling. The factor solution explained 62.7% of variance. 
Figure 1 demonstrates the distribution of the BAI items over the five factors, with 
corresponding factor loadings.
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Associations between anxiety, depression, motor dysfunction and 
autonomic failure in PD
Histograms demonstrated that the residuals of both the total BAI score and 
subscales of the BAI had a positively skewed distribution. Transformation of the 
data did not improve normality. To maintain interpretability of results, we decided to 
use the original data for the analyses. Homoscedasticity was confirmed by plotting 
the regression standardized predicted value against the regression standardized 
residual. Both the correlations (see Table 2) and the VIF (ranging from 1.005 to 1.610) 
indicated non-collinearity of the data.
Table 2. Matrix of the Pearson’s correlation coefficients (r) for the BAI, BDI, SCOPA-AUT, 
UPDRS-III and age.
BAI BDI SCOPA-AUT UPDRS-III Age
BAI 1.000 0.735** 0.616** 0.234** 0.100
BDI 0.735** 1.000 0.535** 0.230** 0.120*
SCOPA-AUT 0.616** 0.535** 1.000 0.330** 0.277**
UPDRS-III 0.234** 0.230** 0.330** 1.000 0.300**
AGE 0.100 0.120* 0.277** 0.300** 1.000
*p-value < 0.05, **p-value < 0.01 (2-tailed).
Results of the multiple regression analyses with the BAI total score and subscales 
of the BAI as dependent variable are presented in Table 3. In this table, the final, 
adjusted models are displayed, showing the influence of each independent variable 
on the outcome variable. The unadjusted and adjusted models, including detailed 
information on confounding, can be found in Supplementary Table S1.
The BAI total score was significantly influenced by age and gender: younger patients 
and females had a higher score on the BAI than older patients and men. The BAI 
score also increased with a higher score on the BDI and SCOPA-AUT. The UPDRS-III 
score no longer significantly influenced the BAI score after adjustment for score on 
the BDI and SCOPA-AUT.
All subscales of the BAI were influenced by the BDI score. Moreover, the subscales 
thermoregulation and hyperventilation were significantly influenced by the SCOPA-
AUT, the trembling subscale by the UPDRS-III, and the hypotension subscale by 
both. The affect subscale was only significantly influenced by the BDI score, and 
not by the SCOPA-AUT and UPDRS-III. The relationship between the BAI total 
score and the subscales of the BAI and the BDI, SCOPA-AUT and UPDRS-III were 
influenced by confounders, as mentioned in the addendum of Supplementary Table 
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S1. The confounding variables were age and the BDI, SCOPA-AUT and UPDRS-III 
score. Although, as demonstrated in Table 2, these variables were all significantly 
correlated with each other, VIF remained within acceptable bounds.
Discussion
In this study, clinically relevant symptoms of anxiety were present in 45% of patients 
in our sample, which corresponds with previously reported rates [1, 2]. PCA of the 
BAI revealed one affective and four somatic symptom dimensions (thermoregulation, 
hypotension, hyperventilation and trembling) of anxiety. The finding of a distinct 
affective factor and multiple somatic factors is in line with previous research on 
dimensionality of the BAI in non-PD samples [11, 13, 18, 19]. In these studies, less 
than five factors were found, probably because the samples consisted of psychiatric 
patients with a mean age under 40 years. These patients are less likely to experience 
somatic symptoms than the patients in our sample, who have a variety of PD-related 
motor and non-motor symptoms that overlap with somatic anxiety equivalents. 
Moreover, differences in the methodology of the factor analysis, such as the choice 
of rotation method, can lead to a different number of obtained factors. 
The BDI significantly influenced all subscales of the BAI, as well as the BAI total score. 
Moreover, there was a high correlation between the BAI and BDI. This suggests 
that the large overlap between anxiety and depression that is found in psychiatric 
patients [20], is present in PD patients as well. In previous studies, anxiety and 
depressive disorders coexisted in 19 to 40% of patients with PD, which is higher 
than in matched controls [21-23].Autonomic symptoms significantly influenced the 
total score on the BAI and on the hypotension, thermoregulation and hyperventilation 
subscales, while severity of motor symptoms influenced the score on the trembling 
subscale. The most obvious explanation for these observations is that the BAI 
is designed to measure episodic anxiety, such as in panic disorder, which is 
accompanied by somatic equivalents of anxiety [19]. Alternatively, symptoms of 
PD-related autonomic and motor dysfunction might be misinterpreted as anxiety, 
resulting in overdiagnosis of anxiety disorders in PD patients [24]. In this study, we 
demonstrated that the score on the affect subscale was not influenced by the SCOPA-
AUT or the UPDRS-III score. One might therefore conclude that the affect subscale 
constitutes the most reliable measure of anxiety in PD, because it is not affected by 
‘noise’ generated by motor and autonomic symptoms. The use of questionnaires 
excluding somatic symptoms for the screening of psychiatric disorders in the 
elderly has been advocated for this reason [25]. In PD patients, however, attempts 
2
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to make a clear distinction between autonomic symptoms caused by anxiety and 
PD-related autonomic dysfunction will probably prove futile. The diagnostic criteria 
for anxiety disorders underline that physical symptoms comprise an integral part 
of the syndrome ‘anxiety’ [26]. Moreover, PD-related autonomic symptoms and 
anxiety frequently co-occur and overlap in symptomatology [2, 24], and there is an 
interplay between anxiety and somatic symptoms [2, 3, 24]. The development of 
autonomic failure in PD may lead to a pathophysiological predisposition towards 
somatic symptoms of anxiety. This hypothesis is supported by research in non-PD 
patients suffering from autonomic failure. For example, in patients with pure 
autonomic failure, hyperventilation causes a larger decrease in blood pressure than 
in healthy controls [27, 28]. In a case-report on a patient with pure autonomic failure 
who experienced dizziness during emotional stress, a significant decrease in blood 
pressure after stressful events was demonstrated [29]. Moreover, PD patients with 
failure of both the sympathetic and parasympathetic nervous system had higher 
levels of anxiety and depression than healthy controls or de novo PD patients [30]. 
One may therefore expect that the presence of autonomic failure in PD patients 
gives rise to a stronger physical response to anxiety. The presence of anxiety is also 
associated with an increase in motor symptoms in PD [6-8]. Vice versa, PD-related 
motor symptoms, such as wearing-off, can give rise to anxiety: a substantial number 
of PD patients suffers from situational anxiety, with phobic avoidance related to 
fear of experiencing off-periods or freezing [3]. The clinical finding that many PD 
patients with response fluctuations experience anxiety and autonomic symptoms 
during wearing-off [6, 31, 32], suggests that dopaminergic transmission is involved in 
the etiology of both motor and non-motor symptoms of PD [33, 34]. These findings 
make the distinction between anxiety and other motor and non-motor symptoms 
of PD appears artificial. In line with this, the MDS task force on rating scales for PD 
recommends an “inclusive approach” when rating possible symptoms of anxiety in 
PD patients, without trying to attribute them to either anxiety or other PD-related 
symptoms [35]. The finding of an affect subscale of the BAI, that is not influenced 
by motor or autonomic symptoms, might nevertheless be relevant for research 
purposes. Moreover, our results can be useful in the development of new measures 
for anxiety in PD.
This study has some limitations. The only measure of anxiety in this study was the 
BAI. The BAI can be used to assess symptoms of anxiety, but is not a diagnostic 
instrument. Moreover, the BAI is more suitable for measuring episodic anxiety than 
the non-episodic anxiety that occurs in generalized anxiety disorder [18], which is 
one of the most prevalent anxiety disorders in PD patients [2]. Strengths of the 
present study are the large number of patients included, and the homogeneity of 
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the sample. Moreover, this is the first study that has successfully performed a factor 
analysis of the BAI in a sample of PD patients.
Conclusions
In this study, we demonstrated that anxiety in PD patients, as measured with the 
BAI, comprises one affective and four somatic symptom dimensions. Scores on the 
BAI and BDI are highly correlated, which can be explained by symptom overlap and 
frequent co-occurrence of anxiety and depression in PD.
The score on the somatic subscales of the BAI is significantly influenced by 
autonomic failure and motor dysfunction, whereas the affect subscale is not. This 
finding suggests that the affect subscale may be a more reliable measure of anxiety 
in PD patients. However, somatic symptoms cannot be completely disregarded in 
the diagnostic process of anxiety disorders. Furthermore, anxiety, autonomic failure 
and motor dysfunction in PD may share underlying etiological mechanisms. The 
strong interplay between motor and non-motor symptoms in PD warrants a holistic 
approach to anxiety in clinical practice. Hopefully, the findings in this study will 
stimulate the development of new and more specific measures of anxiety in PD.
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Supplementary material Chapter 2
Figure S1: Scree plot of the principal component analysis of the BAI
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Introduction: Anxiety disorders occur in approximately one third of people with 
Parkinson’s disease (PD), and have a major impact on patient and caregiver 
wellbeing. In order to better understand and diagnose anxiety in PD patients, 
we investigated the generalizability of the results of a previous factor analysis on 
anxiety symptoms to a sample of PD patients with neuropsychiatric symptoms.
Methods: Anxiety symptoms were measured with the Beck Anxiety Inventory 
(BAI) in 123 PD patients who were referred for neuropsychiatric diagnostics and 
treatment. Subscales of anxiety were analyzed through principal component 
analysis of BAI items. The associations between BAI subscales and motor and other 
neuropsychiatric symptoms were assessed through regression analyses.
Results: Similar to the previous factor analysis, we found one psychological (affective) 
and four somatic subscales of anxiety in the BAI. The affective subscale was the 
principal component explaining 35.9% of the variance. The scores on the total BAI 
and the affective subscale were significantly associated with depressive symptoms. 
In a post-hoc analysis, the affective subscale had equal power as compared to the 
total BAI in predicting whether or not patients received an anxiety disorder diagnosis 
through psychiatric evaluation.
Conclusion: Anxiety in PD is a complicated construct due to symptom overlap and 
mutual interactions. The affective subscale of the BAI shows potential as a screening 
tool for non-episodic anxiety in PD. We highly recommend evaluating anxiety 
symptoms in the context of other PD symptoms, including motor, autonomic, and 
other (neuro)psychiatric symptoms.
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Introduction
Anxiety disorders are present in an estimated 31% of patients with Parkinson’s 
Disease (PD), with generalized anxiety disorder being the most common [1, 2]. 
Around 45% of PD patients suffer from clinically relevant anxiety [3]. Both from 
clinical experience and previous research, anxiety can be linked to fluctuations in 
available dopamine related to timing of PD medication and is often comorbid or 
secondary to depression, psychosis, and cognitive decline [3-5]. Anxiety is therefore 
one of the most prevalent neuropsychiatric features in PD patients and can be very 
debilitating. In addition, its presence is one of the most significant predictors of 
health-related quality of life in PD [6, 7], and greatly impacts caregiver burden [8]. 
Anxiety can worsen motor symptoms, such as tremor and freezing [9, 10] and can 
create a vicious cycle, in which motor symptoms trigger anxiety or distress, which 
can in turn exacerbate motor symptoms. These reciprocal interactions between 
motor and non-motor symptoms are not only seen in clinical practice but are 
supported by scientific research [11-13]. Despite its large impact on patient well-
being and caregiver burden, anxiety in PD is still poorly understood and evidence 
on the treatment of anxiety in PD patients is limited [14, 15].
Since anxiety and other PD-related symptoms are so highly intertwined, diagnosing 
anxiety is complicated by its overlap with motor (e.g., tremor, rigidity, freezing) 
and autonomic symptoms (e.g., excessive daytime sweating) [12, 16]. Self-report 
questionnaires, such as the Beck Anxiety Inventory (BAI), can be used to quantify 
anxiety symptoms [17]. Due to the aforementioned reciprocity, the interpretation of 
the total score on such self-report questionnaires can be complicated. Evaluation of 
the specific symptom dimensions (or subscales of a questionnaire) can be a useful 
approach [18]. One statistical technique for extracting these subscales is principal 
components analysis (PCA). In a previous study in PD patients [19], a factor solution 
of the BAI was not found by using PCA, which might be explained by the great 
heterogeneity of the investigated study population. In a previously conducted PCA 
by our research group, based on a large cohort of patients that were referred to 
our outpatient clinic for movement disorders, we found that the BAI encompasses 
one affective and four somatic factors [18]. A significant association between the 
symptoms of anxiety and depression was found, and severity of motor symptoms 
showed significant associations with the somatic (and not affective) factors of the 
BAI. Another study investigated the dimensionality of the BAI by principal axis 
factoring, and found one distinct PD motor subscale [12].
3
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In the current study we aim to replicate the findings of Rutten et al. [18] in an 
independent sample of PD patients who were specifically referred for specialist 
neuropsychiatric evaluation. Using the same methodology in a different patient 
sample enables us to investigate the generalizability of the previous findings [20].
Methods
Subjects
The data used in this cross-sectional study were routinely collected at the Center for 
Neuropsychiatry in Parkinson’s disease (CNP) of the Amsterdam University medical 
center, location VUmc in Amsterdam, the Netherlands. The CNP is a specialized 
outpatient department for the diagnosis and treatment of PD patients experiencing 
neuropsychiatric symptoms. Patients are referred to the CNP by neurologists, 
general practitioners and specialists in geriatric medicine. Data of 176 patients 
were collected between April 2014 and February 2018. Patients were included if 
they were previously diagnosed with idiopathic Parkinson’s disease and provided 
written informed consent for their clinical data to be used in scientific research. 
Since several patients were included in both the previous and the current databases, 
we excluded overlapping patient data collected within five years after the data 
collection of Rutten et al. [18].
Measurements
Clinical and demographic characteristics
The Montreal Cognitive Assessment (MoCA) was used to screen the patient group 
for possible cognitive decline [21]. The United Parkinson Disease Rating Scale-III 
(UPDRS-III) score was used to assess the severity of motor symptoms [22]. The 
Beck Depression Inventory (BDI) was used to examine self-reported symptoms of 
depression [23]. The BDI cut-off score for clinically relevant symptoms of depression 
is 14 [24].
The patient’s history of psychiatric diagnoses was recorded as well as the psychiatric 
diagnoses given after the diagnostic examination, which was done by clinical 
evaluation by the assessing psychiatrists (OvdH/SR). Due to the time-frame in which 
data was collected, both the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-)IV and the DSM-5 were used [25].
Patient sex, age, time since PD diagnosis (e.g. disease duration), and the use of 
dopaminergic medication (0 = no, 1 = yes) were recorded.
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Anxiety
The BAI is a self-report instrument that consists of 21 items, through which patients 
can report the symptoms of anxiety that they have experienced in the previous 
week. Items are scored on a 4-point Likert scale, which ranges from 0 (not at all) to 
3 (severely), with a total score range from 0 to 63 [17]. The cut-off score used for 
clinically relevant anxiety in PD is > 12 [19].
Statistical analyses
All analyses were performed using SPSS Statistics 22 for Windows with a two-sided 
significance level of p < 0.05. The acceptability of missing values of the BAI and BDI 
was set to less than three missing items, i.e. 16.67%. If this criterion was not met, 
the patient’s data was excluded from further analysis. Mean imputation was used 
for residual missing data of the BAI and BDI. Data were excluded pairwise when the 
total MoCA score and/or the total UPDRS-III score was not available since imputation 
was not considered to be reliable.
PCA was used to assess the dimensionality of the BAI. In PCA, items that share the 
most common explained variance cluster together in factors. In order to determine 
the number of factors that can be reliably extracted, the ‘scree plot’ criterion and 
the Guttman-Kaiser Eigenvalue greater-than-one rule were used. Oblimin rotation 
was used since it was expected that the different factors correlate with each other. 
The resulting factors of the BAI can be considered subscales of the BAI. The scores 
on these subscales were used in further analyses.
The associations between the BAI and its subscales, BDI, MoCA, and UPDRS-III 
were investigated by conducting multiple linear regression analyses. Assumptions 
of normality and homoscedasticity of residuals were checked. Multicollinearity was 
evaluated by calculating the variance inflation factor (VIF) and investigation of the 
correlation matrix.
In the first set of regression analyses, the total BAI score was the dependent variable. 
In the second set, the scores on the subscales of the BAI derived from the PCA 
were the dependent variables. The independent variables were the total score on 
the BDI, UPDRS-III, and MoCA. First, we investigated the association between the 
dependent and independent variables in an unadjusted model. Next, we adjusted 
the model stepwise for age and gender (model 1), use of dopaminergic medication 
(model 2), and the two other independent variables of interest, i.e. the BDI, MoCA, 
and UPDRS-III (model 3).
3




Of the available patient sample of 176 patients, 48 patients were excluded due 
to >16.67% missing BAI-items. Of the remaining 128 patients, five patients were 
excluded due to overlap with the sample of Rutten et al. [18]. Finally, the total sample 
used in our analyses consisted of 123 patients.
Demographic and clinical characteristics
Demographic and clinical characteristics of the patient sample are shown in Table 
1. Due to missing data on the UPDRS-III and unknown disease duration, 14 and 
38 additional patients were excluded in these characteristics data, respectively. 
The majority of patients was male, mean age was 66.1 years. Patients had a mean 
UPDRS-III score of 27.3 and a mean MoCA score of 23.8, with 55.9% of patients 
scoring below the cut-off of 26 points, indicative of cognitive decline [26].
Half of the patients (49.6%) had sought treatment for psychiatric symptoms prior 
to receiving a PD diagnosis. Of this sub-population, 45.5% did so specifically for 
symptoms of anxiety. Currently, the vast majority of the patients (91.9%) received 
at least one psychiatric diagnosis.
Table 1. Clinical and demographic characteristics (N = 123)
Mean SD Range
% Female 38.2
Age 66.1 9.8 34-86
Disease duration (years) (n=85) 8.4 6.9 0-29
MoCA score 23.8 4.7 5-30
UPDRS-III score (n=109) 27.3 14.8 1-76
Total BAI score 20.3 11.4 0-55
Total BDI score 18.2 9.3 1-47
% Use dopaminergic medication 93.5




The mean BAI total score for this patient sample was 20.3 (± 11.4), and 77.4% of the 
patients had a BAI score higher than 12, indicating clinically relevant symptoms of 
anxiety. According to the psychiatrist’s assessment, 65 patients (52.9% of the total 
sample) met DSM-IV or -5 criteria for an anxiety disorder.
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Table 2. Psychiatric diagnoses as given by assessing psychiatrist (N = 123)
Diagnosis given (DSM-IV or –V) %
No diagnosis 8.1
Anxiety disorders 52.9
Due to somatic disorder (PD) 41.5
Panic disorder 6.5
Generalized anxiety disorder 3.3
Social anxiety disorder 1.6
Depressive disorders 41.4
 Due to somatic disorder (PD) 25.2
 Persistent depressive disorder (dysthymia) 0.8
 Major depressive disorder 15.4
Neurocognitive disorder 31.7
Other specified disruptive, impulse-control and conduct disorder* 16.3
Psychotic disorder 12.9
Sleep-wake disorder 15.4
* all patients fulfilling criteria for this DSM category had an impulse control disorder
Of these 65 patients, 79.3% received at least one other psychiatric diagnosis. 
Depressive disorders were the most frequent occurring comorbidity, as they were 
diagnosed in 42.3% of patients with an anxiety disorder. Based on both BAI and BDI 
total scores, 62.4% of the patients had clinically relevant symptoms of both anxiety 
and depression.
Principal component analysis of the BAI
Examination of the scree-plot and the Eigenvalue greater than 1 rule suggested five 
factors. All BAI-items had a loading greater than 0.4 on at least one of the factors 
and therefore all items were included in the factor solution. No items had a loading 
greater than 0.4 on multiple factors.
The five extracted factors were considered subscales with the following labels; 
affective, thermoregulation, cardiopulmonary, unsteadiness and ‘undefined’. The 
last factor included three items (i.e. dizzy/lightheaded, faint/lightheaded, and 
indigestion) that we could not clinically interpret as an evident subdomain of anxiety. 
Therefore, we decided not to label this as a subscale and excluded it from further 
analyses. The factor solution explained a total of 64.6% of the variance, 59.1% 
excluding the last factor, with the affective subscale explaining 35.9% of the total 
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variance. Figure 1 shows the distribution of the BAI items over the five subscales, 
with the corresponding factor loadings.
Associations between anxiety, depression, cognitive and motor dys-
function
The residuals of both the total BAI score and subscales of the BAI had a positively 
skewed distribution, as shown by histograms. Normality was not improved after 
transformation of the data. Therefore, we used the original data for the analyses 
to maintain interpretability of results. Homoscedasticity and non-multicollinearity 
of the data was confirmed. The VIF ranged from 1.02 to 1.44 and the correlation 
matrix is displayed in supplementary table S1.
Table 3 shows the results of the multiple regression analyses with the BAI total score 
and scores on the subscales of the BAI as dependent variable. The final, adjusted 
models are displayed, including all independent variables in the associations with 
the dependent variables. The unadjusted and adjusted models can be found in 
Supplementary table S2.
As displayed in table 3, the BAI total score and the affective subscale of the BAI 
were both significantly associated with the BDI score. The BAI total and affective 
scores were negatively associated with the MoCA score. In the final adjusted model, 
the associations between the MoCA score and BAI total and affective scores were 
no longer statistically significant due to confounding by the BDI score. No other 
significant associations were found.
Discussion
In this study, we replicated the findings of our previous study [18] in an independent 
PD patient sample with neuropsychiatric symptoms necessitating referral to an 
expert neuropsychiatric outpatient clinic.
From the data collected from the current CNP patient sample, PCA uncovered 
four clinically interpretable factors, representing subscales of the BAI (affective, 
thermoregulation, cardiopulmonary, and unsteadiness). As in the results published 
by Rutten et al. [18], there was a partition of psychological and somatic symptom 
dimensions and the highest percentage of the variance was explained by the affective 
subscale. This demonstrates the generalizability to an independent PD sample and 
confirms the robustness of our results. While the affective and thermoregulation 
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subscales were exact replications, the cardiopulmonary and unsteadiness subscales 
showed a slightly different composition to the previously found subscales 
hypotension, hyperventilation, and trembling.
The BAI total score and the BAI affective subscale score were significantly associated 
with the BDI score. This high correlation between the BAI and the BDI was also 
reported in the previous study [18]. This suggests a high co-occurrence of anxiety 
and depressive symptoms [5], as is also supported by Zhu and colleagues [4], who 
found that up to 70% of anxious PD patients also suffer from depression. The BAI 
total score and BAI affective subscale score were also significantly associated with 
the MoCA score. However, in the final adjusted model, this association was no longer 
significant due to confounding by the BDI score, explained by the high correlation 
between the BAI and BDI (see table S1 for Pearson’s correlations between BAI, BDI, 
UPDRS-III, MoCA, and age). In contrast to the previous study [18], no significant 
associations between somatic subscales and motor symptoms were found. The 
current patient sample showed more neuropsychiatric symptoms, but had a similar 
degree of motor dysfunction (see supplementary table S3 for the independent 
samples t-tests results of the comparison of the sample characteristics). The slightly 
different distribution of BAI-items over the somatic subscales might explain the 
absence of the associations with motor symptoms in the current sample.
Based on the BAI total score, 77.4% of the current patient sample showed clinically 
relevant anxiety. However, only 52.9% of patients received a formal DSM-IV or -5 
anxiety diagnosis from the assessing psychiatrist. This could be due to symptom 
overlap and high co-occurrence with depression, in which case a depressive 
disorder might be more fitting with the clinical presentation in some cases. In 
addition, anxiety symptoms can occur in the context of other psychiatric disorders, 
such as psychosis, dementia, and dopamine dysregulation syndrome. Besides 
neuropsychiatric comorbidity, anxiety in PD often has an atypical presentation, 
leading to the symptoms not fitting into the disorders listed in DSM-IV and -5 [27]. 
Another possible explanation is that the severity of anxiety may be overestimated 
by the BAI [16], since motor and autonomic symptoms of PD could have inflated the 
scores on this self-report instrument. Nevertheless, it must also be kept in mind 
that the same motor and autonomic symptoms can mask anxiety symptoms during 
clinical evaluation.
The disentanglement of anxiety from motor symptoms in PD is both scientifically 
and clinically challenging [12, 16]. In our previous study [18], we found that the 
affective subscale was the only factor not associated with autonomic dysfunction, 
3
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as measured with the Scales for Outcomes in Parkinson’s disease – Autonomic 
dysfunctions (SCOPA-AUT), and motor dysfunction as measured with the UPDRS-
III. This is of clinical importance since it could indicate that certain items of the BAI 
should be weighted more heavily when screening for clinically relevant anxiety in PD. 
Therefore, in a post-hoc analysis, we investigated whether the score on the affective 
subscale of the BAI alone was better in predicting an anxiety disorder diagnosis 
given by a psychiatrist compared to the total score of the BAI. We calculated the 
area under the Receiver Operating Characteristic (ROC) curve of both the BAI total 
score and the affective subscale of the BAI in relation to an anxiety disorder diagnosis 
(yes or no). The area under the ROC curve of the BAI total score was 0.77 (sd = 0.04, 
p < 0.001). The affective subscale of the BAI showed an area under the ROC curve 
of 0.75 (sd = 0.05, p < 0.001). We can thus conclude that the BAI total score and the 
BAI affective subscale score have similar power in predicting an anxiety disorder 
diagnosis given by a psychiatrist in this PD patient sample. Using only the score on 
the affective subscale (7 items) in the prediction of an anxiety disorder diagnosis 
saves time and might be more practical compared to using the total BAI (21 items). 
In addition, this subscale might be considered as containing psychological and non-
episodic anxiety items, which suspends the discussion about how to interpret the 
somatic BAI-items.
To evaluate the affective subscale further, comparison with other screening options 
for anxiety in PD is useful. The Movement Disorder Association currently does not 
recommend one specific anxiety screening instrument (latest published research 
from 2008 [28]), but does recommend the non-motor rating scale (the MDS-NMS) 
in which four questions about anxiety are included [29]. Two of those questions 
represent two items of the affective subscale of the BAI, the other two ask about 
panic attacks and social anxiety. Another screening tool for anxiety, the Parkinson 
Anxiety Scale (PAS), is a self-report questionnaire that includes items specifically 
for non-episodic anxiety and avoidance behavior [30]. The PAS excludes almost all 
somatic symptoms of anxiety, except for panic related symptoms (e.g. shortness 
of breath and heart palpitations). All non-episodic anxiety items of the PAS are 
comparable to the items that clustered together in the affective subscale.
This study has some limitations. The BAI focusses mostly on episodic anxiety, 
i.e. symptoms of panic disorder, while non-episodic anxiety, like in generalized 
anxiety disorder, is also common in PD. Unfortunately, autonomic dysfunction 
was not measured in the current patient sample, restricting the investigation of 
its associations with the (subscales of the) BAI. In terms of psychiatric diagnoses, 
this patient sample was not assessed with a structured clinical interview, to 
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systematically check diagnostic criteria for all DSM diagnoses. Such structured 
clinical interviews, however, also risk overdiagnosis due to anxiety features being 
considered as part of a primary anxiety diagnosis, instead of secondary to another 
psychiatric diagnosis or PD-related symptoms of motor or autonomic failure, as can 
be expected in PD patients.
A major strength of this study is that we investigated a sample of PD patients who 
were assessed by two psychiatrists who are specialized in diagnosing anxiety in 
the context of motor and autonomic symptoms in PD patients. We successfully 
replicated the main findings by Rutten et al. [18], which makes these results more 
reliable and generalizable.
Conclusions
In conclusion, anxiety in PD is a complex construct due to symptom overlap and 
interactions with motor and autonomic features of the disease. The 7-item affective 
subscale of the BAI shows potential as a screening tool for non-episodic anxiety in 
PD. It is recommended to evaluate anxiety symptoms in the context of other PD 
symptoms, including motor, autonomic, and other (neuro)psychiatric symptoms.
3
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Supplementary material Chapter 3
Table S1. Matrix of the Pearson’s correlation coefficients (r) for the BAI, BDI, UPDRS-III, 
MoCA, and age.
BAI BDI UPDRS-III MoCA Age
BAI 1.000 0.599** 0.015 -0.248** 0.123
BDI 0.599** 1.000 -0.44 -0.141 0.27
UPDRS-III 0.015 -0.44 1.000 -0.319** 0.306**
MoCA -0.248** -0.141 -0.319** 1.000 -0.519**
Age 0.123 0.27 0.306** -0.519** 1.000
**p-value < 0.01 (2-tailed)
Abbreviations: BAI = Beck Anxiety Inventory; BDI = Beck Depression Inventory; UPDRS-III = Unified 
Parkinson’s Disease Rating Sccale – part three (motor examination); MoCA = Montreal Cognitive 
Assessment. 
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Table S3. Independent samples t-tests results of the comparison of the sample 














BAI 14.2 (9.8) 20.3 (11.4) 6.1 (3.94 – 8.26) 5.58 P<0.001
BDI 11.4 (8.0) 18.2 (9.3) 6.8 (5.03 – 8.57) 7.63 P<0.001
Age 64.5 (10.3) 66.1 (9.8) 1.6 (-.53 – 3.73) 1.48 ns
UPDRS-III 
(n=109)




5.1 (5.6) 8.4 (6.9) 3.3 (1.94 – 4.66) 4.81 P<0.001
Abbreviations: BAI = Beck Anxiety Inventory; BDI = Beck Depression Inventory; UPDRS-III = Unified 
Parkinson’s Disease Rating Sccale – part three (motor examination); MoCA = Montreal Cognitive 
Assessment, n = amount of patients; sd = standard deviation; CI = Confidence Interval; df = degrees 
of freedom; ns = nonsignificant.
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Introduction: Approximately 45% of patients with Parkinson’s disease (PD) experience 
clinically relevant anxiety. Anxiety and motor symptoms are highly intertwined and 
have reciprocal influences. We investigated the associations between motor and 
anxiety symptoms in patients with high levels of anxiety compared to patients with 
low levels of anxiety.
Methods: Data were collected during routine clinical assessments at the outpatient 
clinic for movement disorders. Motor symptoms were measured with the motor 
section of the Unified Parkinson’s Disease Rating Scale (UPDRS-III). A cut-off score 
of 12 on the Beck Anxiety Inventory (BAI) was used to divide patients into high-
anxious versus low-anxious patients. Explorative network analyses and a network 
comparison test were used to investigate the partial correlations between items 
of the UPDRS-III and the BAI, and to statistically compare network architecture 
between the two patient groups.
Results: 316 PD patients were included in the high-anxiety group, versus 253 in 
the low-anxiety group. The high-anxiety group showed significantly worse motor 
and cognitive function, a higher age, and included more female patients. The high-
anxiety group had a higher global strength compared with the low-anxiety group 
(S=7.33, p<0.001). We found no statistically significant differences in strength of the 
connections between motor and anxiety symptoms between both groups.
Conclusion: In spite of clear differences in demographic and clinical profile, we did 
not find differences in the associations between motor and anxiety symptoms, 
comparing high-anxious to low-anxious PD patients. Since associations between 
motor and anxiety symptoms are apparent in both groups, this shows that these 
symptoms are associated, even when patients have no to mild anxiety symptoms. 
These results need to be interpreted with caution and warrant replication in a bigger 
sample.
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Introduction
Parkinson’s disease (PD) is classified as a movement disorder but is also associated 
with non-motor symptoms. These include neuropsychiatric symptoms such as 
depression, anxiety, cognitive decline, and psychotic experiences [1, 2]. A large 
international study of both motor and non-motor symptoms in 411 PD patients 
showed that non-motor symptoms have, as a whole, a greater impact on health 
related quality of life compared to motor symptoms [3]. Martinez-Martin and 
colleagues [3] assessed 545 patients and showed that 98.4% of PD patients reported 
one or more non-motor symptoms. Depression and anxiety symptoms were in the 
top three of most prevalent non-motor symptoms. In PD, motor and non-motor 
symptoms are highly intertwined and show reciprocal influences [3-7]. About 75% 
of patients with fluctuations in motor symptoms experience mood and/or anxiety 
fluctuations in parallel [8]. For example, PD patients can experience anxiety and 
panic attacks during an ‘off’ phase, in which motor symptoms are re-occurring [5].
We previously performed a factor analysis on the Beck Anxiety Inventory (BAI) to 
investigate the different symptom dimensions of anxiety in PD patients [9]. We 
uncovered four ‘somatic’ (containing mostly physical symptoms) and one ‘affective’ 
dimension (containing purely emotional and cognitive anxiety symptoms). A 
regression analysis demonstrated that depressive symptoms were significantly 
associated with the ‘affective’ dimension of the BAI, motor and autonomic symptoms 
were significantly related to the ‘somatic’ dimensions of the BAI. The main results of 
this study were replicated in an independent sample of PD patients that had been 
referred for specialist psychiatric evaluation (under review). These study findings 
demonstrate that some aspects of anxiety in PD are strongly connected to the motor 
symptoms of the disease. However, it is yet unclear which specific characteristics 
of anxiety are responsible for the significant associations with motor symptoms. 
Also, it remains to be determined whether PD patients with high levels of anxiety 
show stronger connections between anxiety and motor symptoms compared to PD 
patients with low levels of anxiety.
An approach that is useful for investigating associations between symptoms is 
network analysis [10]. With this method, it is possible to explore and visualize 
partial correlations between symptoms. This method can establish which symptoms 
are correlated (strongly or weakly, positively or negatively) and can be used to 
compare symptom network architectures between groups [10]. A network analysis 
approaches the multifaceted and complex nature of the relationships between 
anxiety and motor symptoms in PD by calculating the associations between 
4
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symptoms in the context of all other symptoms that are included in the network. 
Using this method, van der Velden and colleagues [11] investigated the influence 
of motor and non-motor symptoms using time-series data of one PD patient and 
showed that higher anxiety scores were longitudinally associated with increased 
rigidity and tremor [11].
To gain more insight in the associations between individual motor and anxiety 
symptoms cross-sectionally, and to investigate whether these associations depend 
on the presence of clinically significant symptoms of anxiety, we performed a 
network comparison analysis on PD patients with high levels of anxiety versus PD 
patients with low levels of anxiety. We expected a significant difference between 
high-anxious versus low-anxious PD patients in symptom network architecture, 
with the high-anxiety group showing significantly stronger associations between 
motor and anxiety symptoms than the low-anxiety group.
Methods
Subjects
Data were collected during routine clinical assessments at the outpatient clinic 
for movement disorders of the Amsterdam University Medical Center (Amsterdam 
UMC), location VUmc, in Amsterdam, the Netherlands, between May 2008 and 
May 2018. In this period, 649 PD patients were assessed. Patients were clinically 
diagnosed with idiopathic PD according to the United Kingdom PD Society Brain 
Bank criteria. A cutoff of 12 on the BAI was used to divide the total patient sample 
into a high-anxiety and a low-anxiety group [12].
All included patients gave written informed consent to use their clinical data for 
scientific purposes. Patients with missing data on the motor or anxiety outcome 
measures were excluded.
Measurements
To describe the patient groups, age and gender were recorded, as well as total 
scores on the Mini Mental State Examination (MMSE), and section III of the Unified 
Parkinson’s Disease Rating Scale (UPDRS-III). Both the MMSE and UPDRS-III were 
assessed by a neurologist in training.
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Scoring of motor symptoms, using the UPDRS-III [16], was performed on a four-point 
Likert scale, ranging from 0 to 3 per item. The UPDRS-III contains 39 items and a 
higher score represents more severe motor symptoms.
Symptoms of anxiety were measured with the BAI. The BAI is a 21-item self-report 
instrument asking for symptoms of anxiety over the past week [13]. Patients answer 
on a four-point Likert scale, ranging from 0 (not at all) to 3 (severely) per item.
Statistical analyses
The analyses were performed in the statistical program R (version 3.6.1, developed 
by the R Core Team, 2015). Differences in descriptive measures were investigated 
using independent t-tests or Mann-Whitney U tests, and chi-square tests where 
appropriate.
The package qgraph was used to perform the network analyses and visualizations 
[14]. Since it concerned ordinal data, a Gaussian Graphical Model with LASSO 
regularization was applied [15]. The tuning parameter, gamma, was set at 0.5 to 
obtain a network structure in which few associations are required to parsimoniously 
explain the covariance among the variables, reducing false positive associations 
[15]. Associations within a network are represented by color-coded lines between 
symptoms, which are green for positive associations and red for negative 
associations. The thicker the lines, the stronger the association between two 
symptoms.
The Network Comparison Test (NCT) was used to investigate differences in 
associations between motor and anxiety symptoms between the two patient 
groups [16]. From the NCT, two types of measures were extracted. The first measure 
concerns global strength, which represents the overall connectedness between 
all symptoms within the network. A higher global strength results from more 
and stronger associations between symptoms. Second, all associations between 
separate symptoms are calculated individually, and can be compared between the 
two patient group networks. The Holm-Bonferroni method was used to correct for 
multiple comparisons.
To investigate the accuracy and stability of our network estimates, a bootstrap 
procedure was applied. Using the R package bootnet, a number of 100 bootstrap 
samples with the nonparametric method was used [15]. The sampling distribution 
was then visually inspected.
4
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It is important to notice that, considering this statistical method, our sample sizes 
are small and these analyses should therefore be considered explorative [17].
Results
Subjects
Of the 649 assessed PD patients, 80 were excluded due to missing data. Using the 
cut-off score of 12 on the BAI, 316 patients were assigned to the high-anxiety group 
and 253 patients were assigned to the low-anxiety group.
We initially matched the two patient groups on age and sex using the matchit 
package, since the NCT is most reliable when two networks of equal sample size are 
compared. However, this resulted in very small sample sizes (n=139 per group) with 
still significant differences in age and sex between the groups. To retain the highest 
possible power we decided to perform our analyses with the largest, unmatched 
sample sizes.
Descriptive statistics
Descriptive and clinical measures of the two patient groups are displayed in table 1. 
The high-anxiety group was older, included more females, and showed significantly 
higher severity of motor impairment and cognitive decline. Since we divided the two 
groups based on anxiety level, there was also an expected difference in severity of 
anxiety symptoms.




Age (sd) 67.3 (9.8)* 65.2 (11.0)*
Sex 44% female** 33% female**
BAI total (sd) 25.5 (10.1)*** 6.7 (3.5)***
UPDRS-III total (sd) 30.4 (20.2)*** 23.0 (11.4)***
MMSE total (sd) 26.7 (3.6)*** 27.7 (3.2)***
* p<0.05; ** p<0.01; *** p<0.001
sd = standard deviation; BAI = Beck Anxiety Inventory; UPDRS = Unified Parkinson’s Disease Rating 
Scale; MMSE = Mini Mental State Examination
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Network comparison analysis
The networks for both groups are displayed in figure 1. In total, the network 
represents the partial correlations between 50 items (i.e. motor and anxiety 
symptoms) and since it concerns a parsimonious network, all visual correlations 
are considered relevant. The network architecture of both the high-anxiety and 
low-anxiety group shows clustering of motor symptoms (i.e. UPDRS-III items) on 
the left side and clustering of anxiety symptoms (i.e. BAI items) on the right side. 
Resting tremor as well as action tremor items are somewhat separated from the rest 
of the UPDRS-III items. The symptoms within the networks of both patient groups 
are mainly positively correlated, which is represented by the green connective lines.
There is a significant difference between the high-anxiety and low-anxiety patient 
group networks in global strength (S=7.33, p<0.001), with the high-anxiety group 
showing higher global strength (20.16) compared to the low-anxiety group (12.83). 
This difference is mostly driven by the higher global strength (i.e. more and stronger 
connections) amongst the BAI items, as can be seen in figure 1. Also, the connections 
between the UPDRS-III items appear stronger in the high-anxiety patient group.
Explorative visual inspection of the specific connections between motor and anxiety 
symptoms shows correlations between BAI item 12 (i.e. trembling hands) and resting 
tremor items of the UPDRS-III. Also, BAI item 8 (i.e. unsteadiness) is associated with 
UPDRS-III items related to gait and posture. We found no statistically significant 
differences between the two patient groups concerning correlations between the 
motor and anxiety items.
Concerning the stability of the networks, bootstrapped confidence intervals are wide 
(figures S1 and S2 in the supplementary materials) in both patient group networks.
Discussion
We investigated the differences in symptom network architecture focusing on the 
connections between motor and anxiety symptoms in PD patients with high levels 
of anxiety versus PD patients with low levels of anxiety.
The high-anxious compared to the low-anxious PD group networks differed in 
global strength. This was expected, since we selected the groups on the amount and 
severity of anxiety symptoms, resulting in more and stronger connections especially 
amongst the BAI items of the high-anxiety group network. Previous research 
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Figure 1a. Network analysis graphs. High-anxious PD patient group. The blue circles represent 
the motor symptoms as measured with the UPDRS-III, the red circles represent the anxiety 
symptoms as measured with the BAI.
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Figure 1b. Network analysis graphs. Low-anxious PD patient group. The blue circles represent 
the motor symptoms as measured with the UPDRS-III, the red circles represent the anxiety 
symptoms as measured with the BAI.
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showed that higher anxiety levels are associated with more motor disability. The 
presence of more and stronger connections amongst the UPDRS-III items in the 
high-anxiety group network visually represent this, and contribute to the difference 
in global strength [3-5, 7, 8].
Visual inspection shows that BAI items 12 and 8 (trembling hands and unsteadiness, 
respectively) are connected with UPDRS-III items related to tremor, gait, and posture 
(see figure 1) in both patient groups. In contrast to our hypothesis that connections 
between motor and anxiety symptoms are stronger in PD patients with more severe 
anxiety, these connections do not differ in strength between the high-anxious 
and low-anxious PD groups. As these connections between symptoms appear 
to be present independent of anxiety level, a possible explanation for the similar 
connectedness between UPDRS-III and BAI items, is that they both quantify the 
same symptom, independent of its etiology. For example, BAI item 12 (trembling 
hands) measures a tremor in the context of anxiety, and UPDRS-III item 20 (resting 
tremor) measures a tremor in the context of PD symptomatology. However, whether 
they often appear together as separate symptoms or appear to measure one 
and the same symptom independent of its etiology cannot be tested here and is 
therefore speculative [17].
We found significant differences in descriptive and clinical characteristics between 
the patient groups. The high-anxiety group was older, included more females, 
and showed significantly more severe motor impairment and cognitive decline. 
The group difference in cognitive functioning is in line with what is seen in clinical 
practice. In general, PD patients with cognitive dysfunction are more anxious [18, 
19]. The group difference in gender distribution is also in line with clinical practice 
and previous research, which shows that females show higher levels of anxiety 
compared to men [20, 21]. In spite of these clear differences in clinical profile, the 
connections between the motor and anxiety items were similar. This indicates that 
in this cross-sectional dataset certain motor and anxiety symptoms are intertwined 
independently of anxiety level and these symptoms are therefore important in 
the differential diagnosis of anxiety in PD. For example, when motor symptoms 
are very much apparent, anxiety symptoms might also be more apparent. When 
these anxiety symptoms mostly include items that appear to represent motor 
symptoms (such as BAI-items 8 and 12), patients might not be particularly anxious 
and treatment should be focused more on the motor symptoms.
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Methodological considerations
Our initial plan to match the two patient groups on age and sex resulted in small 
sample sizes (n=139) without solving the differences in demographic and clinical 
variables. We therefore decided to perform our analyses with the largest sample 
sizes to retain the highest possible power. In network analysis, it is yet to be 
determined what is considered a satisfactory sample size [17]. It is suggested to 
perform network analysis on the largest samples since the networks are then 
estimated more accurately [15]. Relatively small sample sizes are a well-known issue 
in clinical research and with this it is considered challenging to gain an accurate 
estimation of a network [15], which was also the case in the present study. Both 
the low-anxious and high-anxious patient group showed an instable network, 
represented by the wide bootstrapped confidence intervals (figure 2), which limited 
us to draw reliable conclusions. In addition, we selected the patient groups on a 
total score of a questionnaire that was also directly represented as symptoms in 
the networks, which might have increased false positive associations known as 
Berkson’s bias [22]. To avoid false positive results as much as possible, we conducted 
tuned analyses to gain parsimonious networks, and we corrected for multiple 
comparisons.
Obviously, the symptoms in our network are dependent on the items from the 
data sources (i.e. clinical assessments or questionnaires) on which they are based. 
Our network might therefore never be ‘complete’ (i.e. include all symptoms of the 
participating patients) and can involve different items that might measure the same 
symptoms, as is also discussed more in depth in the previous section. In addition, 
there might be other variables that influence the associations between items that 
were not accounted for, such as within-person variability and use of medication.
We studied motor an anxiety symptoms in PD as static measures using a cross-
sectional approach. Therefore, we were not able to determine how these symptoms 
interact over time, as is especially relevant in the context of response fluctuations 
during the day [6, 11]. Network analysis may be very useful to visualize fluctuations 
of motor, autonomic and neuropsychiatric symptoms over time, using high-frequent 
individual time-series data from ecological monitoring assessment tools. It would 
be interesting to apply this statistical method to these response fluctuations and 
investigate the interactions between motor and anxiety symptoms more in depth. 
This also enables the study of direct effects of medication and environmental factors 
on the network architecture over time.
4




In this explorative network comparison analysis, we found a higher global strength 
in the high-anxious PD patients. No differences were found in the associations 
between motor and anxiety symptoms in high-anxiety versus low-anxiety PD patient 
groups. The two groups differed in multiple descriptive and clinical characteristics, 
which is representative for clinical practice and indicates that specific motor and 
anxiety symptoms are intertwined independent of anxiety level. Due to the small 
sample sizes, instability of the network structures, and possible Berkson’s bias, 
these results need to be interpreted with caution. Further research is necessary to 
replicate in an independent bigger sample and to understand network architecture 
characteristics related to response fluctuations over time.
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Supplementary material Chapter 4
Figure S1. Bootstrapped means with confidence intervals of the strengths of the associations 
between symptoms in the low-anxiety patient group.
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Figure S2. Bootstrapped means with confidence intervals of the strengths of the associations 
between symptoms in the high-anxiety patient group.
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Aims: We studied the longitudinal associations between Freezing of Gait (FoG), 
Fear of Falling (FoF) and anxiety, and how these associations are influenced by 
confounding factors.
Materials & methods: We analysed longitudinal motor and non-motor measurements 
from 153 Parkinson’s disease (PD) patients. Possible confounding factors were 
divided into three subgroups: demographics, disease characteristics, medication 
use and adverse effects of medication.
Results: All crude associations between FoG, FoF and anxiety were significant and 
remained so after adjusting for confounders. When analysing FoF and anxiety 
together as independent variables, the association between FoG and FoF remained, 
and the association between FoG and anxiety diminished.
Conclusions: We confirm the complex interactions between motor and non-motor 
symptoms in PD, and plead for a multidisciplinary approach.
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Introduction
Motor features, such as tremor, bradykinesia, hyperkinesia, rigidity, and gait 
disturbance have been the main focus in clinical management in Parkinson’s disease 
(PD) for a long time. However, in the last decades, there is increasing awareness of 
the high prevalence and daily impact of non-motor symptoms, such as anxiety [1, 
2]. More recently, reciprocal interactions between motor and non-motor symptoms 
are being investigated [2-4], leading to multidisciplinary treatment approaches [5].
One of the most disabling motor features of PD is freezing of gait (FoG), an episodic 
disturbance of gait pattern that affects up to 60% of PD patients, where they report 
feeling stuck or glued to the floor [6]. Giladi et al. [7] define FoG as a brief, episodic 
absence or marked reduction of forward progression of the feet despite the 
intention to walk, including episodes in which the patient cannot initiate gait and 
arrests in forward progression during walking (“turn” and “destination” hesitation), 
as well as episodes of shuffling forward with steps that are millimetres to several 
centimetres in length. FoG severely affects quality of life and daily functioning and 
can result in falls and injuries [8, 9].
In clinical observations, the motor feature FoG is often accompanied by non-motor 
features such as fear of falling (FoF) [6], and cross-sectional studies suggest they 
may aggravate each other [3, 4]. FoF can be described as a lasting patients’ loss of 
confidence in balance abilities [10]. With an estimated prevalence in PD of 35-59%, 
FoF is a permanent health concern inducing avoidance and restriction of activities 
and social life with a significant impact on the patient’s independence [11].
Anxiety is another non-motor feature of PD which also contributes to reduced quality 
of life [12]. Anxiety has only recently received attention in the PD literature, despite 
the estimation that up to 40% of all PD patients experience clinically significant 
anxiety symptoms [13-15]. It occurs in various forms, such as social phobia, panic 
disorder, general anxiety disorder (GAD) and anxiety related to medication-induced 
fluctuations such as wearing-off [13, 16]. Studies about the association between FoF 
and anxiety in PD is scarce, however, anxiety has been described as a predictor of 
avoidance behaviour in PD patients with FoF [17].
The interaction between FoG and anxiety has been described in clinical practice as a 
vicious cycle, where anticipation of a FoG episode can trigger an experience of panic 
and the resulting increase in anxiety symptoms can in turn, trigger or exacerbate 
FoG [2, 18]. Recent experimental research supports the notion that anxiety is an 
5
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important contributor to FoG [3]. In addition, recent studies in PD suggest a PD-
associated neurobiological susceptibility to anxiety [19, 20] and involvement of 
serotonergic [21], GABA-ergic and glutamatergic systems [22], in addition to the 
dopaminergic circuits.
Thus far, studies have focused on the cross-sectional association between FoG, FoF 
and anxiety. Longitudinal study designs take the levels of FoG, FoF and anxiety at 
onset into account, as well as the interaction between these symptoms over time. 
Therefore, a longitudinal study is more likely to investigate reciprocal associations 
between these symptoms. Moreover, other demographic and clinical factors may 
be more accurately reflected than a cross-sectional study by virtue of its scope.
The aim of this research was to study the longitudinal associations between FoG, 
FoF and anxiety, and how these associations are influenced by confounding factors 
such as demographics, disease characteristics, medication and adverse effects of 
medication. These results can guide professionals in order to identify and advise 
patients along the line of therapy, and to optimize diagnostic and treatment 
decisions.
Methods
Longitudinal data from the RESCUE trial (Rehabilitation in Parkinson’s disease: 
Strategies for Cueing) was used. RESCUE was an observer-blinded, randomized, 
clinical trial with a crossover design, to evaluate the effects of home/based cueing 
training on gait and related activity in 153 PD patients [23, 24]. We refer to the study 
of Nieuwboer and colleagues [24] for the inclusion and exclusion criteria.
Study design
Subjects were randomly allocated to an early or late intervention group by an 
independent person not involved in the study. The early intervention group 
(n = 76) received a 3 week home cueing program using a prototype cueing device, 
followed by 3 weeks without training. The late intervention group (n = 77) underwent 
the same intervention after a three week waiting list period. After the initial 6 
weeks, both groups had a 6 week follow-up without training. Outcome measures 
included motor impairment scores, questionnaires and physical activities, and 
were measured every 3 weeks by blinded researchers [23-25]. In addition to the 
outcome measures, demographic and disease related measures were assessed at 
baseline (T1). All assessments were executed by a blinded researcher in the patients’ 
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homes, at the same time of day in the “on” [26] phase, approximately 1 hour after 
medication intake. Figure 1 represents the RESCUE trial study design in which the 
T1-T4 measurements represent the time points on which the outcome measures 
FoG, FoF, and anxiety were assessed.
Figure 1. Timeline of the RESCUE trial with cross-over design. T1-T4 represent the moments 
on which outcome measures have been collected.
Outcome measures
The Freezing of Gait Questionnaire (FOGQ) is a validated questionnaire which 
assesses the FoG from a patient’s perspective [27, 28]. The FOGQ consists of 
six questions which refer to the patient’s experiences, related to FoG, in the 
previous week. Each question has a 5-point scale, where 0 represents an absence 
of symptoms and 4 represents the highest prevalence or severity of symptoms. 
Consequently, the total score on the FOGQ ranges from 0 to 24 points. The higher 
the score, the more pronounced the FoG.
FoF was assessed with the Falls Efficacy Scale (FES) [29]. The FES is a questionnaire to 
assess an individual’s confidence and its self-efficacy to avoid a fall. The FES consists 
of 13 questions. Each question has an 11-point scale, where 0 represents an absence 
of confidence and 10 represents complete confidence during the mentioned activity. 
The inverse scale of the questionnaire was used, thus the higher the score the more 
FoF.
For measuring anxiety symptoms, we used the Hospital Anxiety and Depression 
Scale (HADS), a valid and responsive tool for measuring anxiety and depressive 
symptoms in PD over the past four weeks [13, 30]. The HADS is a self-report 
questionnaire that consists of seven anxiety and seven mood items. The total score 
in each subscale ranges from 0 (absence) to 21 (maximum). We used the scores of 
the anxiety (HADSA) and mood (HADSD) subscales separately. The reliability of the 
HADSA, for use in PD, is good with a Cronbach’s alpha of 0.82 and an Intraclass 
Correlation Coefficient of 0.80 [30].
5




Linear mixed model analyses were used to assess the longitudinal associations 
between the outcome measures. Because repeated measurements, four time-points 
over 12 weeks, were nested within subjects, multilevel analyses is most appropiate 
[31]. Concerning missing values, multilevel analysis is quite good in handling missing 
data in the outcome variables because of this estimating method [32].
This longitudinal study consists of four repeated measurements of 153 patients, 
which means that the number of dummy variables would be large, compared to the 
total number of observations, and therefore it would be impossible to analyze the 
data in this way. In multilevel analysis the variance of the intercepts is estimated, not 
the separate intercepts for each patient. In this way, only one variance parameter 
(the ‘random’ intercept) is estimated. Equally, when it comes to the change of the 
outcome measures over the time points, the variance of the slopes is the one 
parameter that is estimated and further used in the analysis.
Separate linear mixed model analyses were used to analyse the following 
longitudinal univariable associations: 1) between FoG and FoF; 2) between FoG and 
anxiety, in which the first-mentioned variable (FoG) of the associations is dependent, 
and the latter the independent variable. Subsequently, the longitudinal multivariate 
association 3) between FoF and anxiety together as independent variables, and FoG 
as dependent variable, was analysed to investigate which variable is contributing 
the most to the association with FoG.
To investigate possible confounding factors, all associations were adjusted for the 
following groups of variables:
* Demographics; including gender [33-35], age [36] and body mass index [37-40].
** Disease characteristics; including UPDRS motor section 3 [41], disease duration 
[42], H&Y, HADSD [43], falls diary, the speed of the 10 meter walking test [44], standing 
balance (single leg stance test [45]), monitored physical activity (accelerometer), 
fatigue (multidimensional fatigue inventory (MFI)), cognitive executive function [46] 
(Mini Mental State Examination and Brixton Test Scaled score [47]).
*** Medication use; including Levodopa, dopamine agonist, catechol-O-methyl 
transferase inhibitor (Entacapone), selegiline and other (the type of medication 
that a patient used was registered), and adverse effects (using the UPDRS part IV B).
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All analyses were adjusted for treatment allocation and performed with MLwiN 
(version 3.00). A two-tailed significance level of 0.05 was used.
Results
Table 1 shows the baseline characteristics of the 153 included PD patients. One 
patient dropped out 3 weeks after randomization because of a necessary change of 
drug treatment. Most patients had mild to moderate disease severity. At baseline, 
41% of patients had at least weekly freezing episodes, defined by a score >1 on 
item 3 of the FOGQ and a quarter reported clinically relevant anxiety symptoms, 
considering the cut-off of 8 on the HADSA [48].
Table 2 shows the mean and standard deviations of the outcome measures over all 
four time points. For elaborate description of the intervention effects we refer to 
the study of Nieuwboer and colleagues [24]. Briefly, after receiving the intervention, 
only patients who experienced at least weekly freezing, reported a reduction in 
severity of FoG. In the total sample, greater confidence as measured with the FES 
and no significant changes in anxiety were reported.




T1 T2 T3 T4
FOGQ
[range: 0-24] 8.7 (5.3) 8.2 (5.2) 7.5 (5.1) 8.3 (5.3)
FES
[range: 0-130] 81.6 (27.9) 84.6 (27.7) 86.9 (27.0) 84.1 (28.6)
HADSA
[range: 0-21] 6.9 (3.9) 6.5 (3.7) 6.4 (3.8) 6.7 (3.8)
Abbreviations: sd = standard deviation; FOGQ = Freezing of Gait Questionnaire; FES = Falls Efficacy 
Scale; HADSA = Hospital Anxiety and Depression Scale – Anxiety.
Figure 2 displays the crude analyses results (regression coefficients) of the 
univariate associations 1) between FoG and FoF, 2) between FoG and anxiety, and 
the multivariate association 3) between FoG (dependent) and FoF and anxiety 
(independent variables). All crude associations were positive and significant.
5
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Table 1. Patients characteristics at baseline (N=153).
Median (IQR)
Demographics
Gender a 88 male/65 female
Age (years) 68 (11)
Body Mass Index 24.21(4.16)
Disease characteristics
Disease duration (years) 8 (8)
Hoehn & Yahr during on 3 (1)
Hoehn & Yahr II/III/IV during on a 71/64/18
Unified Parkinson’s Disease Rating Scale
 total score, during ‘on’ state
54 (17)
UPDRS I during on 3 (2)
UPDRS II during on 16 (8)
UPDRS III during on 32 (14)
Hospital Anxiety and Depression Scale - depression subscale 7 (5)
Brixton Test Raw score 21 (12)
Brixton Test Scaled score 4 (4)
Mini Mental State Examination 29 (3)
Multidimensional Fatigue Index 64 (25)
Static activity (% time) 90 (12)
Dynamic activity (% time) 10 (11)
Speed of 10-meter walking test (m/s) 0.85(0.29)
Single leg stance test left (sec) 7.64(17.3)
Single leg stance test right (sec) 8.68 (17.88)
Medication
Levodopa (mg) 400 (350)
Dopamine agonist a 105
Selegeline a 22
Entacapone a 37
Medication other a 46
Adverse effects
UPDRS IV (ON) 2 (4)
Abbreviations: IQR = Interquartile range, UPDRS = Unified Parkinson’s Disease Rating Scale, a 
Expressed as number of patients.
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Figure 2. Crude analyses results of the univariate associations 1) between FoG and FoF, 2) 
between FoG and anxiety, and the multivariate association 3) between FoG (dependent) and 
FoF and anxiety (independent variables). Abbreviations: FOGQ = Freezing of Gait Question-
naire; FES = Falls Efficacy Scale; HADSA = Hospital Anxiety and Depression Scale; β = beta 
regression coefficient; FoG = Freezing of Gait; FoF = Fear of Falling.
The regression coefficient between FoG and FoF (analysis 1) showed the greatest 
change when adjusted for disease characteristics. The greatest change in regression 
coefficient in the association between FoG and anxiety (analysis 2) was seen after 
adjustments for medication and adverse effects. Table 3 shows the results of all 
crude and adjusted univariate associations.
When analysing FoF and anxiety together as independent variables (analysis 3, see 
table 4), the association between FoG and FoF remained as in the univariate analysis 
(analysis 1), while the association between FoG and anxiety weakened (as compared 
to analysis 2). In this multivariate association model, as in the separate univariate 
associations, the regression coefficient between FoF and FoG decreased the most 
after adjustment for disease characteristics. In addition, the regression coefficient 
between anxiety and FoG decreased the most after adjustment for medication and 
adverse effects, as was also seen in the univariate association.
Discussion
To our knowledge, this is the first study to investigate the longitudinal associations 
between FoG, FoF, and anxiety in a large cohort of PD patients. As expected, crude 
associations between FoG and FoF, and between FoG and anxiety were positive and 
significant. Adjustments for disease characteristics, medication and adverse effects 
showed the greatest decrease in the strength of these associations. When analysing 
5
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Table 3. Crude and adjusted regression coefficients for the following relationships: 1) 
between FoG and FoF, 2) between FoG and anxiety.





Crude 0.06 0.05 to 0.07 <0.001
Adjusted group 1* 0.06 0.05 to 0.08 <0.001 0%
Adjusted group 2** 0.03 0.01 to 0.05 0.001 -50%
Adjusted group 3*** 0.04 0.03 to 0.05 <0.001 -33,3%
2) FoG/anxiety
Crude 0.28 0.17 to 0.38 <0.001
Adjusted group 1* 0.21 0.10 to 0.32 0.001 -25%
Adjusted group 2** 0.18 0.08 to 0.29 0.002 -35,7%
Adjusted group 3*** 0.10 0.001 to 0.19 0.048 -64,3%
Abbreviations: FoG = Freezing of Gait, FoF = Fear of Falling, β = regression coefficient, CI = confidence 
interval. * Adjusted for demographics, **Adjusted for disease characteristics, ***Adjusted for 
medication and adverse effects.
Table 4. Crude and adjusted regression coefficients for the relationship 3) between FoG 
(dependent) and FoF and anxiety (independent variables).
Crude
 FoG
β 95% CI p-value
FoF 0.05 0,04 to 0.07 <0.0001
Anxiety 0.16 0.06 to 0.26 0.003
Adjusted group 1*
Change in β compared 
to crude
FoF 0.06 0,04 to 0.07 <0.0001 +20%
Anxiety 0.11 0.01 to 0.22 0.0363 -31,3%
Adjusted group 2**
FoF 0.03 0,02 to 0.05 <0.0001 -40%
Anxiety 0.16 0.05 to 0.26 0.0034 0%
Adjusted group 3***
FoF 0.038 0,02 to 0.05 <0.0001 -24%
Anxiety 0.042 0.05 to 0.14 0.3816 -73,7%
Abbreviations: FoG = Freezing of Gait, FoF = Fear of Falling, β = regression coefficient, CI = confidence 
interval. * Adjusted for demographics, **Adjusted for disease characteristics, ***Adjusted for 
medication and adverse effects.
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FoF and anxiety together as independent variables to investigate which variable is 
contributing the most to the association with FoG, the regression coefficient of the 
contribution of anxiety decreased.
In the small but evident contribution of FoF to FoG (analysis 1), the confounding 
effects of disease characteristics and medication and adverse effects may be 
explained by the fact that disease characteristics influence both FoG and FoF, and 
that FoG may occur in the ‘on’, ‘transition’ and ‘off’ state [8]. In their cross-sectional 
study comparing PD patients (n=58) with age-matched healthy controls, Adkin et al. 
[49] reported that FoF correlated positively with gait and balance instability in PD. 
Current FoG treatment proves to be insufficient, since 70% [8] of the fall incidents 
occur during a FoG episode. Clearly, FoF and FoG are highly related to one another, 
and it appears that the state (‘on’ and ‘off’) plays an important role in this association.
The positive association between FoG and anxiety (analysis 2) remained significant 
after adjusting for demographics; disease characteristics; medication and adverse 
effects. This finding, using a longitudinal design, is in line with the experimental 
study of Ehgoetz Martens et al. [3], who showed that anxiety directly resulted in 
FoG. Using a cross-sectional design, Lieberman [50] found a correlation between the 
presence of FoG, anxiety and panic scores in PD patients (n=109). In our PD cohort, 
a quarter of the patients reported clinically relevant anxiety symptoms, which rises 
to the assumption that even without high anxiety scores, the impact of anxiety on 
FoG is evident and might even cause episodes of FoG.
When analysing the multivariate association of FoF and anxiety with FoG (analysis 3), 
the contribution of anxiety diminished as the contribution of FoF remained the same 
in comparison with the univariate associations. Therefore, the univariate association 
between FoG and anxiety is largely explained by FoF. One might speculate about 
the direction of the associations, where the most logical direction resulting from 
our analyses would be from anxiety to FoF to FoG. As Rahman and colleagues 
[17] showed, anxiety is a predictor for avoidance behaviour in PD patients who 
experience FoF. FoF [11] and anxiety [51] both can lead to avoidance and restriction 
of activities and social life, and we speculate that this behavior will aggravate FoF 
and lead to even more physical decline. Further research is necessary to investigate 
the possible mediating effect of anxiety on the relationship between FoF and FoG.
We found that crude associations between FoG and FoF and between FoG and 
anxiety (analyses 1 & 2) remain significant after adjustment for demographics 
and disease characteristics. Adjusting the multivariate model (analysis 3) for 
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medication and its adverse effects renders the relationship between FoG and 
anxiety insignificant. FoG is easily exacerbated by multiple factors such as disease 
progression [42], cognitive dysfunctions such as attention [52], long-term use of 
medication, fluctuations and adverse effects [8]. Our results confirm that FoG 
should probably not be addressed with only drug treatment [53], since its adverse 
effects also play an important role. When adjusting the multivariate model for 
disease characteristics, the contribution of FoF to FoG diminishes (although remains 
significant). A low acitivity level has been described as a possible confounder in FoF 
and FoG [51]. FoF studies unrelated to PD show conflicting results, regarding the 
relationship between FoF and physical deterioration [65,66]. These studies in elderly 
without PD reported that FoF is related to physical inactivity and an increased risk 
of falling. In our PD cohort, low activity levels were also found (dynamic activity (% 
time) median = 10, IQR = 11).
With regard to the effect of medication and adverse effects on the reported 
associations between FoG, FoF, and anxiety, literature on response fluctuations is 
relevant. With disease progression and chronic exposure to levodopa, many patients 
develop a range of levodopa-induced motor and non-motor response fluctuations, 
including wearing-off. Patients with wearing-off symptoms report higher depression 
and anxiety scores in the ‘off’ state, as compared to the ‘on’ state [54]. In addition, 
panic attacks, which represent a high level of anxiety, are more frequent in the ‘off’ 
than in the ‘on’ state [55, 56]. Non-motor symptoms, such as anxiety, can fluctuate 
with pulsatile dopaminergic treatment. Also, non-motor fluctuations can vary 
unpredictably during the day [57]. The here reported effect of medication and its 
adverse effects in our FoG – anxiety association may be explained by the fact that 
higher anxiety and depression scores are related to complications of medication 
[51]. Medication and its adverse effects seem to influence both FoG and anxiety 
symptoms [58] and their association.
Psychological approaches, such as cognitive behavioral therapy, explicitly focus on 
anxiety symptoms, which are typically seen separate from the motor symptoms. 
However, due to the mutual interactions between FoG, FoF, and anxiety, and the 
impact of medication and its adverse effects, this artificial separation between 
psychological and somatic health care seems unnatural and may prevent optimal 
diagnostics and treatment. An integrated treatment with psychological and 
physiotherapeutic elements is necessary in order to address the interactions 
between motor and non-motor symptoms. For example, the body awareness 
(BEWARE) training [5] is designed to specifically address these PD related problems.
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Study Limitations
Some limitations need to be acknowledged. Recall bias for the questionnaires is 
a limitation that must be considered. Also, the questionnaires contain different 
periods in time to which the questions apply, which might have altered the direct ‘in 
the moment’ symptom associations. For example, the FOGQ measures symptoms 
of freezing over the past week, the HADS measures anxiety symptoms over the 
past four weeks, which represents a longer period of time as compared to the 
FOGQ. Conclusions about cause-and-effect relationships can therefore not be 
made. Caution must be taken in generalizing the current findings to the general PD 
population, since this cohort had specific inclusion- and exclusion criteria.
Starkstein and colleagues [59] indicate that increased depressive symptoms and 
anxiety often co-exists. In our study, PD patients were excluded when having a 
HADSD ≥ 8 which may have resulted in a study sample with relatively mild anxiety 
and mood disturbances. However, the results are robust within this large sample 
of PD patients and it is to be expected that an even stronger mutual interaction 
between FoG-FoF-anxiety could be found with higher levels of depressive and 
anxiety symptoms.
Conclusion
Our findings, based on a longitudinal design, show positive associations between 
FoG, FoF, and anxiety, suggesting that these symptoms interact and may aggravate 
each other. These reported interactions between motor and non-motor problems 
in PD underline the importance of an integrated interdisciplinary approach in 
diagnostics and treatment in these patients.
Future perspectives
The findings of our study contribute to increased awareness of the reciprocal 
interactions between motor and non-motor symptoms. This insight should lead 
to more multidisciplinairy oriented approaches in the diagnostics and treatment, 
such as the BEWARE training [5], aimed to learn how to deal with the motor and 
non-motor aspects of symptom fluctuations in PD.
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Objective: Psychological distress has a high impact on quality of life in patients with 
multiple sclerosis (MS), Parkinson’s disease (PD), and Huntington’s disease (HD). 
Studies have shown that cognitive behavioral therapy (CBT) and mindfulness-based 
therapies (MBTs) are successful in reducing psychological distress in patients with 
anxiety, depressive, and chronic somatic disorders. We aimed to investigate the 
effectiveness of these therapies in MS, PD, and HD patients.
Methods: We performed a comprehensive literature search in PubMed, PsycINFO, 
Embase and the Cochrane Central Register of Controlled Trials up to March 2018. 
Randomized controlled trials (RCTs) investigating a CBT or MBT and reporting 
psychological outcome measures were included. Two separate meta-analyses 
were performed; one on studies comparing psychological therapy with a treatment 
as usual or waitlist condition and one on studies with active treatment control 
conditions.
Results: The first meta-analysis (N = 12 studies, 8 in MS and 4 in PD populations) 
showed a significant effect size of g = 0.51 in reducing psychological distress. The 
second meta-analysis (N = 7 studies, in MS populations) showed a mean effect 
size of g = 0.36. No RCTs were found in HD populations. The overall quality of the 
included studies was low and considerable heterogeneity was found. No evidence 
was found for publication bias.
Conclusion: CBT and MBTs have a small to moderate effect on reducing 
psychological distress in patients with PD and MS. However, more research with 
better methodological quality and larger study samples is warranted, especially in 
HD patient populations.
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Introduction
Progressive neurological disorders, such as Multiple Sclerosis (MS), Parkinson’s 
disease (PD) and Huntington’s disease (HD), are often accompanied by psychological 
distress [1-3]. Psychological distress can be defined as negative mental health states 
and includes anxiety and depressive symptoms. Psychological distress has a higher 
impact on the quality of life of both the patients and their caregivers as compared 
to the physical symptoms that accompany the diseases [4, 5].
The resemblance between MS, PD and HD includes the progressive nature of 
the disease, uncertainty on disease course, and incurability (only symptom 
reduction is possible), which contribute to psychological distress. In addition to 
these factors, psychological distress can arise from physical symptoms such as 
spasms, rigidity, and autonomic dysregulation, resulting in a vicious circle where 
physical and psychological symptoms reinforce one another. On the neurobiological 
level, frontostriatal circuits are affected by the disease, causing disruptions in 
cognition, affect, motivation, behavior, and stress regulation [6, 7]. Because of 
these similarities, it is likely that these three patient populations can equally benefit 
from psychological treatments. This hypothesis is supported by the finding that a 
standardized psychosocial self-management program proved to be effective in a 
variety of chronic diseases, including MS, PD, and HD [8].
A considerable number of studies has investigated potential effective treatments 
for psychological distress reduction. These treatments are cognitive behavioral 
and mindfulness-based. In an extensive review and meta-analysis, Hofmann and 
colleagues [9], showed that cognitive behavioral therapy (CBT) is an effective 
treatment for psychological distress and, more specifically, anxiety symptoms in 
patients with psychiatric and medical conditions. Besides classical CBT, problem 
solving and self-management therapies are also considered CBT-based since 
these interventions are based on the same principles. In PD patients, CBT also 
showed positive effects in treating anxiety and depressive symptoms [10-12]. In 
MS, Dennison and colleagues [13] concluded that CBT is effective in improving 
the management of somatic symptoms and psychological distress. According to 
Novak and Tabrizi [14], depression and anxiety are usually treated with medication 
in HD patients, but CBT is also effective in well-selected patients that experience 
mild symptoms and who have insight in their psychological problems. However, no 
controlled studies have been performed in this patient group.
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Besides CBT, mindfulness-based treatments (MBTs) receive increasing attention 
in clinical practice. Mindfulness involves ‘paying attention in a particular way: 
on purpose, in the present moment, and non-judgmentally’ [15]. MBTs include 
mindfulness-based stress reduction, mindfulness-based cognitive therapy, 
meditation, and acceptance and commitment therapy. MBTs have been proven to 
be effective in reducing anxiety and depressive symptoms in patients with anxiety 
and depressive disorders [16], and patients with chronic pain [17]. Also, small to 
moderate effect sizes in improving mental health were found in populations with 
different chronic somatic diseases [18, 19], and medium effect sizes were found in 
MBTs for MS patients [20].
To reduce psychological distress in patients with progressive neurological disorders, 
CBTs and MBTs might thus be of potential benefit. Since these interventions are 
considered treatment options, it is warranted to investigate their effectiveness. In 
order to establish the efficacy of CBTs and MBTs on reducing psychological distress 




A comprehensive literature search was conducted in PubMed, PsycINFO, the 
Cochrane library and EMBASE through March 2018. In addition, ClinicalTrials.gov 
was searched for completed but unpublished studies. The following keywords 
were used: “Parkinson”, “Huntington”, “Multiple Sclerosis”, “psychological distress”, 
“stress reduction”, “distress”, “depressive symptoms”, “anxiety symptoms” (see 
the supplementary material for the complete search string). Besides the database 
searches, recent meta-analyses [21-23] were read to find additional studies. Two 
researchers (IG, SR) independently selected the studies for inclusion and when they 
disagreed a consensus was made.
Inclusion criteria for the meta-analyses were:
• Patients: a study population of MS, PD, or HD patients.
• Intervention: the examination of a CBT- or MBT-based intervention.
• Comparison: the intervention was compared with a waitlist or treatment-
as-usual (TAU) condition, or with another active form of therapy. Only 
randomized controlled trials (RCTs) were included in this meta-analysis.
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• Outcome: availability of questionnaires that measure anxiety and/or 
depressive symptoms, or general mental health. These data should allow 
the calculation of standardized mean differences (post-treatment means, 
standard deviations, and number of participants; or other statistics that 
allowed to calculate effect sizes).
The study abstract or manuscript should be available in English or Dutch.
Data extraction
All decisions on the inclusion of outcome measures for psychological distress, 
including depressive and anxiety symptoms, or/and general mental health outcome 
measures, were based on consensus between two researchers (IG, SR). Outcome 
measures of psychological distress were extracted by these two researchers, 
independently. Post-treatment measurements were collected to examine the 
immediate effect of the interventions. When data were not available, the study 
researchers were contacted. In addition, two independent researchers (RB, MH) 
rated the type of interventions (CBT or MBT) investigated in the studies, based on 
the treatment components described in the manuscript.
Quality assessment
The methodological quality of the included studies was assessed with seven criteria 
of the risk of bias assessment tool, developed by Cochrane [24] to assess sources 
of bias in RCTs:
1. Random sequence generation (selection bias)
2. Allocation concealment (selection bias)
3. Blinding of participants and researchers (performance bias)
4. Blinding of outcome assessment (detection bias)
5. Incomplete outcome data (attrition bias)
6. Selective reporting (reporting bias)
7. Other bias
When questionable or unclear risk of bias was found, this was considered a risk of 
bias. Again, quality assessment was performed by two independent researchers 
(IG, SR).
Meta-analyses
The Hedges’ g effect sizes were calculated for each study and pooled with 
Comprehensive Meta-analysis (CMA; version 3 for Windows). Post-treatment means 
6
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and corresponding standard deviations measures were used to calculate Hedges’ g. 
Means and standard deviations from anxiety, depression, and general mental health 
outcome measures within each study were pooled within the CMA program so 
that one ‘psychological distress’ measure for each study was included in the meta-
analyses. Two separate main meta-analyses were conducted: the first to investigate 
psychological interventions that were compared with waitlist or TAU conditions, 
the second to investigate psychological interventions that were compared with 
other active interventions (such as supportive listening, relaxation, and psycho-
education).
Within the first main meta-analysis, besides the combined psychological distress 
measure, the individual effect sizes on anxiety, depression, and general mental 
health outcomes were investigated using separate smaller meta-analyses. Subgroup 
analyses were conducted for disease type, control condition, and high vs low 
risk of bias. In addition, the relationship between risk of bias and effect size was 
investigated with a regression analysis. Within the second main meta-analysis, the 
different types of interventions of interest (CBTs and MBTs) were investigated by 
performing two separate meta-analyses. There were too few studies to perform 
further subgroup analyses.
As considerable heterogeneity was expected, all analyses were conducted using 
the random effects model. The I² statistic was calculated as an indicator of 
heterogeneity. We calculated the 95% confidence intervals (95% CI) around I² [25] 
using the non-central chi-squared based approach within the heterogi module for 
Stata [26]. When the I² estimate reached 40%, this was classified as considerable 
heterogeneity [27].
Subgroup analyses were conducted according to the mixed-effects model [28], and 
the meta-regression analysis was conducted according to the procedures developed 
by Borenstein et al. [28].
Publication bias was examined with Duval and Tweedie’s trim and fill procedure 
which estimates how many studies are missing in the meta-analyses and then 
imputes these [29], as well as Egger’s test for the asymmetry of the funnel plot.
The protocol of this meta-analysis was not pre-registered.
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Results
Selected studies
After removing duplicate studies, 156 records were found. After inspection of the 
titles and abstracts, 24 full-text articles were retrieved. In addition, four studies were 
included from past meta-analyses, resulting in 28 full-text articles that were read. 
Figure 1 presents the flowchart of the inclusion process with reasons for exclusion, 
following the PRISMA statement [30]. Eventually, 19 studies were included, of which 
12 were included in the first meta-analysis, and seven in the second meta-analysis.
Figure 1. PRISMA flow chart of selection and inclusion process. CBT = Cognitive Behavioral 
Therapy, MBT = Mindfulness Based Therapy; RCT = randomized controlled trial.
Characteristics of included studies
Table 1 shows the characteristics of the included studies, displayed separately for 
the two main meta-analyses. Within the first analysis, eight studies included MS 
patients [31-38], four studies included PD patients [39-42], and no RCTs were found 
investigating HD populations. Nine studies examined a CBT-based intervention [31, 
33-37, 39, 41, 42] and three studies investigated an MBT [32, 38, 40].
6
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Within the second analysis, only MS patients were investigated in the included 
studies. Regarding the treatments of interest, four studies investigated a CBT-based 
treatment [43-46] and three examined an MBT [47-49].
Overall, the quality of the included RCTs was low, based on the scores on the risk of 
bias assessment tool. Blinding of participants/researchers was impossible due to 
the nature of studies on psychotherapeutic interventions, and was therefore always 
considered as risk of bias. As allocation concealment was often not well reported, 
two studies had a risk of detection bias [41, 47]. The study by Okai and colleagues 
[41] also showed an attrition bias, as did the study by Calleo and colleagues [39]. 
In the first analysis, four studies showed good quality [31, 33, 38, 42], as shown by 
a total risk of bias of 1 (only risk of performance bias). In the second analysis, only 
the study by Carletto and colleagues had good quality (score of 1 on the risk of bias 
assessment tool: only blinding of participants was not achieved) [49].
Treatment Effects
Meta-analysis 1: psychological therapy versus TAU or waitlist condition
Figure 2 displays the forest plot of the standardized effect sizes of psychological 
therapies on psychological distress in PD and MS patients, compared with a waitlist 
or TAU condition. The mean effect size (g) was 0.51 (95% CI = 0.22 — 0.80) with a 
heterogeneity estimate (I²) of 66 (95% CI = 27 — 80).
As a post-hoc analysis, the studies of Okai et al. [41], Ghielen et al. [40], and 
Kiropoulos et al. [35] were excluded in a separate meta-analysis. These studies 
were considered outliers since the effect sizes with their 95% confidence intervals 
were outside the 95% confidence interval of the pooled main effect size. The effect 
size decreased to g = 0.31 (95% CI = 0.13 — 0.48) and heterogeneity decreased to 
I² = 0 (95% CI = 0 — 56) when these three studies were removed (see table 2).
To investigate the treatment effects on the different types of outcome measure 
separately, three meta-analyses were conducted on anxiety, depression, and 
general psychological distress outcome measures. The treatment effect on general 
mental health outcomes was highest (g = 0.79, 95% CI = 0.32 — 1.25 with I² = 66, 95% 
CI = 0 – 85), followed by the effect on anxiety symptoms (g = 0.36, 95% CI = 0.03 — 
0.66 with I² = 59, 95% CI = 0 — 79), and depressive symptoms (g = 0.33, 95% CI = 0.05 
— 0.62 with I² = 60, 95% CI = 0 — 78) (see table 2).
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In addition, subgroup analyses were conducted (table 2) to investigate differences 
in effect size for disease type, control condition, and risk of bias (high vs low). 
Significantly larger effect sizes were found in MS patient populations, TAU control 
condition, and studies with a high risk of bias.
Meta-regression analyses on risk of bias (β = 0.08, 95% CI = -0.18 – 0.33, p >0.05) did 
not show a significant relationship with effect size.
Meta-analysis 2: psychological therapy versus active control condition
Figure 3 shows the forest plot of the standardized effect sizes of psychological 
therapies on psychological distress in MS patients, compared with an active 
control condition. The mean effect size (g) was 0.36 (95% CI = 0.13 — 0.58) with a 
heterogeneity estimate (I²) of 40 (95% CI = 0 — 74).
To investigate the treatment effects for the types of investigated intervention, two 
separate meta-analyses were conducted on CBT-based treatments and MBTs. The 
treatment effect for CBT-based treatments was highest (g = 0.45, 95% CI = 0.26 — 
0.64 with I² = 0, 95% CI = 0 — 73), followed by a small effect for MBTs (g = 0.06, 95% 
CI = -0.56 — 0.68 with I² = 68, 95% CI = 0-89) (see table 2).
Publication bias
No evidence for publication bias was found in both meta-analyses. Inspection of 
the funnel plots did not indicate significant publication bias (figures 4 & 5). Duval & 
Tweedie’s trim-and-fill procedure resulted in the imputation of four studies in the 
first meta-analysis, and no imputations in the second meta-analysis, according to 
a random model. Egger’s regression intercept indicated no significant publication 
bias (p > 0.05 in both analyses).
Discussion
In this study, we investigated the effectiveness of CBT and MBT on psychological 
distress in patients with PD and MS by conducting two main meta-analyses of 
randomized controlled trials. There were no RCTs found studying these therapies 
in HD populations. Nineteen studies were included in the analyses, of which twelve 
compared the treatment of interest with a TAU or waitlist condition (meta-analysis 
1), and seven studies compared the treatment of interest with an active control 
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condition (meta-analysis 2). A moderate effect size (g = 0.51) was found in the first 
meta-analysis, and a small effect size (g = 0.36) was found in the second meta-
analysis. In both meta-analyses there was considerable heterogeneity, which was 
probably due to the variability in hours of treatment (range: 5-16 hours), different 
delivery forms (for example by telephone or face-to-face), differences in comorbidity 
in the included subjects over all included studies, and specific elements that varied 
between the interventions (such as psycho education in the study of Okai et al [41]). 
The heterogeneity decreased when 1) outliers were removed; 2) depression and 
anxiety outcomes were analyzed separately; 3) only looking at MS patient samples; 
4) studies with waitlist control conditions were analyzed; and 5) studies with a low 
Figure 4. Funnel plot of meta-analysis 1: psychological intervention versus TAU or WL con-
ditions. TAU = treatment as usual; WL = waitlist. The imputed studies are shown in black.
Figure 5. Funnel plot of meta-analysis 2: psychological intervention versus active control 
conditions.
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risk of bias were analyzed. In these post-hoc analyses, the effect sizes decreased to 
small (g = 0.31, g = 0.33, g = 0.36, g = 0.39, g = 0.42, respectively). No evidence was 
found for publication bias.
The small to moderate main effect sizes suggest that CBT and MBT are beneficial in 
reducing psychological distress, but only to a certain extent. Biological approaches, 
e.g. pharmacotherapy, showed a reduction of depressive symptoms in MS patients 
with an effect size of 0.63 (standardized mean difference) [22]. According to the 
review and meta-analysis by Fiest et al. [22], current research is insufficient to 
determine the effectiveness of pharmacotherapy for anxiety in MS as no controlled 
studies were found. In PD, the meta-analysis of Bomasang and colleagues [51] on 
antidepressant medication showed an effect size of 0.54 in reducing depressive 
symptoms. The effect of pharmacotherapy on reducing symptoms of anxiety 
in PD patients has insufficiently been studied. Although the effect sizes of 
pharmacotherapy on depressive symptoms appear to be larger than those of 
psychological treatment, regarding anxiety and global mental health the effect is not 
yet investigated properly. One can imagine that pharmacological interventions show 
larger effect sizes compared to psychotherapeutic interventions, since the latter 
requires cognitive abilities to learn and apply the methods that are taught. Although 
patients with dementia were excluded in most studies, it is possible that these 
populations have reduced cognitive abilities as a result of the neurodegenerative 
process, and are therefore unable to optimally benefit from CBT and MBT. It is also 
argued that a combination of psychotherapy and pharmacotherapy might be most 
beneficial, at least for outpatients with chronic forms of depression [52, 53] and panic 
disorder [53]. In adults with an anxiety or depressive disorder without neurological 
comorbidity, a meta-analysis of Cuijpers and colleagues [54] showed that CBT is 
probably effective. Although effect sizes were larger (around g = 0.80) compared 
to our results, the quality of the included studies was low and publication bias was 
present. Large effect sizes were also found for MBTs in the treatment of anxiety and 
depressive symptoms in participants without neurological comorbidity [55]. Here, 
no publication bias was present but study quality was again unsatisfactory. CBT 
and MBT appear to be more effective in patients without compared to patients with 
neurodegenerative disorders. However, the methodological quality is insufficient 
to draw definite conclusions.
MS patients seem to benefit more from CBT and MBT than PD patients as is 
represented by the significant subgroup difference in effect size regarding disease 
type. However, considerable heterogeneity was present in both subgroups and all 
therapies described here were adapted to the respective study sample. The MS 
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population is best represented in these meta-analyses, including fifteen RCTs of 
which eight were included in the first meta-analysis. The second meta-analysis 
included only studies in MS populations. Overall, the mean age of MS patient 
groups was lower compared to the PD patient groups. One can imagine that having 
a progressive neurological disorder in an earlier or later phase of life results in 
different psychosocial issues and cognitive abilities to benefit from therapy.
A considerably large effect size was found in the pilot study of Okai and colleagues 
[41]. In this study, all PD patients additionally suffered from impulse control disorders. 
When the treatment components were critically investigated, it was notable that this 
was the only CBT-based intervention that included executive dysfunction education. 
PD patients often show an impairment in executive functioning in an early stage of 
the disease [56, 57]. Since this study showed a great improvement in psychological 
distress, this might indicate that executive dysfunction plays an important role in 
regulating negative emotions and cognitions, at least in PD patients with impulse 
control disorders. This, however, needs confirmation in future research.
The pilot study by Kiropoulos et al. [35] also showed a large effect size (g = 1.64). 
This study included newly diagnosed MS patients (< 5 years since diagnosis) and 
the age of these patients was lower compared to other studies that investigated 
MS populations. These patients might be less severely affected compared to other 
study populations. Comparisons, however, could not be made since studies reported 
different measures of disease severity. No differences were found concerning 
treatment components when compared with other CBT-based interventions in MS.
Of great importance is the focus of the treatment types and control conditions. 
The studies by Ghielen et al. [40], Oreja-Guevera et al. [48], and Nordin et al. [47] 
investigated MBTs. These three studies showed (non-significant) negative effect 
sizes of g = -0.45, g = -0.37, and g = -0.10, respectively, favoring the control condition 
in reducing psychological distress symptoms. These studies all included an active 
form of control condition: physical therapy (TAU), psycho education, and relaxation, 
which might have diminished the positive effect. Besides this, the focus of ACT is 
not on symptom reduction but on coping with the disease despite of the symptoms 
that are present. This is achieved by improving awareness of ones bodily sensations, 
thoughts and feelings. As one can imagine, when one is more aware of his/her 
symptoms, these will also be more often reported, resulting in a higher score on 
questionnaires.
6
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This leads us into the discussion concerning the suitability of questionnaires to 
measure treatment effects. Since MBTs are focused on awareness and acceptance, 
and not aim to reduce symptoms, questionnaires that measure the prevalence or 
severity of symptoms are less appropriate. The studies by Bogosian et al. [32] and 
Simpson et al. [38], however, investigated mindfulness interventions and showed 
effect sizes of g = 0.55 and g = 1.04, respectively, in improving general mental health. 
In addition, when overall psychological distress was measured with general mental 
health questionnaires, a high effect size of g = 0.79, although with considerable 
heterogeneity, was found. The focus of an intervention, type of control condition, 
and the outcome measures used seem to be of importance in evaluating the 
effectiveness, and therefore need to be carefully considered when conducting an 
RCT.
Overall, the included studies had low quality, only three out of seventeen studies 
reached good quality according to the risk of bias tool. The findings need to be 
carefully interpreted since risk of bias is present in most of the studies and might 
have influenced the treatment effects. Each study suffers from different types of 
bias, except for the performance bias which is always a risk due to the nature of 
these intervention studies.
Limitations and implications
First, the effect size is solely based on studies in patients with PD and MS, since there 
were no RCTs found in HD that investigated the effect of psychological interventions 
on psychological distress. Second, MS patients might be overrepresented in the 
meta-analysis since fifteen out of nineteen RCTs investigated MS populations, 
resulting in the effect size being driven mostly by MS populations, especially in the 
second meta-analysis in which only MS populations were included. Heterogeneity 
estimates were above 40% in most analyses, reflecting high heterogeneity within 
the meta-analyses, and most studies included small sample sizes, which resulted 
in low power. Finally, the overall quality of the studies was low and the quality of 
one study could not be assessed.
It is therefore recommended to study psychological interventions in more detail 
and in larger patient samples in study designs with higher methodological 
quality. Especially in HD more research is needed, since no RCTs on the effects 
of psychological treatment were found in our literature search. It might also be 
interesting to investigate the addition of psychopharmacological therapies, besides 
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psychotherapy. Besides a primary focus on reducing psychological distress, we 
recommend to investigate the effect on coping with the disease, quality of life, 
valued living, or self-efficacy, especially in RCTs studying the effect of MBTs. Since 
progression of the disease is inevitable, it is therefore important to learn how to 
cope with the disease instead of focusing on symptom reduction only. Furthermore, 
caution is warranted in the choice of outcome measures and the type of control 
conditions as comparators, since these decisions greatly influence the study 
outcome. Lastly, it might be interesting to include executive dysfunction education 
in interventions for PD patients with impulse control disorders.
Conclusion
Despite the abovementioned limitations, we conclude that psychological 
interventions have a small to moderate effect on reducing psychological distress in 
patients with PD and MS. However, more research is warranted, especially in HD and 
PD patient samples. These studies need to have better methodological quality (e.g. 
lower risk of bias) and study samples should be larger to achieve a sufficient power. 6
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Background: The wearing-off phenomenon in Parkinson’s disease (PD) patients 
is a complication of prolonged levodopa usage. During this phenomenon, motor 
symptoms such as rigidity and freezing, re-emerge. This is often accompanied by 
non-motor symptoms including anxiety, the so-called wearing-off related anxiety 
(WRA). Current treatment options are limited and typically focus on either the 
physical or mental aspects of wearing-off. An integrated approach seems warranted 
in order to optimally address the complex reciprocal interactions between these 
aspects. Also, since wearing-off is eventually inescapable, treatment needs to focus 
on coping, acceptance and self-efficacy. We therefore developed an integrated body 
awareness intervention, combining principles from physical therapy with acceptance 
and commitment therapy (ACT) to teach patients to deal with WRA. This study will 
investigate whether this new intervention, named BEWARE, is more effective in 
increasing self-efficacy than treatment as usual.
Methods/Design: This is a single-blinded randomized controlled trial in 36 PD 
patients who experience WRA. Subjects will be recruited from the outpatient 
clinic for movement disorders of the VU University Medical Center. After providing 
written informed consent, patients will be randomly assigned to an experimental 
(BEWARE) or treatment-as-usual (physical therapy) group. Clinical assessments will 
be performed prior to the intervention, directly after the 6 week intervention period, 
and at 3-month naturalistic follow up, by a blinded investigator not involved in the 
study. The primary outcome measure is self-efficacy, while secondary outcomes 
focus on mobility, daily functioning, anxiety and quality of life.
Discussion: Since wearing-off is an inevitable consequence of levodopa therapy, 
and current treatment options are insufficient, a multidisciplinary intervention 
that addresses both physical and mental aspects of wearing-off in PD may foster 
additional benefits for treating WRA in PD patients over mono-disciplinary care 
alone.
Trial registration: ClinicalTrials.gov identifier: NCT02054845
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Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative disorder of the central 
nervous system with a prevalence of 1.6% among people of 65 years or older [1]. 
The neurobiological hallmark of PD is a loss of dopaminergic cells, causing the 
typical motor symptoms such as tremor, rigidity, slowness of movement, postural 
instability and freezing. Non-motor symptoms, such as autonomic failure, fatigue, 
depression and anxiety are also prevalent, likely due to an additional involvement 
of non-dopaminergic systems [2].
To supplement the shortage of dopamine, levodopa treatment is currently the most 
applied and effective symptomatic treatment [3]. When the dopamine replacement 
therapy (DRT) takes effect and symptoms become less prominent, the patient is in 
the ‘on’ state. In contrast, the state in which the patient is in need of a new dose of 
dopamine and experiences intensified PD symptoms, is referred to as the ‘off’-state. 
A re-emergence of PD symptoms, shifting from an ‘on’ state to an ‘off’ state, is called 
wearing-off. This typically occurs prior to the next scheduled dose of dopaminergic 
therapy taking effect [4], and is related to a longer disease duration [5].
Motor and non-motor symptoms have reciprocal influences [6]. About seventy-
five percent of patients with motor fluctuations, including wearing-off, experience 
mood and/or anxiety fluctuations in parallel [7]. This wearing-off related anxiety 
(WRA) is characterized not only by subjective feelings of anxiety but also by physical 
complaints, such as sweating, abdominal distress and shortness of breath. Rutten et 
al [8] showed, by performing a factor analysis on the Beck Anxiety Inventory (BAI), 
that anxiety symptoms in PD show significant overlap with both autonomic and 
motor symptoms. This finding demonstrates that physical and mental symptoms 
are intertwined in PD.
The physical symptoms accompanying WRA are often incongruent with the actual 
severity and physical impact of motor symptoms of wearing-off, suggesting an 
increased sensitivity and reactivity to the occurrence of wearing-off symptoms 
and heightened body awareness in these patients. Body awareness involves an 
attentional focus on and awareness of internal bodily sensations [9]. An abnormal 
increase in body awareness can be maladaptive [9] and is, in general, also related 
to anxiety disorders [10-14].
The anxiety symptoms experienced by PD patients are often responsive to 
dopaminergic medication [15]. Therefore, the first therapeutic approach for treating 
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WRA is to optimize the DRT [16]. As the disease progresses, increasing dopaminergic 
medication (both frequency and dosage) becomes insufficient and complicated due 
to the increased occurrence of dyskinesias [17]. Also, random fluctuations appear 
to be more difficult to treat with pharmacotherapeutic approaches since they are 
unpredictable and not directly related to a lower level of dopamine [17].
Non-pharmaceutical approaches include exercise programs and physical therapy. 
These have shown to improve motor problems, daily functioning and quality of life 
in patients with PD [18-21]. While effective for improving mobility-related problems, 
current physical rehabilitation approaches typically do not offer tools to address 
the non-motor symptoms of wearing-off.
Cognitive behavior therapy (CBT), mindfulness and acceptance & commitment-
based therapies (ACT) have proven to be effective in reducing anxiety symptoms 
and avoidance behavior in patients with anxiety disorders, also enhancing quality 
of life [22,23]. Therefore, classic tools from CBT and ACT might be useful in the 
treatment of the debilitating effects of WRA. A reduction of anxiety symptoms in 
PD patients is observed in most of the CBT studies [24-26]. However, based on 
clinical experience, efficacy of classical CBT is limited in PD care, due to the fact that 
the cognitive methods are suboptimal in addressing the interaction between non-
motor and motor symptoms during wearing-off. Moreover, the classical approaches 
aim to reduce the symptoms, whereas the inevitability of motor and non-motor 
fluctuations in PD demands the ability to maintain physical and mental balance 
despite the presence of those fluctuations. This is of great importance mainly in 
the more advanced stages of PD, where symptom management is more challenging 
[3]. Therefore, interventions need to focus on independence and self-efficacy more 
than on reducing symptoms.
To address both the physical and the mental aspects of PD, Wahbeh et al. [27] 
reviewed mind-body interventions in the treatment of PD and showed that 
participating in tai chi classes improved the patients’ physical condition. Landsman-
Dijkstra and colleagues [28] tested a highly structured and standardized 3-day 
body-awareness program in 14 participants who suffered from chronic non-specific 
psychosomatic symptoms. An increase of body-awareness, self-efficacy and quality 
of life was found after the intervention. However, the researchers did not implement 
a control group in this study.
Mindfulness-based therapies have been proven to be effective in many patient 
groups, such as patients with chronic pain, anxiety and depressive disorders, by 
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improving psychological functions and reducing pain and stress [29]. Since PD is a 
chronic disease and is accompanied by both physical and mental symptoms (motor 
and non-motor symptoms), combing mindfulness-based therapy with physical 
rehabilitation might be of potential benefit for PD patients with WRA.
BEWARE is an integrated body awareness intervention, combining acceptance and 
commitment therapy (ACT), in which mindfulness training is incorporated, with 
physical therapy. We will test the effectiveness of this intervention (compared with 
treatment as usual (TAU)) in terms of self-efficacy in PD patients with WRA. We 
hypothesize that the BEWARE intervention will be more effective in improving self-
efficacy than physical therapy alone (TAU).
Methods/Design
Study design
This will be a single-blind randomized controlled trial. Thirty-six PD patients that 
experience WRA will be randomly allocated to either the BEWARE training group 
(n=18, 3 groups of 6 patients) or to a control group receiving physical group therapy, 
which is a usual form of treatment for wearing-off in PD patients at the VU University 
medical center (n=18, 3 groups of 6 patients). Block-randomization is done using 
concealed opaque envelopes. All participants are asked to maintain the regular 
medication schedule during the six-week intervention. Assessments are conducted 
prior to the intervention, at six weeks directly after the intervention and at 18 weeks 
follow-up. The assessments will be performed by a blinded investigator who is not 
involved in the intervention and/or randomization. Figure 1 demonstrates the study 
design according to the CONSORT statement [30].
Patient recruitment
The patients will be recruited from the outpatient clinic of the VU University medical 
centre. The neurologists and psychiatrist will be asked to approach PD patients who, 
in their view, experience WRA. In addition, an announcement will be placed on the 
website of the Dutch Parkinson patient association (Parkinson Vereniging) and in 
their magazine. In- and exclusion criteria are listed below.
Patient inclusion criteria
1. Diagnosed with idiopathic PD according to the UK PD Brain Bank criteria [31].
2. Experiencing wearing-off symptoms and/or response fluctuations, as 
measured with the Wearing-Off Questionnaire 19 [32]. A patient is considered 
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to be experiencing wearing-off if he or she indicates at least one symptom 
that improves after taking a next medication dose.
3. Presence of clinically relevant anxiety, defined as a Beck Anxiety Inventory 
score > 26 [33].
Patient exclusion criteria
1. Other neurological, orthopaedic, cardiopulmonary problems that may 
interfere with participation in the view of the researchers.
2. Cognitive impairment defined as an MMSE score < 24.
3. Insufficient motivation for participation.
Intervention
Two treatment conditions are investigated in this study: the experimental condition 
(BEWARE) and the TAU (physical therapy). Both interventions consist of 12 sessions, 
each 1 hour long, 2 times per week for 6 weeks. All treatment sessions occur at 
the same time of day on the same two days of the week (Monday and Thursday) 
throughout the study. The treatment groups consist of 6 patients, in both conditions.
Figure 1. Study flow chart. Abbreviations: BEEWARE = body awareness training; PD = Parkin-
son’s disease; TAU = treatment as usual.
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Experimental condition: body awareness training (BEWARE)
The experimental intervention is delivered by professionals from the fields of 
psychology, physical therapy and psychiatry. The BEWARE training is mainly based 
on the principles of ACT [34]. The goal of this training is to acquire and apply 
adequate coping strategies with wearing-off, and live a valuable life despite the 
presence of wearing-off symptoms.
Psycho-education about PD and wearing-off is discussed by the psychiatrist. The 
psychologist explains and trains the concepts of body awareness, cognitive defusion, 
valued living and applies imaginary exposure, in ACT therapy known as FEEL (Feeling 
Experiences Enriches Living) exercises [34]. During the imaginary exposure, patients 
are asked to imagine a real-life situation that easily triggers wearing-off. The patients 
practice with experiencing and daring to allow the feelings that are triggered by 
the ‘off’ during this imaginary exposure. The patients are encouraged to gradually 
take part in activities that they previously avoided because of the (anticipation of) 
wearing-off.
The psychological exercises are alternated by physical exercises that are performed 
by the physical therapist. These exercises include movement strategies and moving 
on rhythmic music which helps the patients to relieve stress after the imaginary 
exposure.
To generalize the intended effect, the patients are given homework assignments, 
such as body awareness exercises and planning value-based committed actions in 
daily life.
Control condition: treatment as usual (TAU)
The patients in the control group receive treatment as usual based on the current 
KNGF guidelines for physical therapy in patients with PD [35]. As in the experimental 
condition, patients are taught movement strategies.
Outcome measures
Primary outcome measure
The primary outcome measure is self-efficacy, assessed with the 10 item General 
Self Efficacy Scale (GSES) [36]. Self-efficacy is defined as the extent or strength of 
one’s belief in one’s own ability to complete tasks and reach goals, in other words; 
a person’s belief in his or her ability to succeed in a particular situation [37]. In this 
questionnaire, patients are asked to rate specific statements on a scale from 1 to 4 
(1 = not at all true, 2 = hardly true, 3 = moderately true, 4 = exactly true).
7




1. The Parkinson’s Disease Questionnaire-39 (PDQ-39)
This questionnaire is a measure of quality of life adapted for people with PD [38]. It 
consists of 39 statements that cover eight domains associated with health, such as 
mobility and emotionality, that can be influenced by PD. Patients can reply by ticking 
the relevant answer that indicates whether they experienced problems during the 
past month (five boxes from ‘never’ to ‘always’). The PDQ-39 is a valid and reliable 
instrument for patients with PD [38,39].
2. The Wearing-off Questionnaire 19 (WOQ-19)
In this 19 items questionnaire [31], PD patients indicate which symptoms they 
experience and whether these symptoms improve after administration of PD 
medication.
3. Beck Anxiety Inventory (BAI)
This self-report questionnaire consists of 21 common symptoms of anxiety [32]. 
Patients indicate how much they have been bothered by these symptoms during 
the past week, including today.
4. Beck Depression Inventory (BDI)
This 21-item self-report questionnaire measures whether patients experience 
depressive symptoms [40]. Patients indicate the statements that are most applicable 
to their own situation during the past week, including today.
5. 10 Meter Walk Test (10MWT)
To measure comfortable walking speed, the patients are asked to walk 10 metres, 
which are characterized by a starting and a finishing point [41]. The researcher 
measures the time needed to cover this distance.
6. Timed One Leg Stance Test (OLST)
This test measures balance by asking the patients to stand on one leg without help 
[42]. The number of seconds that the patients maintain their balance is noted, with 
a maximum of 60 seconds.
7. The Nottingham Extended Activities of Daily Living (NEADL) index
This 22-item self-report questionnaire covers four aspects of daily living: mobility, 
activities in the kitchen, domestic tasks, and leisure activities [43]. Patients indicate 
whether they independently performed activities during the past weeks.
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8. Freezing of Gait (FOG) questionnaire
This 6-item questionnaire is used to identify current problems with walking and 
symptoms of freezing [44]. For each item patients indicate which of the 5 statements 
is most applicable.
9. Visual Analogue Scales (VAS)
Before and after each therapy session patients indicate how they are feeling at the 
actual moment, using 10 VAS. Patients put a cross on a line of 10 cm with extreme 
feelings at the edges, for example ‘relaxed’ or ‘tense’, ‘in control’ or ‘out of control’, 
and ‘happy’ or ‘sad’.
Patient researchers
Since the experimental treatment is a new approach, the opinion and experiences 
of the participating patients are considered very important. Therefore, two patient 
researchers of the Dutch Parkinson patient association (Parkinson Vereniging) 
contribute to the study by anonymously documenting the patients’ expectations 
and evaluation points for qualitative analysis. Prior to, and directly after the 
intervention period, a semi-structured group interview takes place in which the 
patients are asked questions related to the study and can share their experiences 
and suggestions for adaptations in future studies or in the implementation phase. 
This interview is with the patients (both participants and researchers) only.
Statistical analysis
Calculation of sample size
We expect that the experimental group will show a 10% larger improvement on 
the GSES after treatment, compared to the TAU group. Based on data on the GSES 
in other chronic diseases [45], we expect to detect a 10% larger reduction in GSES 
score from 32 to 28.8 with an overall sd of 3.3. A minimum of 16 patients is required 
per arm of the trial. With that, including a dropout of 10%, we estimate that 36 PD 
patients (18 per arm) are needed to achieve a sufficient statistical power of 80% 
with two-tailed significance level set at p<0.05.
Data analysis
To promote data quality, double data entry will be used. Multiple imputation will be 
applied on missing data. ANOVA with repeated measures will be used for normally 
distributed outcomes at interval and ratio level. Friedman’s non-parametric 
repeated measures test will be applied for outcomes with non-interval or ratio 
scale level, or for non-normally distributed variables. Factors in the analysis will be 
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Group (2 levels: control and experimental) and Time (3 levels: baseline, assessment 
at week 6 (directly post-treatment) and assessment week 18 (3 month follow up)).
Ethical considerations
Prior to study participation, all patients will be asked to sign a written informed 
consent. The study was approved by the ethics committee of the VU University 
medical centre (study number: 13.421).
Data monitoring
The data and safety monitoring board will guard the quality and safety during this 
study, according to the Good Clinical Practice guidelines.
Discussion (expected results)
Wearing-off is an inevitable and disabling consequence of long-term DRT in patients 
with PD and WRA is a concept characterized by a complex reciprocal interaction of 
motor and non-motor symptoms. The general neglect of these complex interactions 
in the TAU leaves a gap for treatment innovation. BEWARE is a promising therapy 
for WRA in PD since it specifically focuses on the interaction between physical and 
mental symptoms. The specific and unique combination of elements of the therapy 
aim to increase self-efficacy, by strengthening ones own belief to adequately cope 
with the wearing off and the disproportional concurrent feelings of anxiety, rather 
than symptom reduction or elimination.
Since the development of wearing-off is associated with long-term treatment of 
PD with DRT, as well as to an early onset of disease, longer disease duration, and 
higher doses of levodopa [5,17,46], we will inadvertently include patients that are in 
a more advanced stage of the disease. Therefore, we must pay specific attention to 
the potential additional difficulties with patient compliance regarding the amount 
of effort and commitment we demand from the patients during the twice-weekly 
intervention.
Based on previous research in combination with our own experience based on 
a small open pilot study in four PD patients (results not published), we expect to 
see a significantly bigger improvement in self-efficacy in the BEWARE condition as 
compared with the TAU condition. A decrease in BAI total score was observed in the 
patients that participated in the pilot study. The patients in the pilot study reported 
very positive subjective effects of the intervention. In particular the group aspect 
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and the holistic approach to address WRA were highly appreciated. Patients stated 
they were better able to cope with wearing-off after the intervention period. Based 
on these first experiences, we believe that the BEWARE has the potential to be 
implemented into health care practices once its value has been established using 
proper testing with high methodological standards.
Since the wearing-off phenomenon is eventually inescapable, this study is not only 
of great interest from a patient and caregiver perspective but also from a health 
care system perspective. Group therapy may lower health care costs compared to 
individual treatment due to a reduced therapist:patient ratio, and this treatment 
may allow patients to function longer and in a more independent way in their own 
home environment.
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Background: In Parkinson’s disease (PD) patients, fluctuations in symptoms 
commonly occur after many years of dopamine replacement therapy. The so-called 
wearing-off phenomenon exists of both motor and non-motor symptoms, such 
as rigidity and anxiety. Current treatment options are limited and an integrated 
approach is needed to address the complex interactions between motor and 
non-motor symptoms. Since wearing-off is eventually inevitable, treatment 
needs to focus on coping, acceptance and self-efficacy. We developed the body 
awareness training, named BEWARE, combining physical therapy with acceptance 
and commitment therapy to help PD patients deal better with wearing-off related 
anxiety (WRA).
Methods: This was an investigator-blinded randomized controlled trial. Forty PD 
patients with WRA were randomly assigned to the BEWARE or to the treatment 
as usual (TAU) condition. Assessments were performed prior to and immediately 
after the treatment period, and at 3-months follow up. The primary outcome was 
selfefficacy, secondary outcomes focused on mobility, daily functioning, anxiety, 
depression and quality of life.
Results: There was no significant improvement in self-efficacy in the BEWARE 
treatment condition when compared to TAU. However, standing balance 
and emotional wellbeing showed a significant improvement, and feelings of 
stigmatization showed a trend-significant decrease in the BEWARE condition.
Conclusions: We consider the BEWARE training to be a promising therapeutic 
approach to address WRA. Improvement points from the participants included 1) 
less frequent but longer therapy sessions; 2) active involvement of caregivers; and 
3) the development of a supportive workbook. The optimized treatment protocol 
needs further evaluation in a phase III RCT.
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Introduction
The typical motor symptoms in Parkinson’s disease (PD) include tremor, rigidity, 
slowness of movement, postural instability, and freezing. Besides these symptoms, 
PD is accompanied by non-motor symptoms, such as autonomic failure, fatigue, 
pain, cognitive rigidity, depression and anxiety. Non-motor symptoms often have 
a higher impact on patients’ quality of life than motor symptoms [1]. First line 
treatment for PD symptoms is dopamine replacement therapy (DRT), e.g., levodopa 
[2]. In reaction to chronic DRT, PD patients eventually develop response fluctuations, 
including wearing-off. During wearing-off, both motor and non-motor symptoms 
can occur and/or become more prominent. Wearing-off is common already at the 
early stages of PD and is underestimated by routine neurological clinical evaluation. 
The number of wearing-off symptoms, both motor and non-motor, increases along 
with disease duration and has a negative impact on quality of life [3].
In PD, motor and non-motor symptoms have reciprocal influences [4]. About 
75% of patients with motor fluctuations experience fluctuations in mood and/or 
anxiety in parallel [5], and anxiety is more common in patients that experience 
motor fluctuations compared to those who do not [6]. Anxiety associated with 
wearing-off, referred to as wearing-off related anxiety (WRA), is characterized 
not only by subjective feelings of anxiety but also by physical complaints, such as 
sweating, abdominal distress and shortness of breath. According to Rutten et al [7], 
anxiety symptoms in PD show significant overlap with both autonomic and motor 
symptoms, which makes it difficult to disentangle them.
The high impact of the physical symptoms accompanying WRA on daily life 
functioning is often incongruent with the actual severity of the motor symptoms 
of wearing-off. This suggests heightened body awareness in these patients. Body 
awareness involves an attentional focus on and awareness of internal bodily 
sensations [8]. An abnormal increase in body awareness can be maladaptive [8] 
and is common in anxiety disorders [9]. Normalizing body awareness may therefore 
help patients to cope with WRA.
A first therapeutic approach to treat WRA is optimization of DRT [10], since the 
anxiety symptoms experienced by PD patients are sometimes responsive to 
dopaminergic medication [11-13]. As the disease progresses, this becomes 
insufficient and is complicated by response fluctuations and increased occurrence of 
dyskinesias that become unpredictable in nature [14]. Such random fluctuations are 
difficult to treat with pharmacotherapeutic approaches since they are not directly 
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related to a low level of dopamine [14]. In addition, treating anxiety symptoms with 
pharmaceutics, such as psychotropic medication, might interfere with DRT and 
result in increased tremor or rigidity, which is undesirable.
Non-pharmaceutical approaches to treat wearing-off include exercise programs 
and physical therapy. These have been shown to improve motor problems, daily 
functioning and quality of life in PD patients [15-18]. While effective in improving 
mobility-related problems, current physical rehabilitation approaches typically do 
not offer tools to address the (interaction with) non-motor symptoms, such as WRA.
Cognitive Behavior Therapy (CBT), mindfulness and Acceptance & Commitment-
based therapies (ACT) are effective in reducing anxiety symptoms, distress and 
avoidance behavior and enhancing quality of life in patients with anxiety disorders 
and PD [19-23]. Therefore, tools from CBT and ACT might also be useful in the 
treatment of the debilitating effects of WRA in PD. However, the classical approach 
aims to reduce symptoms, whereas the inevitability of motor and non-motor 
fluctuations in PD demands a coping strategy on dealing with these fluctuations. 
In addition, cognitive rigidity becomes more prominent with disease progression 
and complicates a mono-disciplinary cognitive treatment approach.
To address both the physical and the mental aspects of PD, Wahbeh et al. [24] 
reviewed mind-body interventions in the treatment of PD and showed that 
participating in tai chi classes improved the patients’ physical condition. Landsman-
Dijkstra and colleagues [25] tested a highly structured and standardized 3-day 
body-awareness program in 14 participants who suffered from chronic non-specific 
psychosomatic symptoms. After the intervention body awareness, self-efficacy and 
quality of life had significantly improved. The main limitation of this study, apart 
from the small sample size, was the lack of a control group. In summary, mind-body 
interventions seem promising for the treatment of WRA in PD patients, but the 
therapeutic efficacy has yet not been investigated.
We therefore developed an integrated body awareness training combining ACT with 
physical therapy for patients with PD, named BEWARE. We investigated the feasibility 
and the efficacy of this group intervention using a pilot randomized controlled study, 
with conventional group physical therapy as active control condition.
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Methods
For a detailed description of the methodology, including the intervention protocol, 
we refer to the article of Ghielen et al. [26].
Study design
We conducted an investigator-blind randomized controlled trial. Forty PD patients 
with WRA were randomly allocated to either the BEWARE training (4 groups of 4-6 
patients) or to the treatment as usual (TAU) receiving group physical therapy (4 
groups of 4-6 patients). Block-randomization with 2 blocks of 4 was done using 
concealed opaque envelopes and conducted by an independent investigator. 
Assessments were conducted prior to the intervention (baseline), directly after 
the six-weeks intervention (post-treatment) and at 18 weeks follow-up (3 months 
after completing the intervention). A blinded investigator, who was not involved in 
the intervention and/or randomization, performed all assessments.
Patients
Forty participants were recruited from the outpatient clinic of the VU university 
medical center and through the Dutch Parkinson patient association (see figure 1 
for the flow chart according to the CONSORT-statement [27]). Inclusion criteria were: 
1) a diagnosis of idiopathic PD according to the UK PD Brain Bank criteria [28]; 2) 
the presence of one or more wearing-off symptoms, as measured with the 19-item 
Wearing-Off Questionnaire (WOQ-19) [29]; 3) clinically relevant anxiety, defined by a 
Beck Anxiety Inventory (BAI) score >26. Patients with cognitive impairment defined 
as a Mini Mental State Examination (MMSE) score of <24, insufficient motivation 
for participation, or neurological, orthopaedic or cardiopulmonary problems that 
could interfere with participation in the view of the researchers, were not eligible 
for participation. The patients were asked to maintain a stable medication schedule 
throughout the treatment period of six weeks. To detect a 10% larger reduction in 
the General Self Efficacy Scale (GSES) in the BEWARE condition compared to TAU, a 
minimum of 16 patients was required per treatment condition to achieve a statistical 
power of 80% with a two-tailed significance level set at p<0.05. Considering a 
maximum dropout of 10%, 36 PD patients (18 per condition) were needed.
Interventions
Two treatment conditions were investigated in this study: the experimental condition 
(BEWARE) and the conventional physical therapy (TAU). Both interventions consisted 
of 12 sessions, each 1-hour long, 2 times per week for 6 weeks. Each group consisted 
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of 4-6 patients. All treatment sessions occurred at the same time on the same two 
days of the week (Monday and Thursday) throughout the study.
Experimental condition: body awareness training (BEWARE)
The experimental intervention was delivered in a group setting by professionals 
from the disciplines psychology, physical therapy and psychiatry. The BEWARE 
training is mainly based on the principles of ACT [30]. The goal of this training is to 
acquire and apply adequate coping strategies with wearing-off, and live a valuable 
life despite the presence of wearing-off symptoms. The intervention consists of 
the following elements: psycho-education, training in ACT, imaginary exposure 
using FEEL (Feeling Experiences Enriches Living) exercises, diminishing avoidance 
behaviour, physical exercises and homework assignments. Homework assignments 
Figure 1. Study flow chart
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included inventory and planning of value-based committed actions and performing 
mindful body scans.
Control condition: treatment as usual (TAU)
The patients in the control group received TAU based on the current Royal Dutch 
Society guidelines for physical group therapy in patients with PD, consisting of 
movement strategies for improving balance, gait, transfers and posture [31]. No 
homework assignments were assigned in this condition.
Ethical considerations
Prior to study participation, all patients were asked to sign a written informed 
consent. The study was approved by the ethics committee of the VU university 




The primary outcome measure was self-efficacy, assessed with the 10 item GSES 
[32]. Self-efficacy is defined as the extent or strength of one’s belief in one’s own 
ability to complete tasks and reach goals [33]. In the GSES, patients are asked to 
rate 10 specific statements on a scale from 1 to 4, with a higher rating representing 
better self-efficacy.
Secondary outcome measures
We measured symptoms of wearing-off by means of the WOQ-19, in which patients 
can check 19 symptoms they experience and indicate whether these symptoms 
usually improve after their next medication dose [29]. The BAI (range 21-84) [34] and 
the Beck Depression Inventory (BDI; range 0-63) [35] were used to measure anxiety 
and depressive symptoms, respectively. A higher score on these questionnaires 
indicates more (severe) symptoms. The Parkinson’s Disease Questionnaire-39 
(PDQ-39) was used to assess quality of life, which contains the subscales mobility, 
activities of daily living, emotional wellbeing, stigma, social support, cognitions, 
communication, and bodily discomfort [36]. Higher scores on these subscales 
indicate more (severe) symptoms, e.g. lower quality of life. We measured activities 
of daily living with the Nottingham Extended Activities of Daily Living (NEADL) index 
[37]. A higher score represents more independence in performing daily life activities. 
To assess symptoms of freezing the Freezing of Gait (FOG) questionnaire was used, 
where a higher score represents more severe freezing [38]. The 10 Meter Walk Test 
8
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(10MWT) [39] and the Timed One Leg Stance Test (OLST) [40] were used to assess 
walking speed and standing balance, respectively.
Qualitative evaluation
Since the experimental treatment was a new approach, the opinion and experiences 
of the participating patients were considered very important. Therefore, two patient 
researchers of the Dutch Parkinson patient association (Parkinson Vereniging) 
contributed to the study by providing input in the design phase and by conducting 
a group interview on the patient’s expectations at baseline and evaluation points at 
post-treatment. These interviews were in the absence of the academic employees 
and were documented anonymously for qualitative analysis. We thought that the 
participants felt more comfortable to address critical feedback points anonymously 
and towards the patient researchers, compared to the researchers.
Data analysis
The means, standard deviations, and ranges of the descriptive measures were 
calculated. Differences in demographic, disease related, and outcome measures 
were investigated using independent t-tests or Mann-Whitney U tests, and chi-
square tests where appropriate. Linear mixed model analyses were used to estimate 
the effect of BEWARE (compared to TAU) on the outcome measures. Besides an 
overall intervention effect, the separated effects at both post-treatment and follow-
up were estimated. For the latter, time and the interaction between condition and 
time were added to the model. We corrected for baseline differences in all analyses, 
also when baseline measures did not significantly differ between conditions. The 
intervention effect was estimated by the regression coefficient (β) and its related 
p-value. The significance level was set at a p-value of 0.05, two-tailed. In addition, we 
separately included covariates such as cognition, anxiety, LEDD score, and number 
of wearing-off symptoms at baseline as interaction-effects (with condition) in the 
model to investigate whether they were of significant influence on the intervention 




Table 1 shows the descriptive statistics of the 38 patients that completed the study, 
per condition. No significant baseline differences between the two conditions were 
found on demographic, disease related, or outcome measures. All participants had 
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a Hoehn & Yahr (H&Y) staging of 2 or 3 in the ON stage, as retrospectively assessed 
by the physical therapists. We assessed this retrospectively over 12 treatment 
sessions to obtain a reliable indicator of the disease stage, since H&Y scores are 
dependent on the (moment of the) day. Twelve patients, six in each condition, used 
pharmacotherapy for anxiety and/or depressive symptoms during the study (see 
table 1). There was a non-selective drop-out of 26%, which was mainly due to the 
burden related to the frequency of therapy sessions (including travel distance).
Outcomes
In table 2 the means and standard deviations of the outcome measures are shown, 
per group treatment.
Primary outcome: There was no significant differential treatment effect over time on 
the primary outcome measure ‘self-efficacy’ (see table 3).
Secondary outcomes: There was a significant improvement in emotional wellbeing, 
as measured with the PDQ-39, in the BEWARE condition compared with the TAU 
condition, both at post-treatment and at follow-up. In addition, the timed balance 
test significantly improved with the BEWARE training compared with the TAU, 
also both at post-treatment and at follow-up. The regression coefficient of the 
stigmatization subscale of the PDQ-39 showed a trend-significant improvement 
in the BEWARE condition compared to the TAU condition. Figure 2 illustrates the 
changes over time, separately for the two conditions.
Covariates
Severity of wearing-off, represented by the number of wearing-off symptoms that 
patients reported at baseline, the level of anxiety, represented by the BAI total 
score, and the LEDD score, did not influence the effect of the intervention. However, 
cognitive status, represented by the MMSE total score, modulated the treatment 
effect for depressive symptoms (BDI): patients that had a higher score on the BDI, 
but were cognitively most intact, showed larger improvements after the BEWARE 
treatment. Besides this finding, the MMSE score had a significant influence on the 
intervention effect for freezing-of-gait (p=0.009), quality of life (PDQ) - emotional 
wellbeing (p=0.045), PDQ - social support (p=0.049), activities of daily living (NEAI) 
– household (p=0.047), and NEAI - leisure time (p=0.026).
8
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Figure 2. Graphical representation of interesting outcome measures.
Abbreviations: GSES = General Self Efficacy Scale, PDQ-39 = Parkinson’s Disease Questionnaire – 
39 items, BEWARE = body awareness intervention, CONTROL = treatment as usual, * = significant 
overall treatment effect.
Qualitative analysis
The patient researchers systematically documented the patients’ evaluations 
and revealed that the majority (84%) of patients that participated in the BEWARE 
treatment group experienced the new treatment as positive. Eight (21%) participants 
found it burdensome to visit the outpatient clinic twice every week. For future 
adaptation of the intervention, the patients suggested to lower the frequency (e.g. 
once instead of twice per week) but increase the duration (e.g. one and half hour 
instead of one hour) of the therapy sessions. In addition, all patients suggested to 
more actively involve partners/caregivers and to develop a tool to keep managing 
WRA and applying the principles learned during the sessions in the home-
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Discussion
This pilot randomized controlled phase II study investigated a newly developed 
intervention involving body awareness training (BEWARE) for WRA in patients with 
PD. Patients that participated in the BEWARE treatment (compared with TAU) showed 
improved emotional wellbeing as well as standing balance, both at post-treatment 
and follow-up. Feelings of social stigmatization trend-significantly decreased in the 
BEWARE condition compared with the TAU condition.
The BEWARE treatment was not superior to TAU with regard to the primary outcome 
measure self-efficacy (GSES). One explanation involves the content of the BEWARE 
intervention, that will be further optimized. The efficacy of the treatment might 
increase by removing or adjusting exercises that appeared less applicable to 
WRA according to the therapists. Since roughly half of the time of each BEWARE 
treatment session focused on ACT principles, instead of physical exercises as in 
the TAU condition, the treatment contrast regarding time that is spent on coping 
with WRA between the two conditions might not have been large enough to 
achieve significant between group differences in self-efficacy. In addition, based 
on the experience and feedback of participants, the frequency of the intervention 
sessions could be reduced while the duration of each session should be increased 
to improve feasibility and compliance. Also, more home-assignments or tools should 
be developed to achieve a better implementation of the principles in daily life.
Another explanation might be that the GSES is not responsive enough to measure 
changes in coping-related aspects of WRA in patients with PD. Certain self-efficacy 
beliefs that relate to controlling the disease and its symptoms may be unhelpful 
in the context of WRA, as Dennison and colleagues [41] also argue in a review of 
psychological correlates of adjustment in patients with multiple sclerosis. Critical 
review of the GSES reveals that while several items focus on dealing with unexpected 
situations, other statements in the questionnaire involve problem solving. In an ACT-
based intervention like BEWARE, the effect might be measured better by specifically 
focusing on the subject’s perceived capability to deal with WRA, instead of solving 
or controlling the situation. Since patients are taught to focus on what they find 
important, despite of their illness, another questionnaire might be more applicable 
and sensitive to change. While no such specific questionnaire is currently available 
nor validated for PD, one may consider the Engaged Living Scale [42] or the Goal 
Attainment Scaling [43]. These questionnaires focus on personal goals and values, 
which may be more closely related to the main focus of the BEWARE treatment, 
but would need to be validated in PD prior to implementation in a follow up study.
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The BEWARE treatment did improve emotional wellbeing, which is well explained by 
the psychological principles of ACT. The valued living exercises may have resulted 
in an attitude shift in the patients, now focusing more on what is important for 
them and trying to live life according to those positive values. Another possibility is 
that the body awareness exercises might have normalized the patients’ awareness 
of internal body sensations so that the perceived impact and actual severity of 
motor symptoms are more congruent, resulting in a less stressful experience 
during wearing-off. The improvement in standing balance might be explained by 
the additional physical therapy components. The combination of physical and 
mental components in the BEWARE treatment might have increased patients’ 
balance confidence, which could have improved their standing balance. Since this 
improvement was superior to the TAU group, the improvement in mental state 
might have been beneficial, due to strong reciprocal interactions between physical 
and mental symptoms. The connection between an improved mental state and 
balance is, however, not yet been investigated. Future research should therefore 
include the falls efficacy scale to assess fear of falling and relate this outcome to 
psychological outcomes [44].
Although feeling stigmatized did not show a statistically significant reduction in the 
BEWARE condition compared with the TAU condition, the regression coefficient is of 
potential interest for future investigation, especially at follow-up (table 3). The items 
of the stigma subscale of the PDQ-39 assess avoidance behavior and the experience 
of being in public places in the context of the disease. Reducing avoidance behavior 
is being specifically addressed in the BEWARE treatment, using FEEL exercises. A 
recent review [45] states that a more avoidant personality predicts heightened 
anxiety in PD patients. The fact that the stigma subscale shows an improvement only 
at trend-level might be explained by the limited number of items, also not covering 
the whole spectrum of stigmatization. In addition, the treatment and follow-up 
duration might not have been long enough to measure a longer term decrease in 
avoidance behavior and social distress related to disease characteristics.
The BEWARE treatment seemed to be most beneficial for patients that were 
emotionally most affected (e.g. higher BDI score), but were cognitively most intact. 
Therefore, patients should be better screened on cognitive dysfunction before 
starting an adapted and improved BEWARE treatment study. In addition, because 
of the small sample size, this result needs to be further investigated in a larger 
(multi-center) study sample.
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The number of wearing-off symptoms at baseline did not seem to influence 
the treatment effect. However, the number of wearing-off symptoms might not 
be a good criterion to assess the severity of the wearing-off, since patients may 
experience just one but very disabling wearing-off symptom versus several, less 
disabling wearing-off symptoms. The severity of discomfort, instead of the number 
of symptoms, is not included in the WOQ-19. In the future it might be better to use 
other measures to assess disease severity, such as the Movement Disorder Society-
Unified Parkinson’s Disease Scale (MDS-UPDRS) part III and IV [46], in combination 
with times of medication intake.
Results from the qualitative analysis indicate that the burden of the frequency of 
therapy sessions was high for several patients while the duration of each session 
could be increased. In addition the involvement of caregivers was missed. In a 
follow-up study, the frequency of therapy sessions should be reduced (to once a 
week), while the length of the sessions can be extended to one and half hour. In 
addition, more homework with proper monitoring can be implemented to promote 
implementation of the treatment principles in daily life, and the addition of 1 or 2 
home sessions also involving the partner and/or the caregiver might add to the 
long-term effects of the intervention. In addition, a booster session at 12 weeks after 
treatment completion might also facilitate better implementation into daily life and 
long-term effects, as is also argued by Morris and colleagues [47]. Self-help material 
should be developed so that patients have something they can fall back on at home 
in between sessions and after completion of the training. Concerning the content 
of the BEWARE training, more time will be spent on exercises concerning valued 
living and less time will to be spent on repetition of previously trained elements. 
Homework will focus more on the involvement of the patients’ daily life (motor and 
non-motor) struggles, and the amount of homework will be increased with the goal 
to perform one exercise with a duration of 10-15 minutes every day. In addition, 
cognitive demands will be decreased by focusing more on the body and daily life 
activities, and by more repetition using the self-help material and a booster session.
A major strength of this study is the implementation of a TAU group, which controlled 
for the physical therapy elements that were also implemented in the BEWARE group. 
The additional effect of the psychological elements was therefore investigated. This 
was the first time this new approach to the treatment of PD patients with wearing-
off, which includes both psychological and physical elements, was investigated. 
The number of participants, although calculated prior to study set-up, could have 
been insufficient to achieve sufficient statistical power, which can be considered a 
limitation.
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In conclusion, this pilot randomized controlled study provided preliminary evidence 
that the BEWARE treatment, as compared with conventional physical therapy, is a 
promising therapeutic approach to address WRA. In its current form, the BEWARE 
training is most effective in patients with healthy cognition. The results provide 
important clues to optimize the BEWARE treatment protocol for testing in a future 
large-scale clinical trial, which is necessary to underpin its added therapeutic value 
before future implementation can be considered.
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In clinical practice, patients with PD often present a complex variety of symptoms. 
Although PD is classified as a movement disorder, non-motor symptoms (including 
anxiety) are an important elements of the disease. In this thesis, it is hypothesized 
that in PD patients motor and non-motor symptoms have reciprocal influences and 
interact with one another, complicating diagnosis and treatment.
In the first part of this thesis (chapters 2 - 5) we focused on the associations 
and complex interactions between anxiety, other non-motor symptoms and 
motor symptoms in PD. We used the findings from these chapters, together with 
clinical experience and other research in the field, to develop a potentially better, 
multidisciplinary treatment for wearing-off related anxiety in PD. In the second part 
(chapters 6 - 8) we focused on the efficacy of psychological and multidisciplinary 
treatment of motor and non-motor symptoms in PD.
In the sections below, I summarize the results of each chapter of this thesis. Several 
methodological strengths and limitations of our work are considered, as well as the 
clinical implications of our findings. Finally, I discuss directions for future research 
and final conclusions.
Summary of the results
In chapter 2 we investigated the phenomenology of anxiety in PD by performing a 
principal component analysis to explore underlying symptom dimensions of anxiety 
as measured with the Beck Anxiety Inventory (BAI) [1]. We showed that the BAI 
consists of one affective and four somatic anxiety symptom subscales. We found 
significant associations between the somatic subscales and motor and autonomic 
symptoms, whereas the affective subscale showed a significant association with 
depressive symptoms and no association with motor or autonomic symptoms. The 
total BAI score also showed a significant association with severity of depressive 
symptoms.
To investigate the generalizability of the findings in chapter 2, in chapter 3 we 
replicated these findings using a principal component analysis on the BAI in PD 
patients that were referred for neuropsychiatric assessment [2]. Again, we found 
one affective and four somatic anxiety symptom subscales, and a strong association 
between anxiety and depression. In a post-hoc analysis, the score on the affective 
subscale showed equal predictive value as compared to the total BAI score in 
predicting whether or not patients received an anxiety disorder diagnosis through 
psychiatric evaluation.
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In Chapter 4 we used an explorative network analysis to study the associations 
between motor and anxiety symptoms, comparing symptom networks of high-
anxious versus low-anxious PD patients. We investigated whether anxiety and 
motor symptoms are more strongly connected in the high-anxiety PD patient group, 
compared to the low-anxiety PD patient group [3]. The high-anxiety PD patient 
network showed higher global strength. In spite of group differences in which 
the high-anxiety group showed significantly worse motor and cognitive function, 
a higher age, and included more female patients, the network comparison test 
showed a significant difference in global strength, but did not show statistically 
significant differences in strength of the connections between motor and anxiety 
symptoms between the patient groups.
Chapters 2,3, and 4 focused on the associations between motor, anxiety, and 
other symptoms, not taking into account their temporal relationships. In chapter 
5, we investigated the longitudinal associations between anxiety, fear of falling, and 
freezing of gait in 153 PD patients [4]. Across 4 measurements, with three weeks 
between each measurement, all associations were significant, with the strongest 
association between fear of falling and freezing of gait. Adjustments for disease 
characteristics and adverse effects of medication diminished all associations.
After a description of the phenomenology of anxiety, and its cross-sectional and 
longitudinal associations with motor and other non-motor symptoms, part 2 of 
this PhD thesis focusses on the treatment of these complex symptom interactions 
in PD patients.
In chapter 6, we describe two meta-analyses on the effects of cognitive behavioral 
and mindfulness-based therapies on psychological distress in patients with 
neurodegenerative disorders [5]. The included studies were divided in those 
comparing the treatment of interest with an active control condition and those 
with a treatment as usual or waitlist control condition. The results showed 
that psychological interventions have a small to moderate effect on reducing 
psychological distress in patients with PD and Multiple Sclerosis (MS). The overall 
quality of the included studies was low and showed considerable heterogeneity. No 
evidence was found for publication bias.
Chapters 7 & 8 present the study protocol and results of a pilot randomized 
controlled trial (RCT) in which we described and investigated a newly developed 
multidisciplinary group treatment for wearing-off related anxiety in PD named 
BEWARE [6, 7]. BEWARE is a body awareness group training in which we combine 
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elements from Acceptance and commitment therapy (ACT) with physical therapy. 
We compared the BEWARE training with group physical therapy. In chapter 8 we 
describe the results of this pilot RCT. Patients that participated in the BEWARE 
training showed no significant improvement in the primary outcome measure, 
self-efficacy, compared to the control condition. Patients that received the BEWARE 
training (more than patients that received physical therapy only) showed improved 
emotional wellbeing as well as standing balance, both at post-treatment and follow-
up. Feelings of social stigmatization decreased in this group as well, however, this 
was not statistically significant.
General reflection and clinical implications
In chapters 2 and 3, we describe the overlap between anxiety, depression, 
autonomic failure and motor dysfunction in different PD patient populations [1, 2]. 
Autonomic and motor symptoms were associated with the somatic subscales of 
the BAI, while depressive symptoms were associated with the affective subscale. 
The network analysis presented in chapter 4 also showed connections between 
symptoms of motor failure and anxiety. This gives rise to the question whether 
motor and (somatic) anxiety symptoms often co-occur, or that these items show 
overlap because they measure one and the same symptom. For example, somatic 
symptoms such as trembling and feeling unsteady can be interpreted both as motor 
symptoms of PD and as somatic equivalents of anxiety. This complicates diagnosing 
anxiety in PD, which can lead to either under- or overdiagnosis, since the somatic 
symptoms can both be interpreted as either PD-related or as anxiety-related. 
Within the explorative network analysis, the overlap between motor symptoms and 
somatic anxiety symptoms was present in both patient groups, in spite of the level of 
anxiety. This argues in favour of the hypothesis that the specific somatic anxiety and 
motor symptom scores represent one and the same symptom. To eliminate room 
for interpretation and measure anxiety without somatic equivalents, one could 
advise to solely use the 7-item affective subscale of the BAI that does not include 
motor aspects, as presented in chapter 2 and 3 [1, 2]. This subscale showed equal 
predictive value as compared to the total BAI in whether or not patients received an 
anxiety disorder diagnosis through psychiatric evaluation. However, despite of its 
equal predictive power, we do not recommend to disregard the somatic symptoms 
completely, as they are also an important part of anxiety [8]. The affective subscale 
might be useful as a first screening tool for anxiety in PD, to then interpret anxiety 
symptoms in the context of motor and autonomic symptoms.
Chapters 2,3, and 4 described analyses on cross-sectional data, however, symptom 
fluctuations over time are very much apparent in PD patients. Over 65% of PD 
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patients experience motor fluctuations within 5 years of dopamine replacement 
therapy [9]. With these motor fluctuations, another 75% of PD patients experience 
mood and anxiety fluctuations in parallel [10]. Motor and anxiety symptoms might 
interact over time, so longitudinal data may represent the interplay between these 
symptoms better than cross-sectional data. In chapter 5 we showed that motor 
and anxiety symptoms influence one another over time, in which fear of falling and 
potentially anxiety precede freezing of gait. In addition, medication and its adverse 
effects (including fluctuations) seem to influence both freezing of gait and anxiety 
symptoms as well as their association, which is in line with previous research [11]. 
Motor and anxiety symptoms can co-occur simultaneously, as is shown in chapters 
2,3, and 4. These symptoms might originate in a subsequent manner over time, 
possibly creating a vicious cycle, which is indicated by our longitudinal analysis in 
chapter 5. This is also what is seen in clinical practice, and is evidenced by previous 
research [12, 13]. This vicious cycle can be a process that takes place within minutes 
[14] and we only investigated the symptom interactions over a time-period of a few 
weeks. Our results indicate that anxiety can have an impact on motor symptoms 
and vice versa, which is important to take into account in the treatment of both 
anxiety and motor symptoms in PD patients.
Besides PD, other progressive neurological disorders such as MS and Huntington’s 
disease are also accompanied by both motor and psychiatric symptoms [15, 16]. 
Resulting from our meta-analyses in chapter 6, psychological treatments show 
small to moderate effects in reducing psychiatric symptoms in patients with PD and 
MS, which indicates that treatments can be optimized. Optimizing psychological 
treatments could include taking the interactions with motor symptoms into 
account. Since the nature of neurodegenerative diseases involves progressive 
decline and inevitability of occurring symptoms, especially motor symptoms, the 
effects on symptom reduction can be expected to be unsatisfactory. The effect on 
psychiatric symptoms, however, can result in reduction of psychiatric symptoms. 
The interaction with inevitable motor symptoms, thereafter, makes the treatment 
of psychiatric symptoms in PD patients challenging.
Especially regarding wearing-off, it is important to discuss treatment options to 
improve motor symptom fluctuations. First line treatment in improving motor as 
well as non-motor fluctuations is dopamine replacement therapy [17]. When motor 
symptom fluctuations diminish, non-motor symptoms (including anxiety) might 
also diminish [18]. However, available pharmacological treatments are considered 
insufficient to alleviate the complications (e.g. response fluctuations) of PD [19]. Also, 
a small percentage of patients can develop a dopamine dysregulation syndrome 
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(DDS) as a complication of dopamine replacement therapy, especially when the 
accompanied anxiety remains untreated [20, 21]. DDS is an impulse control disorder 
characterized by an addiction-like PD medication overuse [22].
One can also consider more advanced treatment options, such as Deep Brain 
Stimulation (DBS), continuous levodopa-carbidopa intestinal gel infusion, and 
continuous subcutaneous apomorphine infusion. These advanced treatment options 
are considered when PD patients experience debilitating response fluctuations and/
or dyskinesias in spite of optimal dopamine replacement therapy [23]. However, 
since PD is a neurodegenerative disease in which progressive decline is inevitable, 
patients eventually still develop symptom fluctuations and the abovementioned 
advanced therapies are considered rather invasive and/or contraindicated in some 
patients.
It is therefore warranted to explore non-pharmacological and non-invasive 
treatments, to teach PD patients longterm coping strategies in order to deal 
with symptom fluctuations and interactions, as is also suggested by some of the 
studies included in our meta-analyses in chapter 6 [24-26]. To achieve acceptance 
of symptoms and healthy coping strategies, it is important to increase awareness 
of ones bodily symptoms, thoughts and emotions [27]. Especially, it is important 
to improve interoceptive accuracy, which refers to the accurate sensing of internal 
bodily changes, which includes both awareness and interpretation of bodily 
sensations [27]. Based on our clinical experience with PD patients that experience 
wearing-off related anxiety, we see inaccuracies in body awareness, which is an 
element of interoception. These inaccuracies can present themselves as either a 
hyperawareness or an unawareness. Hyperawareness refers to an excessive focus 
on bodily sensations and is characteristic in patients with an anxiety disorder, 
especially panic disorder [28-30]. A common factor in anxiety disorders is an 
attentional bias toward threat [28], and when one interprets bodily sensations as 
dangerous, hyperawareness on these sensations is a logical consequence and is 
evidenced to increase anxiety [30-32].
Unawareness can be seen as avoidance behavior, which can result in an 
overwhelming sense of anxiety (e.g. panic attack) when bodily sensations are 
so intense they cannot longer be ignored. Patients with functional neurological 
symptoms, chronic pain, and somatoform disorders show lower interoceptive 
accuracy [33-35]. In addition, reduced interoceptive accuracy was predictive of 
depressive symptoms [34] and correlated with symptom severity in these patients 
[33].
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Body awareness and interoceptive accuracy have not yet been investigated 
in patients with PD. Based on the overlap with somatic symptom and related 
disorders and anxiety disorders, we hypothesize that it would be helpful to improve 
interoceptive accuracy and subsequently alter the catastrophic interpretations of 
bodily sensations, in order to bring body awareness to a more healthy and neutral 
experience. This is specifically relevant for PD patients that experience wearing-off 
related anxiety, where motor symptoms directly interact with anxiety symptoms.
Body awareness therapies show positive results in patients with chronic pain and 
somatic symptom and related disorders [36, 37]. In the treatment of patients with 
chronic pain, positive effects are also found regarding multidisciplinary treatment 
in which body awareness therapy is included [36]. The BEWARE training (chapters 
7 and 8) was the first attempt in improving body awareness and in addressing the 
complex interactions between motor and anxiety symptoms in PD, by combining 
physical therapy with Acceptance and Commitment Therapy (ACT). Besides body 
awareness and learning how to cope with the complex symptom interactions, 
the BEWARE training also focuses on acceptance and incorporates exposure as an 
important element in the treatment of anxiety.
Patients with intact cognitive abilities benefited the most from the BEWARE training, 
which indicates that the treatment requires cognitive abilities to be largely intact. 
Reflecting upon the non-significant results on the primary outcome measure self-
efficacy, the items on this questionnaire mainly concern problem solving. However, 
the progressive debilitating symptoms of PD cannot always be solved. At the time of 
designing the pilot-RCT, there was no suitable outcome measure available in Dutch 
to really grasp the intention or goal of ACT, namely the acceptance and commitment 
to valued living despite of the debilitating symptoms. We are currently investigating 
an imnproved version of the BEWARE treatment in a multicenter RCT. Now, we use 
the Chronic Illness Acceptance Questionnaire (CIAQ) as a primary outcome measure, 
which may be more suitable for the goal of the treatment. Since the CIAQ was 
not available in Dutch and is not validated in PD patients, we officially translated 
(and back-translated) the CIAQ and are investigating its validity and reliability in an 
independent group of PD patients.
In clinical research, and specifically in investigating the effectiveness of a treatment, 
it is important to take the patients’ experience and perspective into consideration. 
Patients can give valuable information about what they find most troublesome 
in dealing with their disease, what helps them the most or what is effective in 
treating their symptoms, and what is considered to have the highest impact on 
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their lives. Practical suggestions for improvement in the BEWARE study, both for the 
treatment and study design, resulted from qualitative assessments in which patient 
researchers from the Dutch Parkinson Patient Association (Parkinson Vereniging) 
performed interviews with the participating patients. We incorporated these 
suggestions to improve the BEWARE treatment and our study design.
To date, the BEWARE study is the only RCT that investigated a treatment for anxiety 
in PD patients and is anxiety still considered to be an ignored but important 
aspect of PD [19]. Because of the co-occurrence of motor and mental symptoms, 
we recommend treating anxiety in PD in a multidisciplinary manner, increasing 
effectiveness using a holistic approach. In this way, we can break through the vicious 
cycle of subsequent motor and anxiety symptoms. For PD patients that experience 
wearing-off related anxiety, one can imagine this makes the wearing-off experience 
less stressful and increases psychological wellbeing [6].
Methodological considerations
The methodological strengths and limitations were discussed in each individual 
chapter. Here we summarize and further discuss important strengths and limitations 
of the research in this thesis.
A major strength of this thesis is the use of different statistical techniques that 
together provide important insights in the complex relationships between motor 
and non-motor symptoms, mainly anxiety, in PD. The different symptom dimensions 
of anxiety were first investigated in a large patient sample (chapter 2) and were 
replicated in a patient sample with considerable neuropsychiatric symptoms 
(chapter 3), which improves the generalizability of our findings. Cross-sectional 
associations were investigated in large patient samples (chapters 2, 3, and 4) using 
principal component analyses and network analysis, from which we gained insights 
in these associations on the level of anxiety dimensions and on single symptom-level. 
The principal component analyses address the shared variation amongst symptoms, 
while the network analysis shows unique symptom-to-symptom variations within 
different patient groups [38]. The longitudinal study design in chapter 5 allowed us 
to draw conclusions regarding temporal relationships and the influence of possible 
confounders between motor and anxiety symptoms in PD. Another major strength 
of this thesis is that we investigated the first multidisciplinary treatment combining 
ACT and physical therapy using an RCT design (chapters 7 and 8). Moreover, it is 
the first and only RCT investigating a treatment for anxiety in PD to date. In this RCT, 
we collaborated closely with patient researchers of the Dutch Parkinson Patient 
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Association (Parkinson Vereniging) which enabled us to systematically involve the 
patients to further improve the BEWARE training.
Nonetheless, there are some methodological limitations that are important to 
discuss. First of all, the BAI was used in three of our studies, in which we investigated 
the cross-sectional associations (chapters 2 through 4). The BAI is considered not 
the most reliable measure of anxiety in PD patients, since it contains mainly items 
measuring episodic forms of anxiety, disregarding non-episodic forms of anxiety 
such as generalized anxiety disorder, which is the most common anxiety disorder in 
PD [39, 40]. For future research, it is therefore recommended to use, for example, 
the Parkinson Anxiety Scale (PAS) developed by Leentjens and colleagues [41], which 
includes items referring to both episodic and non-episodic forms of anxiety. Also, it 
includes avoidance behaviours, which is an important part of anxiety [8].
In chapter 5 we used the Hospital Anxiety and Depression Scale to assess anxiety 
symptoms on multiple time points to investigate longitudinal relationships. 
Measurements were three weeks apart, which did not allow us to investigate the 
motor – anxiety interactions over shorter periods of time (e.g. minutes or hours), 
which might be more interesting in PD patients with fluctuations. In addition, 
the questionnaires that were used inquired about symptoms over different time 
periods, e.g. one versus four weeks, which resulted in average scores over different 
time periods and refrained us from drawing causal conclusions about symptom 
interactions. The associations investigated in chapters 2 through 5 showed that 
motor and anxiety symptoms can co-occur, however, the interactions might be 
better investigated using time-series data in which symptom measurements are 
performed in much shorter time intervals (e.g. multiple times a day) using, for 
example, expierence sampling method.
Regarding anxiety diagnoses, the diagnosis that patients received in chapter 3 
was not assessed through a structural clinical interview, but through psychiatric 
evaluation in daily clinical practice. Although the primary diagnosis was correctly 
reported, secondary diagnoses of anxiety might not always have been reported, 
mainly in cases with a primary psychiatric disorder that could also explain the 
present anxiety symptoms (e.g. psychotic disorder, parkinson’s disease dementia). 
A structured interview might have resulted in more secondary anxiety diagnoses.
Unfortunately, in the PD patient sample used in chapter 4, data on psychiatric 
diagnoses were not available to divide our patient group on whether or not patients 
had an anxiety disorder. We divided the patient group into high- versus low-anxious 
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patients on based on the total score on the BAI (cut-off >12) [42]. This might have 
resulted in some false positive associations between BAI-items in the network. 
Although the patient groups were relatively large (316 and 253 PD patients) and 
we corrected for multiple comparisons, for this type of analysis it is preferred to 
test even larger groups [43]. It is therefore important to interpret the results of this 
chapter with caution.
The described BEWARE training in chapters 7 and 8 and the studies included in the 
meta-analyses described in chapter 6 included small numbers of participants. This 
results in low power, and therefore we cannot draw hard conclusions concerning the 
effectiveness of psychological treatments. Although the psychological treatments 
and the BEWARE training show promising results, there is room for improvement.
Suggestions for future research
This thesis elaborately investigated the complex interactions between motor 
and non-motor symptoms in PD patients, including the treatment of anxiety in 
the context of response fluctuations. However, more research is needed to fully 
understand these complex interactions to improve diagnosis of anxiety and 
wearing-off related distress and its treatment.
Since these complex interactions are very much apparent in PD patients with 
fluctuations, we expect that in these patients the interactions might be even more 
evident when symptoms are measured in shorter time periods (e.g. minutes or 
hours). For example, a panic attack occurs suddenly [8] and usually diminishes 
within several minutes. PD patients that experience panic attacks in the context 
of wearing-off related anxiety can experience subsequent symptoms that occur 
in a time-period of minutes. To further investigate symptom interactions, it is 
therefore recommended to apply methods with more finegrained time resolution 
to study interactions between motor, automic and affective symptoms of response 
fluctuations. An interesting example of such approach is the N = 1 study performed 
by van der Velden and colleagues [44], investigating time-series data from an 
individual patient using network analysis. Building onto our own research, it would 
be interesting to include both somatic symptoms (such as freezing, tremor, rigidity, 
and autonomic symptoms) as well as cognitive of affective anxiety symptoms (such 
as fear of losing control and rumination). We hypothesize that, in anticipation of an 
‘off’ period, patients feel more tense and therefore experience an earlier onset of 
or a more severe subsequent ‘off’ period. In addition, by using time-series data in a 
network analysis for a single PD patient, we can investigate which symptoms interact 
with other symptoms and are therefore potential treatment targets. This might 
Binnenwerk_Ires.indd   172 12-3-2021   13:47:37
173
General discussion
be very useful in clinical practice, and facilitates a more personalized treatment 
approach.
Research on the treatment of anxiety in PD, and especially in the context of motor 
symptoms, is extremely limited. More research is warranted, both pharmacological 
and non-pharmacological, in order to treat anxiety in PD more effectively. We 
investigated a multidisciplinary treatment combining Acceptance & Commitment 
therapy with physical therapy. This showed promising results and together with 
the feedback of the participants, we optimized this BEWARE training, and we are 
currently investigating its effectivity in a better powered multicenter study. When 
the BEWARE training is considered effective, we intend to optimize the treatment 
further and add an online training module in order for patients to practice more 
intensively at home. Since patients with intact cognitive abilities benefited the most 
from BEWARE, it would be interesting to develop a more behavioural variant of 
the treatment that demands less cognitive abilities. In this variant, the primary 
focus lies on behavioural change. The Patient Education Program Parkinson (PEPP) 
also incorporated a more behavioural option in their CBT-based program, showing 
good results [45]. After proving its effectiveness, the BEWARE treatment can be 
implemented in clinical practice. Implementation is achieved by training therapists 
in the treatment protocol and making the treatment available for patients through 
health care providers. Ideally, in order to increase evidence for its effectiveness, the 
treatment needs to be investigated in an independent PD patient sample.
Final conclusions
PD is characterized by a variety of motor and non-motor symptoms. This thesis 
confirms that consideration of motor and other PD-related symptoms is important 
in diagnosing anxiety and in the treatment of response fluctuations. The reciprocal 
associations between motor and anxiety symptoms should be taken into account in 
both the diagnostic and treatment process. Especially the temporal interactions of 
these symptoms are in need of further investigation, as well as alternative treatment 
options for anxiety and wearing-off in PD.
The suggested strong interplay between motor and non-motor symptoms in PD 
warrants a holistic approach to treatment of anxiety in clinical practice. The BEWARE 
training is the first attempt to treat anxiety in a multidisciplinary manner, in the 
context of response fluctuations with the aim to improve coping and valued living 
in spite of (inevitable) PD symptoms.
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Parkinson’s disease (PD) is a neurodegenerative disorder with a prevalence of 100 to 
200 per 100,000 people and an annual incidence of 15 per 100,000 people. Due to 
ageing and other factors such as genetic mutations and environmental risk factors 
(e.g. pesticides), the occurrence of PD is increasing. Recently, PD has even been 
described as a pandemic.
PD is characterized by its main motor symptoms bradykinesia, rigidity and tremor, 
and additional motor and non-motor symptoms. Non-motor characteristics may 
include cognitive dysfunction, autonomic failure, and neuropsychiatric symptoms 
and disorders such as anxiety, depression, psychosis, impulse control disorders, 
sleep disorders, and apathy.
As compared to the motor symptoms, neuropsychiatric symptoms are often 
reported to have a higher impact on quality of life of both patients and their 
caregivers. Amongst neuropsychiatric symptoms, anxiety and depression are 
considered major predictors of reduced quality of life, followed by cognitive 
dysfunction.
Currently, up to 45% of PD patients experience either clinically relevant anxiety 
symptoms or fulfill the criteria for an anxiety disorder, including generalized anxiety 
disorder, panic attacks, and social phobia. Anxiety in PD can also occur in the context 
of response fluctuations in PD symptoms, especially related to wearing-off, i.e., the 
re-emergence of PD symptoms while transitioning from an ‘on’ state to an ‘off’ state, 
typically occurring prior to the next scheduled dose of dopaminergic medication 
taking effect. About 75% of patients with motor fluctuations experience fluctuations 
in mood and/or anxiety in parallel. Therefore, diagnosing and treating anxiety in 
PD is complicated, due to overlapping motor and autonomic symptoms, comorbid 
psychiatric symptoms, and the interplay between anxiety and motor symptoms 
over time.
This thesis mainly focuses on understanding (part 1) and treating (part 2) anxiety 
symptoms in the context of motor symptoms. Chapter 1 provides a general 
introduction on anxiety in PD including the multiple factors that complicate 
diagnosis and treatment. 
The first part of this thesis (chapters 2 through 5) focuses on understanding the 
complex associations and interactions between anxiety, motor and other non-motor 
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symptoms in PD. In chapter 2 we investigated the phenomenology of anxiety in 
PD by performing a principal component analysis on the items of the Beck Anxiety 
Inventory (BAI) in a sample of 294 PD patients to explore underlying symptom 
dimensions and to relate these to other motor and non-motor features. We showed 
that the BAI consists of one affective (clustering anxious cognitions and emotions) 
and four somatic symptom subscales (clustering physical symptoms). We found 
significant associations between the somatic subscales and motor and autonomic 
symptoms, as measured with the UPDRS-III and SCOPA-AUT, respectively. The 
affective subscale showed a significant association with depressive symptoms (as 
measured with the BDI), but no association with motor or autonomic symptoms. 
To investigate the generalizability of the findings in chapter 2, chapter 3 describes 
the replication of the principal component analysis in 123 PD patients that were 
referred for neuropsychiatric evaluation to a specialized neuropsychiatric outpatient 
department. Again, we found one affective and four somatic anxiety symptom 
subscales, and a strong association between anxiety and depression. In a post-
hoc analysis, the score on the affective subscale showed equal predictive value as 
compared to the total BAI score in predicting whether or not patients received an 
anxiety disorder diagnosis through psychiatric evaluation. The associations of the 
subscales of the BAI with the BDI, UPDRS-III and SCOPA-AUT confirm the overlap 
of anxiety in PD with both depression and with motor and autonomic symptoms. 
The affective subscale might be used to screen for anxiety in order to eliminate 
somatic equivalents of anxiety that can also be interpreted as motor or autonomic 
PD symptoms. However, we do not recommend to disregard the somatic symptoms 
completely, and rather suggest to interpret anxiety symptoms in the context of 
motor symptoms, taking this overlap and interaction into consideration.  
To investigate whether the associations between motor symptoms and anxiety 
differed in strength between high- versus low-anxiety PD patients, we used an 
explorative network analysis to study these associations in chapter 4. In the high-
anxiety group, 316 PD patients were included, in the low-anxiety group, 253 PD 
patients were included. The high-anxiety PD patient network showed higher global 
strength. In spite of group differences in clinical and demographic characteristics, 
with the high-anxious group showing significantly worse motor and cognitive 
function, a higher age, and more female patients, the network comparison test 
did not show statistically significant differences in strength of the connections 
between motor and anxiety symptoms. Since associations between motor and 
anxiety symptoms are apparent in both groups, this shows that these symptoms 
are associated, even when patients have no to mild anxiety symptoms.
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Chapters 2,3, and 4 focused on the associations between motor, anxiety, and 
other symptoms, not taking into account their temporal relationships. As symptom 
intensity may vary over time, we investigated the longitudinal associations between 
anxiety, fear of falling, and freezing of gait in 153 PD patients in chapter 5. Across 
four measurements, with three weeks between each measurement, all associations 
were significant, with the strongest association between fear of falling and freezing 
of gait. Adjustments for disease characteristics (such as disease duration, depressive 
and cognitive symptoms) and adverse effects of medication (such as response 
fluctuations) diminished all associations, which confirms the complex interactions 
between motor and anxiety symptoms.
After a description of the phenomenology of anxiety, and its cross-sectional and 
longitudinal associations with motor and other non-motor symptoms, part 2 of 
this PhD thesis focuses on the treatment of these complex symptom interactions 
in PD patients. 
In chapter 6, we describe two meta-analyses on the effects of cognitive behavioral 
therapy and mindfulness-based therapies on psychological distress in patients 
with neurodegenerative disorders. The included studies were divided into those 
comparing the treatment of interest with an active control condition and those 
with a treatment as usual or waitlist control condition. The results showed 
that psychological interventions have a small to moderate effect on reducing 
psychological distress in patients with PD and Multiple Sclerosis (MS). The overall 
quality of the included studies was low and showed considerable heterogeneity, 
which pleads for more studies with better quality.
Chapters 7 and 8 present the study protocol and results of a pilot randomized 
controlled trial (RCT) in which we described and investigated a newly developed 
multidisciplinary group treatment for wearing-off related anxiety in PD named 
BEWARE. BEWARE is a body awareness group training in which we combine 
elements from acceptance and commitment therapy (ACT) with physical therapy. 
We compared the BEWARE training with group physical therapy. In chapter 8 we 
describe the results of this pilot RCT. Patients that participated in the BEWARE 
training showed no significant improvement in the primary outcome measure, self-
efficacy, as compared to the control condition. However, this group did show a more 
improved emotional wellbeing as well as standing balance, both at post-treatment 
and follow-up. Feelings of social stigmatization decreased as well, however, the 
difference with the control group was not statistically significant. The BEWARE 
training was the first attempt in improving body awareness and in addressing the 
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complex interactions between motor and anxiety symptoms in PD. An optimized 
Beware intervention is currently being investigated in a large multicenter RCT.
Finally, in Chapter 9, the findings of this thesis are summarized and reflected 
upon. I describe the reciprocal interactions between anxiety, motor, and 
autonomic symptoms. I link our findings to the research field on body awareness 
in psychosomatic disorders, discussing the commonalities in the inaccuracy of 
interpretation of bodily symptoms that is seen in both PD patients with wearing-
off related anxiety and patients with psychosomatic disorders. Subsequently, 
I provide suggestions for improving this inaccuracy. Regarding the reciprocal 
interactions between motor and anxiety symptoms, I discuss how this interaction 
should be taken into account through multidisciplinary treatment, of which the 
BEWARE training is a first attempt in PD. This thesis helps to understand and treat 
anxiety symptoms in the context of motor symptoms in PD patients, aiming to 
improve psychological wellbeing irrespective of disease progression. Since patients 
experience symptom fluctuations during the day, I provide suggestions for more 
in-depth investigation of interactions between motor and anxiety symptoms during 
response fluctuations, for which we propose using high-frequent time-series data. 




De ziekte van Parkinson (ZvP) is een neurodegeneratieve aandoening met 
een prevalentie van 100 tot 200 per 100.000 mensen, en een jaarlijkse 
incidentie van 15 per 100.000 mensen. Door veroudering en andere factoren 
zoals genetische mutaties en omgevingsrisicofactoren (bijv. Pesticiden), neemt 
het voorkomen van de ZvP toe. Onlangs werd de ziekte zelfs omschreven als een 
pandemie.
De ZvP wordt gekenmerkt door de belangrijkste motorische symptomen 
bradykinesie, stijfheid en tremor, en bijkomende motorische en niet-
motorische symptomen. Niet-motorische symptomen kunnen cognitieve disfunctie, 
autonoom falen en neuropsychiatrische symptomen en stoornissen zijn, zoals 
angst, depressie, psychose, stoornissen in de impulsbeheersing, slaapstoornissen 
en apathie.
In vergelijking met de motorische symptomen, wordt vaak gemeld dat 
neuropsychiatrische symptomen een grotere invloed hebben op de kwaliteit 
van leven van zowel patiënten als hun naasten. Van de neuropsychiatrische 
symptomen worden angst en depressie beschouwd als belangrijkste 
voorspellers van verminderde kwaliteit van leven, gevolgd door cognitieve 
disfunctie.
Momenteel ervaart tot 45% van de Parkinson-patiënten klinisch relevante 
angstsymptomen of voldoet aan de criteria voor een angststoornis, waaronder 
gegeneraliseerde angststoornis, paniekaanvallen en sociale fobie. Angst bij de 
ZvP kan ook optreden in de context van responsfluctuaties, vooral gerelateerd 
aan het opnieuw optreden van Parkinson-symptomen tijdens de overgang van 
een ‘on’-toestand naar een ‘off’-toestand, die meestal optreedt vlak vóór de 
volgende geplande dosis dopaminerge medicatie. Ongeveer 75% van de patiënten 
met motorische fluctuaties ervaart tegelijkertijd stemmingswisselingen en/
of angst. Het diagnosticeren en behandelen van angst bij Parkinson is gecompliceerd 
vanwege overlappende motorische en autonome symptomen, comorbide 
psychiatrische symptomen (zoals depressie) en de wisselwerking tussen angst- en 
motorische symptomen in de loop van de tijd.
Dit proefschrift richt zich voornamelijk op het begrijpen (deel 1) en behandelen 
(deel 2) van angstsymptomen in de context van motorische symptomen. Hoofdstuk 
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1 geeft een algemene inleiding over angst bij de ZvP, inclusief de vele 
factoren die diagnosticeren en behandelen bemoeilijken.
Het eerste deel van dit proefschrift (hoofdstukken 2 t/m 5) richt zich op 
het begrijpen van de complexe associaties en interacties tussen angst, motorische 
en andere niet-motor ische s ymptomen bi j  de ZvP. In hoofdstuk 
2 onderzochten we de fenomenologie van angst bij de ZvP door een principale 
componentenanalyse uit te voeren op de items van de Beck Anxiety Inventory 
(BAI), in een steekproef van 294 Parkinson-patiënten, om onderliggende 
symptoomdimensies te onderzoeken en deze te relateren aan andere 
motorische en niet- motorische symptomen. We toonden aan dat de BAI 
bestaat uit één affectieve (clustering van angstige cognities en emoties) en 
vier somatische symptoomsubschalen (clustering van fysieke symptomen). We 
vonden significante associaties tussen de somatische subschalen en motorische 
en autonome symptomen, zoals gemeten met de UPDRS-III en SCOPA-AUT, 
respectievelijk. De affectieve subschaal vertoonde een significant verband met 
depressieve symptomen (zoals gemeten met de BDI), en had geen verband met 
motorische of autonome symptomen.
Om de generaliseerbaarheid van de bevindingen in hoofdstuk 2 te onderzoeken, 
beschrijft hoofdstuk 3 de replicatie van de principale componentenanalyse bij 123 
Parkinson-patiënten die voor neuropsychiatrische evaluatie waren verwezen naar 
een gespecialiseerde neuropsychiatrische polikliniek. Opnieuw vonden we een 
affectieve en vier somatische subschalen, en een sterke associatie tussen angst en 
depressie. In een post-hoc analyse vertoonde de score op de affectieve subschaal 
dezelfde voorspellende waarde als de totale BAI-score bij het voorspellen of 
patiënten al dan niet een diagnose van een angststoornis kregen door middel van 
psychiatrische evaluatie. De associaties van de subschalen van de BAI met de BDI, 
UPDRS-III en SCOPA-AUT bevestigen de overlap van angst bij Parkinson met zowel 
depressieve als met motorische en autonome symptomen. De affectieve subschaal 
kan worden gebruikt om op angst te screenen om somatische equivalenten van 
angst te elimineren die ook kunnen worden geïnterpreteerd als motorische of 
autonome Parkinson-symptomen. Echter, raden we niet aan om de somatische 
symptomen volledig te negeren, en angstsymptomen in het kader van de motorische 
symptomen te interpreteren, deze overlap en interactie in overweging nemende.
Om te onderzoeken of de associaties tussen motorische symptomen en angst 
verschilden in sterkte tussen Parkinson-patiënten met hoge en lage angst, 
hebben we een exploratieve netwerkanalyse gebruikt om deze associaties te 
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bestuderen in hoofdstuk 4. In de groep met hoge angst werden 316 Parkinson-
patiënten geïncludeerd, in de groep met lage angst 253 Parkinson-patiënten. Het 
angstige patiëntennetwerk vertoonde een grotere algehele sterkte. Ondanks de 
groepsverschillen op klinische en demografische kenmerken, waarbij de angstige 
patiëntengroep aanzienlijk slechter motorisch en cognitieve functioneren liet zien, 
een hogere leeftijd en meer vrouwelijke patiënten bevatte, leverde de netwerk-
vergelijkingstest geen statistisch significante verschillen op in de sterkte van de 
verbanden tussen motorische en angstsymptomen. Aangezien associaties tussen 
motorische en angstsymptomen in beide groepen aanwezig zijn, toont dit aan dat 
deze symptomen geassocieerd zijn onafhankelijk van hun angstniveau.
De hoofdstukken 2, 3 en 4 waren gericht op de associaties tussen motoriek, 
angst, en andere symptomen, zonder rekening te houden met hun relaties 
over de tijd. In hoofdstuk 5 onderzochten we de longitudinale verbanden 
tussen angst, angst om te vallen, en freezing (bevriezing van het lopen) bij 153 
patiënten met de ZvP. Over vier metingen, met drie weken tussen elke meting, 
waren alle associaties significant, met de sterkste associatie tussen angst om 
te vallen en freezing. Aanpassingen voor ziektekenmerken (zoals ziekteduur, 
depressieve en cognitieve klachten) en bijwerkingen van medicatie (zoals 
responsfluctuaties) verminderden alle associaties, wat de complexe interacties 
tussen motorische en angstsymptomen bevestigt.
Na een beschrijving van de fenomenologie van angst, en de cross-sectionele en 
longitudinale associaties met motorische en andere niet-motorische symptomen, 
richt deel 2 van dit proefschrift zich op de behandeling van deze complexe 
symptoominteracties bij Parkinson-patiënten.
In hoofdstuk 6 beschrijven we twee meta-analyses naar de effecten van 
cognitieve gedragstherapie en op mindfulness gebaseerde therapieën op psychische 
problemen bij patiënten met neurodegeneratieve aandoeningen. De geïncludeerde 
onderzoeken werden verdeeld in een groep met een actieve controle conditie en 
een groep met een gebruikelijke behandeling of wachtlijst controle conditie. De 
resultaten toonden aan dat psychologische interventies een klein tot matig effect 
hebben op het verminderen van psychisch leed bij patiënten met de ZvP en Multiple 
Sclerose (MS). De algehele kwaliteit van de geïncludeerde onderzoeken was laag en 
vertoonde een aanzienlijke heterogeniteit, wat pleit voor meer onderzoeken met 
betere kwaliteit.
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Hoofdstukken 7 en 8 presenteren het studieprotocol en de resultaten van 
een pilot gerandomiseerde gecontroleerde trial (RCT) waarin we een nieuw 
ontwikkelde multidisciplinaire groepsbehandeling voor angst in het kader van 
responsfluctuaties bij patiënten met de ZvP, genaamd BEWARE, hebben beschreven 
en onderzocht. BEWARE is een groepstraining voor lichaamsbewustzijn waarin 
we elementen van acceptance and commitment therapie (ACT) combineren met 
fysiotherapie. We vergeleken de BEWARE-training met fysiotherapie in 
groepsverband. In hoofdstuk 8 beschrijven we de resultaten van deze pilot 
RCT. Patiënten die deelnamen aan de BEWARE-training toonde geen significante 
verbetering in de primaire uitkomstmaat, zelfredzaamheid, in vergelijking met de 
controle conditie. Echter, deze groep liet wel een verbetering in emotioneel welzijn 
en staande balans zien, zowel direct na de behandeling als 3 maanden na de 
behandeling. Gevoelens van sociale stigmatisering namen ook af, maar het verschil 
met de controlegroep was niet statistisch significant. De BEWARE-training was de 
eerste poging om het lichaamsbewustzijn te verbeteren en de complexe interacties 
tussen motorische en angstsymptomen bij de ZvP geïntegreerd te behandelen. Een 
geoptimaliseerde BEWARE-interventie wordt momenteel onderzocht in een grote 
multicenter RCT.
Tenslotte, in hoofdstuk 9, worden de resultaten van dit onderzoek samengevat 
en overdacht. Ik beschrijf de wederzijdse interacties tussen angst, motorische 
en autonome symptomen. Ik link onze bevindingen aan het onderzoek over 
lichaamsbewustzijn bij patiënten met een psychosomatische stoornis, en ik bespreek 
de overeenkomsten in de misinterpretatie van lichamelijke signalen die wordt gezien 
in zowel Parkinson-patiënten met angst gerelateerd aan responsfluctuaties, als in 
patiënten met een psychosomatische stoornis. Vervolgens doe ik suggesties om 
deze misinterpretatie te verbeteren. Wat betreft de wederzijdse interacties 
tussen motorische en angstsymptomen, bespreek ik hoe we met deze interacties 
rekening moeten houden door middel van multidisciplinaire behandeling, 
waarvan de BEWARE-training een eerste poging is bij de ZvP. Dit proefschrift 
helpt bij het begrijpen en behandelen van angstsymptomen in de context van 
motorische symptomen bij Parkinson-patiënten, met als doel het psychologisch 
welzijn te verbeteren, ongeacht de progressie van de ziekte. Aangezien symptomen 
bij Parkinson-patiënten kunnen schommelen gedurende de dag, bied ik suggesties 
om meer diepgaand onderzoek te doen naar de interacties tussen motorische en 
angstsymptomen tijdens responsfluctuaties, waarbij gebruik kan worden gemaakt 
van meerdere meetmomenten per patiënt per dag. 
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Voor mijn dankwoord moet ik eigenlijk terug naar 8 jaar geleden, toen mijn tijd bij de 
afdelingen psychiatrie en Anatomie & Neurowetenschappen, sectie Neuropsychiatrie 
begon. Want vanaf toen is de weg ingezet waardoor mijn promotie, en nog zoveel 
andere dingen, op mijn pad zijn gekomen.
Ten eerste wil ik mijn dank uitspreken naar mijn promotoren en co-promotor.
Te beginnen bij het begin, richt ik mij eerst tot jou, Odile.
Ik kan me het moment dat ik jou voor het eerst zag nog goed herinneren, ik wilde 
zo ontzettend graag bij jou onderzoek komen doen, omdat jij je richtte op de 
neuropsychiatrie bij Parkinson en echt de patienten als uitgangspunt nam. Voor 
mij voelde het als DE plek waar ik moest zijn om daar deel van uit te maken en iets 
te kunnen bijdragen.
Al 8 jaar heb ik onder jouw vleugels mogen groeien en leren, en gaf je mij het 
vertrouwen om het BEWARE-onderzoek op te zetten en er een prominente rol in 
in te nemen. 
Jij kent me denk ik vooral als eigenwijs, wat koppig, en (te) zelfstandig, waarmee 
ik weet dat ik het je niet altijd even gemakkelijk heb gemaakt. Toch kreeg ik de 
vrijheid van jou om te exploreren, bijvoorbeeld met nieuwe statistische methoden, 
om letterlijk op onderzoek uit te gaan. Ook stond jouw deur altijd open en was je 
met mij begaan, wat ik goed kon gebruiken (al deed ik dat wellicht niet vaak genoeg) 
tijdens mijn mindere perioden.
Bij het BEWARE project was ook de revalidatiegeneeskunde betrokken, waardoor 
ik jou, Erwin, leerde kennen. Jouw begeleiding was meer hands-on en praktisch, 
wat voor mij erg prettig was. Bewegingswetenschappen stond vroeger ook op mijn 
lijstje van potentiele studies, en ik vond het daarom extra tof om jou aan mijn zijde 
te hebben. Het belang van bewegen en de nadruk op het lichamelijke tijdens onze 
meetings vond ik enorm waardevol, omdat ik als (neuro)psycholoog meer met het 
mentale aspect bezig ben. Ik ben supertrots dat wij samen de kar hebben getrokken 
om de subsidie binnen te halen voor BEWARE, en ik ben je enorm dankbaar voor 
alles wat jij van mij hebt overgenomen tijdens mijn burn-out, zodat ik de ruimte 
kreeg om te herstellen en daar ook de tijd voor kon nemen. 
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Vanaf moment 1 was ook jij daar, Sonja, destijds als dagelijkse begeleider binnen 
mijn bachelor onderzoeksstage. Mijn eerste artikel heb ik samen met jou geschreven, 
en we hebben samen vaak ons hoofd gebroken over de factor analyse waar we ons 
stap voor stap meer in thuis gingen voelen. Jouw rol was veranderlijk door de jaren 
heen, waarmee jij je naadloos aanpaste aan mijn ontwikkeling als zowel onderzoeker 
als persoon. Jij fungeerde voor mij vaak als tussenpersoon en bekeek alles met 
afstand en overzicht, waardoor het voor mij ook overzichtelijk en helder werd. Ik heb 
enorme bewondering voor jou en ik vind het nog steeds jammer dat ik niet bij jou 
verdediging kon zijn, maar ik vind het super dat jij bij de mijne bent als co-promotor!
Mijn paranimfen, waar ik zo trots op ben om ze naast me te hebben staan, 
representeren mijn verleden en mijn toekomst, en ook een beetje van allebei tegelijk. 
Eerst het verleden, in de zin dat ik tegelijk met jou aan het onderzoeks-avontuur 
begon; Anita. Tijdens mijn eerste stage kwam jij ook stage lopen, waar we al 
snel een goede klik hadden. We vonden ons in elkaars karakter maar ook in onze 
interesse voor de neuropsychologie. Op een gegeven moment besloot jij een ander 
team op te zoeken, waar je altijd het label ‘overloper’ voor zult houden ;-) (you know 
I love u!). Jij was mijn rots in de branding, jaar op jaar, jij kende de mensen om mij 
heen en kende mij. Voor wijze raad kwam ik dan ook altijd graag naar jou toe. Op 
het einde van mijn PhD heb ik jou vaak gebruikt om tegenaan te zeuren en om te 
spuien, en jij incasseerde maar, haha! Hierdoor kon ik stoom afblazen, kreeg ik een 
spiegel voor, vond ik geruststelling wanneer jij het allemaal wat normaliseerde en 
een nuchtere blik erop wierp, of motiveerde jij me om door te zetten en niet op te 
geven. Onze koffie-momenten zijn GOUD waard! Ik hoop dan ook dat wij van elkaars 
leven onderdeel mogen blijven, zowel sociaal als misschien wel professioneel… Wie 
weet!
Dan de toekomst, maar ook verleden omdat we daar de zaadjes al hebben gezaaid; 
Rosalie. Tijdens onze intreeweek van psychobiologie hebben wij elkaar ontmoet. Jij 
was in mijn ogen het mooiste meisje van de klas, en ik ben nog steeds verbaasd over 
hoe jij alle sociale ballen in de lucht houdt. Jij bent een vriendin voor iedereen, en 
ik ben heel dankbaar dat er ook voor mij altijd een plekje is. We hervonden elkaar 
bij klinische neuropsychologie, en de afgelopen jaren hebben we allebei veel ups 
en downs meegemaakt. In mijn gedachten was jij er altijd, en stond ik nooit alleen. 
Jij hebt mij het zetje en het vertrouwen gegeven om als zelfstandige aan de slag 
te gaan, wat een van de beste zetten ooit is geweest (nu al!). Dit helpt ons beiden 
om onze dromen te realiseren, en daarom sta jij ook voor de toekomst, omdat ik 
dolgraag samen met jou (en ook samen met Aafra) van die dromen werkelijkheid wil 
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gaan maken. Laten we over een paar jaar terug kijken of we dat ook daadwerkelijk 
hebben gedaan ;-). Want ik weet 1 ding zeker, wij kunnen dit!
Dankjulliewel mijn twee powervrouwen, ik heb me altijd gesterkt gevoeld door jullie!
Ook bedank ik alle co-auteurs, die er samen met mij voor hebben gezorgd dat 
er mooie stappen zijn gemaakt binnen het Parkinson-onderzoeksveld, en eraan 
hebben bijgedragen dat (met name) angst bij Parkinson beter gesignaleerd en 
behandeld kan worden. Dankjulliewel dat jullie samen met mij aan dit nobele doel 
hebben bijgedragen!
Graag bedank ik mijn leescommissie, die allemaal meteen enthousiast JA zeiden 
om mijn proefschrift te lezen. Wat een eer om mijn proefschrift ten aanzien van 
jullie te mogen verdedigen.
Waar ik natuurlijk enorm dankbaar voor ben, is voor de betrokkenheid van alle 
patiënten, deelnemers, en hun naasten, die het mogelijk hebben gemaakt om onze 
onderzoeken uit te voeren. Ik verbaas mij nog zo vaak over jullie flexibiliteit en 
veerkracht, waar ik enorm veel respect voor heb! 
Ook heb ik de samenwerking als enorm waardevol ervaren, dank aan Kees Vermunt 
en Rob Hagen, en in de vroege jaren ook Bep van de Parkinson Vereniging. Jullie 
vertaalden de stem van de deelnemers en lieten mij een nieuw perspectief zien, 
waar ik van overtuigd ben dat het mij een betere onderzoeker, (neuro)psycholoog, 
en beter mens heeft gemaakt. Dankjulliewel!
Ook iedereen die ‘along the way’ kortstondiger op mijn pad is gekomen en met 
mij heeft samengewerkt in andere hoedanigheden, of waarbij ik een deel van 
hun project mocht uitmaken, veel dank voor jullie vertrouwen, inzet, en fijne 
samenwerking.
Team Neuropsychiatrie en afdeling Anatomie & Neurowetenschappen, 
dankjulliewel voor alle borrels, feestjes, inhoudelijke discussies, intervisies, 
spelletjes, Blauwe Engel’s, Mahler’s, kerstdiners, een top weekendje weg, biertjes 
en bitterballen. 
Dankjewel Ysbrand, Niels, nieuwe Niels (of zou eerdere Niels ‘oude’ Niels moeten 
zijn? ;-) ), Chris, Max, Tim (mede GZ-er, yes!), Sofie, Inga, Jari (leukerd!), Emma, James 
(die tatoeage is er nog steeds niet van gekomen, oeps!), Stella, Mardien, Kathleen, 
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Hein, ex-buurman & knuffelbeer Piet, Marijn, Cees, Christa (ooit dansen wij een 
keer salsa of bachata!), Dilene, Thecla, Hanneke, Menno, Tommy, volleybal-Tommy 
;-), Taco, Michael, Stefanos, Alexander, Maureen, Marike, Shanna, Floor, bedankt alle 
PANDA’s en LoetjeSquad!
Premika; jij bent echt een killer! Ik heb ontzettend veel bewondering voor jou en 
hoe jij jouw professionele carriere hebt vormgegeven. Jij had altijd je prioriteiten 
helder, en je hebt me geïntroduceerd in de Indiase keuken. Onze dinertjes @ Mayur 
zal ik altijd koesteren, en wat een eer was het om jouw paranimf te mogen zijn en 
zo ook van jou te mogen leren.
Sarah; thanks for all your wisdom and crazy evenings. The first time I saw you, you 
were sleeping on the table in our office, but this first impression was way off! You 
gave a real positive energy to the office and I loved visiting you in NYC! 
Anders; so far away but sometimes very close, what I absolutely enjoy so much! 
Hopefully you will be visiting us soon and can I visit you again in Norway. Maybe a 
hike together? :-) Thank you for all your kindness, hospitality, and love.
De stagiaires die ik heb mogen begeleiden, met veel plezier, hebben ontzettend 
veel werk verzet. En daarom wil ik graag mijn dank uitspreken naar Marloes, Bridget, 
Liza, en Perrie. Mede dankzij jullie is dit proefschrift tot stand gekomen, ik had het 
niet zonder jullie kunnen doen. 
Omdat ik mijn promotietraject gecombineerd heb met de GZ-opleiding, hebben mijn 
poliklinische werkplekken zeker ook een plek verdiend in het dankwoord. Dank aan 
poli Psychosomatiek en poli Angst & Dwang van GGZ inGeest, dat ik van jullie 
mocht leren, en dat ik daar de ruimte voor kreeg. Dankjewel Karoline, Michel, Marga, 
Eva, en Len, voor jullie werkbegeleiding en supervisie, en natuurlijk Patricia voor 
jouw betrokkenheid als praktijkopleider. 
Vaak hebben we het over werk-privé balans. Voor mij is dit niet altijd gemakkelijk 
te scheiden, ook omdat ik daar vaak bewust voor kies. Mijn passie voor lichaam & 
geest, neuropsychologie, en de wetenschap maken dat ik vaak verzeild raak in deze 
zaken tijdens mijn vrije tijd. 
Persoonlijke ontwikkeling vind ik enorm belangrijk, waar mijn interesses dan ook 
in terugkomen. De volgende mensen wil ik bedanken omdat ze met name in mijn 
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persoonlijke ontwikkeling een grote rol hebben gespeeld, zoals vanzelfsprekend 
ook in mijn ontwikkeling tot wetenschapper en (neuro)psycholoog.
Lieve Annelieke, Mary, en Didi; door jullie kon ik aarden in Amsterdam. Jullie 
hebben mij een thuis gegeven. Friends are like stars, you can’t always see them but 
they are always there. Liekje, jouw dappere stap heeft mij altijd enorm geïnspireerd! 
Arjen; als ex-buurman en goede vriend mis ik jou nu je naar LA bent gegaan, waar 
je na heel wat frustraties en enorm veel geduld eindelijk lekker samen met Bettine 
bent. Veel dank voor al jouw steun en luisterend oor. Jij stond altijd voor me klaar, 
en was heerlijk dichtbij. Of het nou volleybal, knuffelen, even de natuur in, gezellig 
eten, een wetenschappelijke onderonsje, of een dansje doen was, dankjewel!
Al mijn volleybalmaatjes, en in het bijzonder DAMES 4 (inclusief Frank en Bart 
;-) ), wat heb ik heerlijk kunnen afschakelen en genieten op al die trainingen en 
zaterdagen. Dankjulliewel voor alle steun in blessure-tijd, voor al dat fanatisme op 
en naast het veld. 
In het bijzonder wil ik Dorien, Joany en Jasper bedanken. Naast volleybal was 
wintersport echt top, al zijn mijn gevoelens over wintersport natuurlijk ietwat 
gemengd, haha. Ik was gelukkig altijd in goede handen mentaal bij Joans en fysiek 
bij mijn persoonlijke huisarts ;-). Onze trip naar Indonesie zal ik nooit vergeten, 
Dorien, we hebben zoveel toffe dingen gezien en meegemaakt! 
Mijn leukerds, mijn dansmarietjes! Dankjulliewel voor alle afleiding en ontspanning 
die jullie mij hebben gegeven. Door te dansen en door alle heerlijke avonden en 
avonturen waarvan ik hoop dat er nog velen gaan komen. In het bijzonder Tanja en 
Ricardo, you know why ;-).
Alle zorgprofessionals die mij keer op keer (want ja, dat waren een heel aantal 
keer!), zowel fysiek als mentaal weer op de been hebben geholpen, veel dank! 
Lieve pap en mam, jullie hebben jullie meisje moeten loslaten richting de grote stad, 
dat zag volgens mij niemand zitten (inclusief mezelf). Zonder de basis die ik vanuit 
jullie heb meegekregen had ik niet kunnen aarden in Amsterdam. Jullie hebben mij 
altijd gesteund, want jullie weten ook wel dat tegen mijn eigenwijsheid ingaan niet 
goed werkt ;-). Ik trek mijn eigen plan, en jullie behoeden mij voor alle risico’s die ik 
hiermee neem. Hierdoor helpen jullie mij de juiste beslissingen te nemen, die het 
beste bij mijzelf passen. De afstand maakt het niet altijd gemakkelijk, maar we weten 
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elkaar gelukkig vaak te vinden. Ik heb altijd op jullie mogen varen, en me altijd bezig 
kunnen houden met wat ik graag wilde doen, zonder zorgen over praktische zaken, 
want die faciliteerden jullie. Dankjulliewel!
Ook Jorn en Kristin; dankjulliewel, voor jullie interesse, mentale steun, humor, 
SinterNIETklaas, en allerlei feestelijke dagen. In 5x Beringen, Duitsland, Venlo, 
Panningen, Amsterdam, en nu ook Wormerveer. Jullie reizen stad en land letterlijk 
af! Natuurlijk ook de familie Ghielen, Korsten en Hartel, voor alle gezelligheid, 
het delen van zowel lief als leed, gastvrijheid, en Heidegeist ;-).
Eric en Berry, Rogier; dankjulliewel voor het verwelkomen met open armen. Even 
uit de waan van de dag, doet het me ontzettend goed om bij jullie terecht te kunnen, 
altijd. Formule 1 kan nooit meer zonder plankje ;-).
Mijn allerliefste Paul, mijn cheerleader! Ik hoefde nooit boos te worden, want jij 
werd boos voor mij. Ik hoefde nooit mijn best te doen, want ik was al meer dan goed 
genoeg. Ik hoefde nooit bevestiging te vragen, want die gaf jij zonder te vragen. En 
zo kan ik eindeloos doorgaan. Wat ben ik blij met jou. Nog nooit heb ik zoveel rust 
ervaren dan met jou in mijn leven, de perfecte woorden zal ik er nooit voor kunnen 
vinden. Jij moedigt al mijn dromen aan en dat doe ik ook bij de jouwe, samen kunnen 
wij ALLES. Rechtdoor! ;-)
Het laatste (dank)woord gaat natuurlijk uit naar Opa. 
Jij bent degene die mij inspireerde om Parkinson-onderzoek te gaan doen en iets 
te betekenen voor alle mensen met deze ziekte. Jij was altijd mijn drijfveer en jij liet 
mij zien, keer op keer, samen met oma, hoe belangrijk het is om iets te betekenen 
voor iedereen die te maken heeft met Parkinson. Grote bewondering voor jou, 
en ook voor oma, hoe jullie ermee omgaan, hoe zwaar het ook is. Dit proefschrift 
draag ik op aan jou.
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Ires Ghielen was born on October 29, 1990 in Helden. She 
grew up with a younger brother and both her parents 
in the village of Beringe. At the end of her athenaeum 
studies at high schools Bouwens van der Boijecollege 
in Panningen and the VAVO in Venlo, her grandfather 
got diagnosed with Parkinson’s disease (PD). When she 
gained some knowledge about the disease, and saw how 
the disease impacts the lives of her grandfather and her 
family as a whole, she decided to become a researcher 
and help PD patients. Therefore, in 2010, she moved to 
Amsterdam to study Psychobiology at the University of 
Amsterdam. After a research-internship in which she 
came into contact with a lot of PD patients, Ires’ ambition for combining research 
with clinical work grew. After obtaining her Bachelor’s degree, she transferred to a 
Research Master in Clinical Neuropsychology and she took a clinical internship at the 
Medical Psychology department of Amsterdam UMC, location VUmc. She obtained 
her Master’s degree in 2017.
Ires’ first employment was in 2014 at the University of Amsterdam, where she 
was a teaching assistant in statistics for first-year students. Within the same year, 
she started working as a research assistant at the department of Anatomy and 
Neuroscience within the Amsterdam UMC, location VUmc. For more than one year, 
she coordinated the Randomized Controlled Trial (RCT) named BEWARE under 
the guidance of prof. dr. Odile A. van den Heuvel and dr. Erwin E.H. van Wegen, 
which became an important part of this thesis. The BEWARE project investigates a 
multidisciplinary group treatment combining physical therapy with psychotherapy 
in order to learn PD patients to better cope with their fluctuating motor and anxiety 
symptoms. In 2017, Ires got the opportunity to start a PhD position on this very 
same project and set up an improved and more extensive RCT, collaborating with 
two other centers to further investigate the BEWARE treatment. This project was 
supervised by promotor prof. dr. Odile A. van den Heuvel, promotor dr. Erwin 
E.H. van Wegen, and copromotor dr. Sonja Rutten. Together with her promoters, 
Ires received a grant from the Hersenstichting to financially support this research 
project.
Besides her PhD position, Ires also started a post-master education for health care 
(GZ-)psychologist at RINO Amsterdam and GGZ ingeest in 2017. She specifically 
gained practical experience in diagnosing and treating patients with psychosomatic 
and anxiety disorders. 
In 2020, Ires started her online business: Hulp bij Wetenschappelijk Onderzoek. 
She helps health care professionals in doing their scientific research. After finishing 
her PhD, Ires will continue her work as a researcher within her online business. 
Still within her ambition to combine research with clinical practice, she will also 
continue her work with patients as a health care (GZ-)psychologist within the field 
of Neuropsychology. Ires currently lives in Wormerveer with her partner Jean Paul.
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